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1.1 Neurodegenerative diseases 
Neurodegenerative diseases (NDDs) can be characterized by the progressive 
degeneration of neurons in the central nervous system (CNS) as well as in the peripheral 
nervous system. The neurodegeneration is the fundamental pathology of NDDs but the 
symptomatology of NDDs differs depending on the affected cell types and brain structures. 
For instance, a decline of motoric, sensory or cognitive functions is triggered depending on 
the affected brain areas. Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s 
disease, amyotrophic lateral sclerosis (ALS) and prion diseases belong to the most 
prominent and frequently occurring NDDs worldwide (Stroo et al., 2017).  
Although earlier research put focus on the differences of NDD pathomechanisms, it 
is known that NDDs share certain characteristics, such as protein aggregation. Misfolding, 
aggregation and accumulation of proteins seems to be one major reason for 
neurodegeneration in the brain. Depending on the individual NDD, different proteins are 
involved in the pathophysiology such as amyloid-beta (Aβ) and Tau in AD, alpha-synuclein 
(α-syn) in PD, superoxide dismutase 1 (SOD1) and TAR DNA-binding protein 43 (TDP-
43) in ALS. However, amyloidogenic proteins were found to interact and reinforce 
aggregation thereof mutually. For instance, recent insights indicated a supportive effect of 
Aβ on Tau aggregation (Bennett et al., 2017; He et al., 2017; Vasconcellos et al., 2016), of 
Tau on α-syn (Arai et al., 2001; Badiola et al., 2011; Ishizawa et al., 2003) and SOD1 (Pace 
et al., 2018), of α-syn on Tau (Oikawa et al., 2016) and SOD1 (Helferich et al., 2015; Koch 
et al., 2016) as well as an effect of SOD1 on TDP-43 accumulation (Jeon et al., 2019; 
Zeineddine et al., 2017). Not only protein aggregation causes neuronal loss, also 
mitochondrial dysfunction or pathways of programmed cell death are involved. Iron 
dyshomeostasis is also suggested as a causative agent for such devastating mechanisms in 
NDDs such as AD or PD (Ashraf et al., 2018). 
It is still under investigation if protein misfolding and iron accumulation are causative 
mechanisms for the pathology or if they are caused by other mechanisms. Since aging 
appears to be a risk factor for NDDs, the constantly rising age is additionally challenging 
the whole society (Fu et al., 2018; Gan et al., 2018). No cure can be provided so far and in 




important to investigate the underlying pathomechanisms of NDDs to identify biomarkers 
and curative medicine preventing and stopping disease progression.  
1.2 Parkinson’s disease 
In 1817, James Parkinson firstly described the disorder by publishing his 
observations about the symptomatology (Parkinson, 1817). Affecting approximately 1 % 
of the population above 60 years of age, PD is the second most common neurodegenerative 
disorder after AD (De Lau and Breteler, 2006). In 2016, globally 6.1 million people were 
affected from PD. The prevalence was greatly increasing since 1990 when just 2.5 million 
cases were reported. This observation is not only explicable by increased numbers of aging 
people. Other reasons for increased prevalence numbers could be for example an increase 
in awareness for NDDs and the improvement of study methodology. Due to the 
industrialization also in rural areas of the world, the population is also affected by 
occupational environmental factors, such as pesticides or solvents. Moreover, the disease 
duration of PD patients increases resulting in a higher prevalence even with unchanged 
incidence (Dorsey et al., 2018). Based on the Global Burden of Disease Study it is assumed 
that with the currently existing growth rate of PD cases the number will increase up to 12.9 
million cases in 2040 (Dorsey and Bloem, 2018). Focusing at the United States solely, it is 
estimated that by 2030 1 million people in the US will be affected by PD (Marras et al., 
2018). A recent literature search (Abbas et al., 2018) separating the whole world’s 
population into Western (Russia, Europe, Australia, New Zealand and whole America) and 
Eastern countries (Asia and Middle East) revealed interesting differences regarding 
incidence, prevalence and gender dominance. Accordingly, PD is an age-dependent disease 
which is predominant for males and the rates for prevalence and incidence are slightly 
higher in the Western countries compared to the Eastern countries (Abbas et al., 2018).  
1.2.1 Symptomatology  
PD patients show a progressive and chronic loss of the motor function which affects 
for example balance, control of fine motor and gross motor skills. PD patients show 
symptoms such as bradykinesia (slowing of movements) accompanied with resting tremor, 
rigidity, postural instability, freezing of movements or circular hand movements called pill-
rolling type of tremor (Sveinbjornsdottir, 2016). The main cause of the symptoms is the 




apparent. At the timepoint of diagnosis already 40-60 % of neurons in the substantia nigra 
(SN) are degenerated (Berg et al., 2012).  
Besides motor function abnormalities non-motor symptoms have been reported 
several years before the initial motor symptomatology. Fatigue, pain, anxiety, hypophonia, 
dysphagia, hallucinations, cognitive dysfunction and dementia are exemplary non-motor 
symptoms. It has been suggested that these non-motor anomalies can be classified into 
different stages based on the disease progression (Schapira et al., 2017). The earliest 
symptoms occurring years before the diagnosis are reduced olfaction (hyposmia), REM 
sleep behavior disorder, development of depression and constipation. However, due to their 
limited specificity, these alterations are usually not recognized as prodromal PD symptoms 
(Schapira et al., 2017; Schrag et al., 2015).  
The onset time of symptoms, such as freezing of gait, is related to disease progression 
and to an occurrence of specific non-motor symptoms (Virmani et al., 2015). Accordingly, 
forming PD subtypes based on age at diagnosis or specific symptoms can help estimating 
disease progression, survival or related non-motor symptomatology (De Pablo-Fernández 
et al., 2019; Virmani et al., 2015). Another study found that specific non-motor symptoms 
and their severity levels can also be assigned to subtypes formed on the occurrence of 
specific motor symptoms (Huang et al., 2019). This leads to the assumptions that patients 
possibly express different symptomatic patterns and PD is a collective term incorporating 
several subtypes. 
1.2.2 Pathophysiology 
One of the major hallmarks of PD is the degeneration of neuromelanin-containing 
dopaminergic neurons within the SN pars compacta (SNpc) as part of the midbrain (Lees 
et al., 2008). The SN belongs to the extrapyramidal system which contributes to the control 
processes of the motor function. The loss of cell bodies within the SN is likely a 
downstream finding in PD. In accordance to the ‘dying back’ hypothesis firstly described 
by (Hornykiewicz, 1998), it is assumed that axonal terminals within the striatum degenerate 
prior to the death of neuronal cell bodies within the SN. Studies could show that motor 
symptoms are observed when approximately 30 % of dopaminergic neurons are lost. 
However, at this time point approximately 50-60 % of striatal projections are degenerated 




SN, a depletion of dopamine arises which triggers the prominent motor impairments in PD 
patients broadly described in chapter 1.2.1.  
Neuromelanin-positive dopaminergic neurons in the SN belong to the basal ganglia 
and, therefore, they contribute to voluntary movement control. The nuclei of the basal 
ganglia are interconnected. Since long axons of nigral dopaminergic neurons project into 
the striatum, dopamine modulates the activation of spiny neurons in the striatum through 
dopamine receptors. Striatal neurons are in turn directly and indirectly connected with the 
globus pallidus and the SN. According to the direct pathway, an excitatory input leads to 
an activation of the dopamine receptor D1 on GABAergic spiny cells in the striatum which 
project to the internal globus pallidus (GPi). This induces an inhibition of the GPi which in 
turn triggers an excitation of the thalamus and motor cortex. In an indirect pathway, the 
transmission of inhibitory inputs to the external globus pallidus (GPe) is dependent on other 
spiny neurons expressing D2 dopamine receptors. This leads to a decrease of the excitatory 
output of the subthalamic nucleus which in turn activates the GPi and thus inhibits the 
thalamus and motor cortex. Being the brain region of motor behavior controlling, the motor 
cortex is targeted by efferences from the ventral nucleus of the thalamus and it provides 
further input to the spinal cord, striatum and SN pars reticulata (SNpr) (DeLong and 
Wichmann, 2007; Obeso et al., 2000).  
Dopamine transmitted from neurons in the SN plays an important role in these basal 
ganglia circuits. The release of dopamine within the striatum either supports the direct 
pathway or suppresses the indirect pathway. Thereby dopamine ensures that both pathways 
are balanced. Since voluntary movement can just be controlled when these circuits operate 
efficiently, motor disturbances in PD can be explained by a transmitter dyshomeostasis. 
Accordingly, in PD patients, a dopamine depletion in axon terminals within the striatum 
increases the activation of the GPi which thereafter triggers an activity decrease of the 
thalamus and motor cortex (DeLong and Wichmann, 2007; Obeso et al., 2000). 
1.3 Etiology of PD 
PD patients are assigned to either idiopathic/sporadic or familial disease etiology. It 
is presumed that the majority of patients suffer from idiopathic PD. Estimations on the 
proportion of cases with a genetic linkage vary, but in recent reviews it is assumed that 5-




2019; Billingsley et al., 2018; Zhang et al., 2018). The development of an inherited form 
of PD can be triggered by autosomal mutations in different genes such as SNCA, LRRK2, 
PARKIN, PINK1, ATP13A2 and DJ-1 (Fu et al., 2018).  
Although the genetic predisposition determines the development of PD in the 
inherited cases, idiopathic and inherited PD cases show several common underlying 
mechanisms which possibly trigger neurodegeneration such as α-syn misfolding and 
aggregation, reactive oxygen species (ROS) production as well as mitochondrial 
dysfunction or neuroinflammation (Johnson et al., 2019). These possible pathomechanisms 
can affect each other mutually. For instance, α-syn is able to trigger reactive microgliosis 
as a part of neuroinflammation which leads to neurodegeneration (Duffy et al., 2018). 
Another study highlighted that neuroinflammation and α-syn show synergistic effects (Gao 
et al., 2011). Furthermore, α-syn can trigger oxidative stress and mitochondrial dysfunction 
(Hsu et al., 2000), whereas oxidative stress enhances α-syn aggregation (Scudamore and 
Ciossek, 2018). Metal dyshomeostasis, especially of iron, also plays an important role in 
neurodegeneration and can mediate the above-mentioned mutual effects of α-syn and 
oxidative stress (Deas et al., 2016; Levin et al., 2011; Li et al., 2011).  
This multitude of mechanisms possibly causing, facilitating or aggravating PD 
pathology leads to the assumption that PD describes a cluster of pathological subtypes 
which differ regarding their exact pathomechanism (Johnson et al., 2019). Aggregation of 
α-syn and its spreading as well as metal dyshomeostasis play an essential role in the 
pathogenesis of PD and are regarded as important disease causes or triggers. Therefore, 
both pathological events are discussed in detail in the following chapters.  
1.3.1 The role of α-syn and its aggregation 
Consisting of 140 amino acids, α-syn is a small protein with a molecular weight of 
around 14 kDa. It is part of the synuclein protein family which is completed by β- and γ-
syn. All together they are neuronal nuclear proteins, but α- and β-syn are also present in 
axons and presynaptic nerve terminals (George, 2002). Even if not all functions of α-syn 
are known, membrane remodeling, vesicle packaging as well as their release and trafficking 
have been studied in detail (Bendor et al., 2013; Rocha et al., 2018). Furthermore, α-syn is 
an important player in the synaptic machinery due to its high numbers of interaction 
partners at the synapse (reviewed in (Longhena et al., 2019). In the last decades, α-syn was 




system atrophy (MSA) or dementia with Lewy bodies (DLB) so that all of these α-syn-
affiliated disorders were summarized under the synonymous ‘synucleinopathies’ (Goedert 
et al., 2010). 
In PD pathophysiology, special attention is paid to the protein α-syn due to the 
involvement of the SNCA gene, encoding for α-syn, in the familial type of disease. Either 
point mutations or an α-syn overproduction triggered by multiplications of the SNCA gene 
was shown to cause PD. Six identified point mutations for SNCA named A30P, E46K, 
H50Q, G51D, A53T, and A53E were found to trigger a biophysical change in terms of 
amino acid substitutions (Appel-Cresswell et al., 2013; Ki et al., 2007; Krüger et al., 1998; 
Lesage et al., 2013; Pasanen et al., 2014; Zarranz et al., 2004). 
Furthermore, α-syn has been related to another pathological hallmark in brains of PD 
patients: Lewy bodies (LBs). LBs are intracytoplasmatic protein aggregate inclusions 
containing for example ubiquitin and neurofilaments, but the most abundant protein in LBs 
is α-syn (Spillantini et al., 1997, 1998). Whereas LBs are globular structures found in the 
perikarya of cells, spindle-shaped, aggregated structures in neurites are called Lewy 
neurites (Spillantini et al., 1998). Such aggregates were not only found in dopaminergic 
neurons within the SN, as the mainly affected brain region in PD, they rather spread 
throughout the whole brain (Braak et al., 2003).  
It is still a contentious issue if LBs are neurotoxic and trigger neurodegeneration 
(Braak et al., 2003; Lu et al., 2005) or if they act neuroprotectively by trapping pathological 
species of α-syn (Kramer and Schulz-Schaeffer, 2007; Recasens et al., 2014). Studies 
suggest that the toxicity originates from presynaptically available α-syn species (Kramer 
and Schulz-Schaeffer, 2007) and that oligomeric species are neurotoxic that are formed 
preceding to aggregates contained in LBs. Accordingly, a study verified that cell damage 
was caused before aggregate structures were detected (Pinotsi et al., 2016). Therefore, the 
misfolding and different conformational states of α-syn play an important role in the disease 
progression.  
The sequence of α-syn is fundamental to explain its structural plasticity and is 
comprised of three different parts: the amino terminus (residues 1-60), the non-amyloid-
component (NAC) domain (residues 61-95) and the negatively charged carboxyl terminus. 
The NAC region constitutes the central hydrophobic region and it enables β-sheet 




al., 2002). Based on the environmental circumstances, α-syn adopts different 
conformations (Uversky, 2003). It is supposed that α-syn undergoes structural shifts from 
monomer to β-sheet enriched fibrils by passing conformational changes to oligomers, 
ribbons and protofibrils. These intermediate, pathogenic stages are also called α-syn 
‘strains’. Various α-syn strains show different levels of neurotoxicity and provoke thereby 
different PD-characteristic effects such as cell loss or motor deficits in animal models. 
These observations possibly explain pathological heterogeneity of synucleinopathies 
(Peelaerts and Baekelandt, 2016; Peelaerts et al., 2015). However, a recent study might 
refute that one specific strain belongs to one specific disease, since fibrils amplified from 
tissue of PD and MSA patients showed a strong structural variability. Patient-derived fibrils 
differed from recombinant α-syn fibrils and extracts from PD brains showed more structural 
heterogeneity compared to MSA brain extracts. This might suggest that different α-syn 
aggregate structures can be associated with specific PD subtypes identified by distinct 
phenotypes or characteristics in disease progression (Strohäker et al., 2019).  
Investigating aggregation processes in the genetic context, different α-syn mutations 
were found to trigger its oligomerization similarly. However, the effect on the aggregation 
process and inclusion formation depend on the specific mutation (Lázaro et al., 2014). Even 
if in some patients the genetic component explains α-syn pathology, tissue of idiopathic PD 
patients also exhibit LB pathology with α-syn aggregate formation (Baba et al., 1998; Braak 
et al., 2003), assuming that the machinery of protein handling and degradation is defected 
in both disease types. For instance, it is supposed that oxidative stress affects control 
systems for conformational changes of proteins. As key mechanisms to handle intracellular 
protein aggregates under physiological conditions the ubiquitin proteasome system (UPS) 
and the autophagy-lysosomal pathway (ALP) have been reviewed. Regarding the ALP, 
mainly chaperon activity and macroautophagy via autophagosomes are involved in α-syn 
degradation (Stroo et al., 2017; Xilouri et al., 2013). It has been shown that UPS and the 
ALP are linked and exhibit a complex crosstalk, so that in case of malfunction one 
mechanism is able to compensate the other (Ebrahimi-Fakhari et al., 2011; Yang et al., 
2013). However, LB-like α-syn aggregates can affect these mechanisms. For instance, in 
one study the aggregates induced an impairment of the macroautophagy and were resistant 
against degradation (Tanik et al., 2013).  
In case of extracellular aggregate deposits, different cell types are supposed to help 




to be the major scavenger cells of α-syn aggregates. However, the phagocytic ability of 
microglia is dependent on the conformational state of α-syn (Choi et al., 2015; Lee et al., 
2008; Park et al., 2008). Also astrocytes were shown to affect α-syn degradation by trapping 
α-syn and clearing the deposits (Loria et al., 2017). Taken together, α-syn misfolding and 
aggregation plays an important role in PD development. Available clearing processes of α-
syn species are multifaceted but are not able to prevent aggregation. 
1.3.1.1 Propagation of α-syn 
Even if the neurodegeneration process within the SN is the main characteristic of PD 
responsible for the motor dysfunctions in patients, it is now common sense that PD 
pathology is not initiated within this region. Braak and colleagues described that LB 
pathology as conceivable trigger of neurodegeneration possibly starts within the medulla 
oblongata/pontine tegmentum and the olfactory bulb/anterior olfactory nucleus (Braak et 
al., 2003). The authors suggest a LB pathology progression through the brain in accordance 
to six different stages. The findings support the hypothesis that α-syn pathology affects 
interconnected brain regions and therefore follows hierarchical, predictable patterns (Braak 
et al., 2003, 2004).  
Furthermore, the hypothesis of a prion-like behavior of α-syn arose due to several 
observations. It is proposed that α-syn may self-propagate and its cell-to-cell transmission 
finally triggers misfolding and aggregation of endogenous α-syn. This assumption was 
firstly supported by the identification of host-to-graft transmission of aggregates in brains 
of PD patients (Kordower et al., 2008a, 2008b; Li et al., 2008). Accordingly, it was assumed 
that extracellularly available α-syn due to neuronal release or dying cells is uptaken by the 
grafted neurons. In grafted tissue, α-syn triggers misfolding of endogenous α-syn and 
thereby transfers its pathogenic conformation to native proteins. The conversion of an α-
helical structured protein to the β-sheet structured fibrils of α-syn seems to be a crucial step 
for the self-propagation and resembles the process shown by prion proteins (Fonseca et al., 
2015; Recasens and Dehay, 2014). However, more research is needed to confirm these 
suggested mechanisms underlying pathology progression in PD. In this context it is also 
still investigated how α-syn spreads from cell to cell. Spreading to interconnected regions 
suggests anterograde and retrograde transport of α-syn variants which has been verified in 
vitro (Emmanouilidou & Vekrellis, 2016; Tran et al., 2014; Volpicelli-Daley et al., 2011) 




(Jang et al., 2010; Lee et al., 2005), exosomal transport (Alvarez-Erviti et al., 2011; 
Emmanouilidou et al., 2010; Xia et al., 2019) and tunneling nanotubes (Abounit et al., 
2016; Dieriks et al., 2017) play also a role in the transmission of pathological α-syn 
variants. 
1.3.2 Metal dyshomeostasis 
Being the most abundant trace element in the brain, iron contributes to many 
important processes in neurons and glia cells such as the mitochondrial respiration, oxygen 
transport or the metabolism of neurotransmitters (Ashraf et al., 2018; Ward et al., 2014). 
Under physiological conditions, iron import, export and storage proteins, which are 
important for iron metabolism, are regulated by the iron responsive elements (IREs). The 
mRNA translation of the mentioned proteins is controlled by an iron regulatory protein 
(IRP) which binds to IREs in the presence of iron (Joppe et al., 2019). In the aging process, 
it is known that the metabolism of iron is impaired and iron accumulates in specific brain 
regions (Ward et al., 2014). During aging, the L- and H-subunits of the iron storage protein 
ferritin were shown to be more abundant and within the first two decades of life 
concentrations of both subunits were increasing within the SN. Afterwards, the levels of 
H- and L-ferritin does not change significantly (Zecca et al., 2001). In contrast, in brains of 
PD patients reduced ferritin levels but increased iron accumulation were documented in the 
SN (Dexter et al., 1991). This increased nigral iron content could be verified in other studies 
analyzing postmortem tissue (Genoud et al., 2017; Popescu et al., 2009; Szczerbowska-
Boruchowska et al., 2012) or the living patients (An et al., 2018; Chen et al., 2019). The 
disturbance of the iron homeostasis induces an excessive formation of ROS and 
accompanied oxidative stress. Iron provides the basis for catalyzed redox processes, which 
are described by the Fenton and Haber-Weiss reactions. Specifically, iron reacts with 
intracellularly abundant hydrogen peroxide (H2O2) and leads to the formation of free 
hydroxyl radicals (HO•). The thereby formed ROS result in oxidative stress which in turn 
induces a dysfunction of mitochondria and cell death (Singh et al., 2014; Zecca et al., 2004). 
Therefore, iron is supposed to play a crucial role in the neurodegeneration of PD patients. 
Besides the dyshomeostasis of iron, also other trace elements were shown to be 
dysregulated in PD. SN samples of PD patients exhibited decreased copper and increased 
zinc levels (Dexter et al., 1991). Alterations in copper could be verified in SN tissue from 




techniques, whereas zinc level alterations were inconsistent (Davies et al., 2014; Genoud 
et al., 2017). These results indicate that it is still not fully understood which other elements 
are in dyshomeostasis in the context of PD and whether and how they might contribute to 
disease progression. Since other trace elements also potentially undergo redox reactions, it 
is likely that they lead to the formation of ROS. 
1.4 Need for therapeutic approaches 
The diagnosis of PD is made based on the occurring motor symptoms in patients. 
However, at this time point, the underlying pathology is already progressed so that markers 
are needed which spot earlier disease stages. The case that available drugs for PD only lead 
to a relief of symptoms but do not prevent or cure PD pathology point to the need of new 
therapeutic strategies. To name a widespread treatment of PD patients, L-3,4-
dihydroxyphenylalanine also known as levodopa (L-DOPA) is a common orally applied 
prodrug to increase the dopamine precursor level attenuating the symptomatology. An 
attenuation of the dopamine breakdown is aimed by administering inhibitors of monoamine 
oxidase-B (MAO-B) to patients. Furthermore, dopamine agonists, anticholinergics or 
catechol-O-methyltransferase inhibitors are also used for treatment in the early disease state 
(Connolly and Lang, 2014; Hayes et al., 2019). Since iron dyshomeostasis as well as α-syn 
aggregation and spreading describe particular hallmarks of PD, new approaches try to 
intervene in the underlying mechanisms of these two pathological events. The effectiveness 
of iron chelation in PD is stated in chapter 1.4.1. Regarding the α-syn pathology, in chapter 
1.4.2 Rho-kinase inhibition by fasudil is described in more detail as a potential treatment 
strategy in PD, which is so far only tested in cell culture and animal models.  
1.4.1 Iron chelation 
Since iron accumulation is a widespread finding in brains of NDD patients, iron 
overload is a popular experimental therapeutic target. Aim of these experimental 
approaches is to cope with the overload of iron by therapeutically removing excess iron. 
Chelators show a high affinity for metals and lead to their sequestration. Iron chelators were 
extensively tested in preclinical cell culture and animal models of PD to reveal their effects 
on the underlying pathomechanisms. Various beneficial effects such as the prevention of 
iron accumulation in SN, less formation of nigral α-syn aggregates, loss of dopaminergic 




observed (Billings et al., 2016; Carboni et al., 2017a; Finkelstein et al., 2016, 2017; Mandel 
et al., 2004). Therefore, iron chelators were also used in clinical trials analyzing the effect 
of chelators in patients.  
The most common iron chelators are deferoxamine, deferiprone and deferasirox, 
clinically approved by the US FDA. Deferoxamine has a short plasma half-life period so 
that subjects require continuous injections to ensure an optimal treatment. Further 
disadvantages of deferoxamine are dose-dependent neurotoxicity and the time-consuming 
and expensive treatment application (Mobarra et al., 2016). For therapeutic usage a chelator 
should be non-toxic and brain-permeable (Zecca et al., 2004), which is valid for deferasirox 
and deferiprone so that they can be applied orally. Deferiprone is the most promising iron 
chelator to treat patients with regional iron overload, since this substance can cross the 
blood-brain-barrier (BBB) and mobilizes iron. Furthermore, it has a well-known safety 
profile. Various clinical studies exist which tested the efficiency of different chelators in 
patients suffering from NDDs such as ALS (Moreau et al., 2018) or Friedreich ataxia 
(Boddaert et al., 2007; Pandolfo et al., 2014; Velasco-Sánchez et al., 2011). 
In PD, deferiprone was already used for clinical trials. With deferiprone treatment, 
patients reached better scores in the Unified Parkinson’s Disease Rating Scale (UPDRS) 
and showed a reduced iron content within the SN measured by R2* magnetic resonance 
imaging (MRI; FAIR-PARK-I, NCT00943748) (Devos et al., 2014). Another clinical trial 
(DeferipronPD, NCT01539837) showed reduced iron content inside the dentate and 
caudate nucleus for deferiprone-treated patients (Martin-Bastida et al., 2017). Due to these 
promising results a new randomized, parallel-grouped and placebo-controlled phase III trial 
was initiated, including multiple European centers (FAIRPARKII, NCT02655315) 
(recently reviewed in (Joppe et al., 2019)). 
1.4.2 Fasudil-induced Rho-kinase inhibition 
In NDDs, the signaling pathway of the Rho-associated protein kinase (ROCK) has 
been described as an interesting target. As recently reviewed, ROCK is involved in several 
cellular processes of particular importance in NDDs such as autophagy, synaptic 
dysfunction or degeneration of axons (Koch et al., 2018). Already a decade ago, first studies 
revealed neuroprotective and pro-regenerative properties of pharmacological inhibitors of 




The isoquinoline-derivative fasudil is one inhibitor of ROCK. Fasudil was approved 
in 1995 for clinical human use in Japan and is used to treat subarachnoid hemorrhage-
induced vasospasms (Suzuki et al., 2007, 2008). In the last years, fasudil gained attention 
in the field of neurodegeneration for its beneficial effects on animal- and cell-based ALS 
models (Günther et al., 2017; Tönges et al., 2014). A multicenter clinical phase IIa trial is 
currently investigating disease-modifying effects of fasudil treatment in ALS patients 
(Lingor et al., 2019).  
Furthermore, the interest arose to test the effects of fasudil in the context of PD. In 
PD models using a treatment with the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), fasudil effected a reduced loss of dopaminergic neurons in an in vivo and an in 
vitro setup. Motor behavior of MPTP-treated mice was also rescued with fasudil treatment 
(Tönges et al., 2012). Other studies using the MPTP mouse model verified improvements 
in motor behavior and neuroprotective effects on dopaminergic neurons with fasudil 
treatment. Additionally, the inflammatory response was suppressed by fasudil treatment 
(Li et al., 2017; Zhao et al., 2015). The therapeutic combination of fasudil and bone 
marrow-derived neural stem cells further enhanced the mentioned positive effects of fasudil 
in an MPTP mouse model (Li et al., 2017). In mice with an intranasal administration of 
lipopolysaccharide (LPS) fasudil treatment improved motor behavior and attenuated the 
inflammatory response, the loss of dopaminergic neurons and the accumulation of α-syn 
(He et al., 2016). Another study emphasized the connection of fasudil with α-syn in PD. 
The authors described that fasudil can bind to α-syn at two tyrosine residues of its C-
terminal region (Y133 and Y136) and showed that α-syn aggregation was attenuated by 
fasudil supplementation in vitro. In A53T mice, fasudil treatment via drinking water 
prevented cognitive and motor decline of the mice and effected less α-syn pathology in the 
midbrain (Tatenhorst et al., 2016). Therefore, fasudil seems to be a promising candidate for 
new treatment strategies in PD. 
1.5 The interplay of iron and α-syn 
Iron and α-syn are important therapeutic targets in PD. As described in chapter 1.4, 
several drugs used to affect the iron dyshomeostasis have been tested in animal models and 
some of them were even verified in PD patients. However, it is important to investigate 
how different pathological hallmarks are connected to each other to identify appropriate 




was the accumulation of iron in LBs (Castellani et al., 2000). Since α-syn has been 
previously described as a major component in LBs (Spillantini et al., 1998), an interaction 
with iron is likely. 
Supporting this hypothesis, it has been found that both oxidation states of iron can 
bind to α-syn. Whereas for Fe2+ a binding constant of 5.8 × 103 M−1 was revealed, the 
binding constant of Fe3+ was 1.2 × 1013 M−1 (Peng et al., 2010b). Fe2+ specifically binds at 
Asp-121, Asn-122, and Glu-123, located at the C-terminus of α-syn (Binolfi et al., 2006). 
The affinity of Fe2+ to bind α-syn is even increased when α-syn is phosphorylated at pY125 
or pS129 (Lu et al., 2011). Fe3+ is also supposed to have two bindings sites at the C-terminus 
of α-syn (Davies et al., 2011). Besides direct binding, there is further evidence that iron has 
an influence on the transcriptional and translational level of α-syn. One study suggests that 
α-syn levels are regulated by iron due to its 5´-UTR which shows a close homology to the 
IRE of the ferritin mRNA (Friedlich et al., 2007). In HEK293 cells, the polysome-
associated endogenous α-syn mRNA was decreased by the iron chelator deferoxamine. 
Thereby, an Fe3+-related control of the α-syn mRNA translation was assumed (Febbraro et 
al., 2012). Since an IRP knockdown in the SK-N-SH cell line induced an upregulation of 
the α-syn transcription and thereby enhanced its aggregation, the authors suggested that the 
aggregation process is partially controlled by iron through the IRE/IRP system (Li et al., 
2011). 
Almost two decades ago, it has been shown that iron directly induces α-syn 
aggregation and fibrillation (Uversky et al., 2001). Several studies could verify this 
observation (Golts et al., 2002; Kostka et al., 2008; Levin et al., 2011). Even low Fe3+ 
concentrations in a micromolar range triggered the formation of large sodium dodecyl 
sulphate (SDS)-resistant α-syn oligomers (Kostka et al., 2008). In contrast, α-syn did not 
form this kind of oligomers in the presence of Fe2+ (Levin et al., 2011). Since oxidative 
stress induced by H2O2 treatment did not trigger α-syn oxidation and oligomerization, it 
was suggested that trivalent ions plan an important role in the oligomerization (Kostka et 
al., 2008). Oxidizing agents such as H2O2 rather affect α-syn aggregation indirectly by 
oxidizing ferrous iron to ferric iron through the Fenton reaction. Accordingly, the authors 
reported that Fe2+ treatment triggered the oligomerization of α-syn in the presence of H2O2 
(Levin et al., 2011). Therefore, oxidative stress could play an important indirect role for 
iron-mediated α-syn aggregation. Another study also emphasized the effect of oxidative 




of the α-syn aggregation (Li et al., 2011). Furthermore, external circumstances such as 
aerobic or anaerobic conditions could also have an influence on the α-syn aggregate 
conformation triggered by iron. In vitro, it was observed that under aerobic conditions 
treatment with Fe2+ triggered a polymerization into antiparallel soluble α-syn oligomers. 
Under anaerobic conditions, parallel β-sheet α-syn aggregates were formed by Fe2+ but also 
by Fe3+ treatment (Abeyawardhane et al., 2018).  
Iron was also shown to provoke α-syn aggregation indirectly by affecting the 
autophagosome-lysosome pathway. Accordingly, in SN4741 cells, iron promoted α-syn 
aggregation by decreasing the expression of the nuclear transcription factor EB (TFEB). 
TFEB functions as transcriptional regulator of the autophagosome-lysosome pathway. The 
nuclear translocation of TFEB was inhibited through an activated Akt/mTORC1 pathway. 
The inhibition of the TFEB-mediated autophagosome-lysosome fusion resulted in an 
enhanced α-syn aggregation. In addition, the authors showed that cell-to-cell transmission 
of α-syn was also enhanced by iron enrichment, whereas TFEB overexpression attenuated 
this effect (Xiao et al., 2018).  
Therefore, the current state of research offers different mechanisms on how iron 
interacts with α-syn or fosters the aggregation and spreading. On the one hand, direct 
binding of iron and α-syn could form the basis. On the other hand, studies suggest indirect 
influences which affect the interaction of iron on α-syn.  
Vice versa, some studies showed that α-syn has an influence on iron. Accordingly, in 
PC12 cells α-syn overexpression fostered an increase of iron and its accumulation which 
was predominantly observed in the perinuclear region of PC12 cells (Ortega et al., 2016). 
Furthermore, it was shown that α-syn acts as a ferrireductase which implicates the ability 
of α-syn to reduce Fe3+ to Fe2+ (Davies et al., 2011). In contrast, another study indicated 
the formation of an α-syn-Fe3+ complex which inhibited the reduction of Fe3+ to Fe2+ (Levin 
et al., 2011). It is supposed that ferrireductase activity is exerted by a membrane-associated 
helical-rich α-syn tetramer (Angelova and Brown, 2018; McDowall et al., 2017). 
In addition to iron also other trace elements are discussed to interact with α-syn in 
PD. It has been shown that α-syn has different metal binding sites (McLeary et al., 2019). 
Furthermore, some trace elements such as aluminum, copper or manganese were able to 
foster the aggregation of α-syn (Uversky et al., 2001). A recent study could demonstrate 




through exosomes in both in vitro and in vivo models (Harischandra et al., 2019). Therefore, 
the interaction of trace elements and α-syn can offer new approaches to investigate 
pathomechanisms in PD.  
Taken together, the current state of research shows on the one hand that iron can 
interact with α-syn directly and indirectly and this interaction affects the aggregation of α-
syn. On the other hand, α-syn can act as a ferrireductase and can influence the homeostasis 
of iron. The mentioned interactions of iron and α-syn are schematically summarized in 
Figure 1 (adapted from Joppe et al., 2019). 
 
Figure 1. The interaction of iron and α-syn. Iron-induced aggregation of α-syn could be accomplished 
by direct binding or via oxidation. Iron also impacts α-syn indirectly affecting the transcriptional and 
translational level of α-syn. In contrast, iron accumulation is fostered by the overexpression of α-syn, which 




1.6 Animal models of PD 
Animal models of PD enable to investigate underlying pathomechanisms even if the 
complex pathophysiology of PD in humans cannot be entirely mimicked. The advantage of 
several disease-related animal models is that specific parts of the disease pathology and 
symptomatology can be investigated untangling the complexity of the disease into 
underlying single mechanisms. Since neurodegeneration is one of the main hallmarks of 
PD, toxin-based models were firstly tested in animals to mimic the degeneration of the 
nigrostriatal pathways. On the one hand, intracerebral injections of the toxin 6-
hydroxydopamine (6-OHDA) were used, since 6-OHDA is not able to cross the BBB 
(Schober, 2004). On the other hand, the toxin MPTP is able to cross the BBB so that it can 
be applied intraperitoneally or subcutaneously to induce a Parkinsonism-like disease in 
mice mimicking different pathological aspects of PD. The conversion of MPTP into the 
toxic compound MPP+ occurs in glial cells (Konnova and Swanberg, 2018). Thereby, 
neurotoxicity is triggered which effects for instance neurodegeneration, behavioral deficits 
or increased α-syn levels and inclusion formation depending on an acute or chronic 
treatment of MPTP (Fornai et al., 2005; Jackson-Lewis and Przedborski, 2007; Meredith 
et al., 2002; Zhang et al., 2017a). Similar to MPTP and 6-OHDA toxin-based pathology 
models, a treatment with the pesticides rotenone and paraquat has also been used to study 
the underlying mechanisms of PD-like symptoms (Konnova and Swanberg, 2018).  
Based on known gene mutations causing familial PD (e.g. SNCA, LRRK2, PRKN, 
DJ-1, PINK-1 or UCH-L1) also genetic animal models are frequently used to analyze PD 
pathology. Since α-syn pathology is a crucial step in the disease progression, transgenic 
disease models with mutations in the SNCA gene encoding for α-syn have been widely 
investigated (Konnova and Swanberg, 2018). Frequently, the transgenic α-syn mouse 
model B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J (A53T mice) (Giasson et al., 2002) is used 
to analyze disease progression in PD.  
Since α-syn spreading and iron enrichment are common pathological events in PD, 
in the following subchapters models of iron intoxication and α-syn preformed-fibrils (PFFs) 
injections will be described in more detail, forming the basis for the related studies of this 




1.6.1 Iron intoxication models 
Iron dyshomeostasis and accumulation is a well-known hallmark in PD as extensively 
described in chapter 1.3.2, therefore the relevance of iron in context of PD has been 
analyzed in different animal models. MPTP treatment of transgenic A53T mice was shown 
to induce an increase of nigral iron levels, which could be caused by the MPTP-dependent 
decrease in levels of the iron export protein ferroportin. This observation highlights the 
generation of an iron dyshomeostasis in PD pathology (Finkelstein et al., 2017). The result 
that iron chelator treatment of A53T mice showed positive effects e.g. on behavior or α-
syn aggregate formation additionally emphasizes the role of iron in PD (Finkelstein et al., 
2016). Therefore, further studies used an iron application model to investigate the 
consequences of iron overload in the brain. 
Most commonly iron was administered to rodents per gavage, either in form of Fe2+ 
ions (Fredriksson et al., 1999, 2000; de Lima et al., 2005a, 2007) or as elemental carbonyl 
iron (Billings et al., 2016, 2019; Carboni et al., 2017a; Chen et al., 2015; Kaur et al., 2007; 
Peng et al., 2009, 2010a). In most cases carbonyl iron was applied at a daily rate between 
postnatal day 10 and 17 (p10-17) (Billings et al., 2016, 2019; Carboni et al., 2017a; Chen 
et al., 2015; Kaur et al., 2007; Peng et al., 2009, 2010a) in a dosage of 120 mg/kg body 
weight (Chen et al., 2015; Kaur et al., 2007; Peng et al., 2009, 2010a). The model of iron 
enrichment itself is not PD-specific and is rather used to investigate general effects of iron, 
for instance iron-induced behavioral abnormalities of rodents (Fredriksson et al., 2000; de 
Lima et al., 2005b). To further relate effects of iron enrichment to PD pathology, some 
studies used A53T mice overexpressing human α-syn. In both species, A53T and wild-type 
mice, neonatal oral iron application induced iron enrichment in the midbrain, specifically 
in the SN. In addition, iron overload triggered a significant increase of protein carbonyls 
and a loss of dopaminergic neurons (Billings et al., 2016, 2019; Kaur et al., 2007). In one 
study the authors suggested that iron treatment of A53T mice led to a resistance against 
iron chelation with clioquinol (Billings et al., 2016). These results indicate detrimental 
effects if iron overload is paired with a PD-specific model. Furthermore, the effect of iron 
overload in PD-specific toxin-based models was investigated by treating mice with MPTP 
or paraquat. Iron and paraquat treatment led to a strong microglia increase in the SN and a 
loss of dopaminergic neurons, which differed significantly to the effect of paraquat 




iron treatment augmented the effect on nigral neuron loss compared to mere MPTP 
treatment (Kaur et al., 2007). 
Taken together, several studies proved the deleterious effects of iron overload in 
context of PD and showed that Parkinsonian models could consequently trigger a 
dyshomeostasis of iron. Therefore, different iron chelators such as deferiprone, 
desferrioxamine and clioquinol or other components such as green tea, therapeutical 
nanoparticles and the quinazoline compound PBT434 were tested in animal models. Trying 
to affect the iron dyshomeostasis and related pathological events, the mentioned 
components showed a wide range of beneficial effects on pathology and symptomatology 
(Carboni et al., 2017a; Dexter et al., 2011; Finkelstein et al., 2017; Kaur et al., 2003; Wang 
et al., 2017; Xu et al., 2017). 
1.6.2 The α-syn PFFs spreading model 
The spreading pathology of α-syn has been recently studied administering α-syn PFFs 
to different animal species and using different application methods such as an intraglossal 
application or an intramuscular, intraperitoneal, intracerebral, gut or sciatic nerve injection. 
Most commonly, intracerebral injections were conducted into brain regions such as the 
hippocampus, olfactory bulb, cortex, SN or striatum (Chung et al., 2019). Interestingly, a 
recent study showed that intravenous or oral application of PFFs led to an infiltration of 
phosphorylated α-syn fibrils into the CNS and to a similar extent of α-syn pathology in the 
brain compared to an intracerebral injection (Lohmann et al., 2019). 
Due to the frequent usage of intracerebral PFFs injections, precise protocols of the 
preparation of α-syn monomers, generation of PFFs, surgery process, perfusion, tissue 
processing and cleaning after α-syn usage are available (Patterson et al., 2019a; Polinski et 
al., 2018; Zhang et al., 2019a). Besides different injection areas, studies differ also in the 
genotype of the used animals (e.g. wild-type, A53T or A30P mice), in the injection side 
(unilateral or bilateral injections), species of the injected recombinant PFFs (e.g. mouse or 
human), the amount of injected PFFs (e.g. 5 or 10 µg) or the post-injection observation 
period which ranges mostly between 30 days and 9 months post injection (Chung et al., 
2019). In general, it was shown that the injection site determines the distribution of α-syn 
aggregates through the brain. Accordingly, the α-syn spreading pattern at one month 
following an intrastriatal injection differed from its distribution after an injection into other 




From now on, studies are reported which performed unilateral, intrastriatal PFFs 
injections in mice to analyze the spreading of α-syn. Investigations showed that the longer 
the evaluation period the stronger is the α-syn spreading pathology respectively the 
presence of α-syn inclusions in different brain regions (Luk et al., 2012b, 2012a; Okuzumi 
et al., 2018; Paumier et al., 2015). In a recent study, separating both hemispheres through 
callosotomy before or one day after the intrastriatal PFFs injection could reveal that α-syn 
only need one day to spread to the contralateral hemisphere in a rate that is comparable to 
mice without callosotomy. When hemispheres were separated before PFFs injection, α-syn 
deposits spread almost exclusively to the ipsilateral hemisphere. In this case, the spreading 
to cortex, entorhinal cortex or amygdala was more than double compared to mice without 
callosotomy (Okuzumi et al., 2018). In general, α-syn spreads stronger to brain regions 
such as SN, amygdala or striatum in the ipsilateral hemisphere than to the contralateral 
hemisphere (Luk et al., 2012b; Okuzumi et al., 2018; Paumier et al., 2015).  
Different studies investigating PFFs-induced α-syn spreading at 90 days post 
injection (dpi) showed α-syn pathology in similar brain regions. In some of these studies 
no spreading maps were available and only few brain regions were analyzed. However, it 
has been commonly reported that for instance the striatum, SN, amygdala and different 
cortex areas were strongly affected. Most of the affected regions were innervating the 
striatum so that the results support the hypothesis of a connectivity-dependent spreading 
pattern (Blumenstock et al., 2017; Kim et al., 2016; Luk et al., 2012b, 2012a; Terada et al., 
2018). At 90 dpi, a marmoset monkey injected with PFFs into the putamen and caudate 
nucleus showed α-syn signal especially within the neocortex, SN, globus pallidus, thalamus 
and amygdala, resembling spreading pattern in rodent studies (Shimozawa et al., 2017).  
Besides PFFs-induced α-syn spreading through the brain, studies investigated other 
effects of the intrastriatal injection such as impairment in motor behavior. Whereas an 
injection of 5 µg mouse α-syn PFFs only resulted in significant motor abnormalities at 180 
dpi (Luk et al., 2012a), an injection of 10 µg mouse PFFs made an impact at 90 dpi in the 
rotarod test (Masuda-Suzukake et al., 2014). Both beforementioned studies used the wire 
hang test as another motor behavior test. Interestingly, mice injected with 5 µg PFFs 
showed a motor decline in this test at 90 dpi (Luk et al., 2012a), but mice injected with 10 
µg showed no significant results (Masuda-Suzukake et al., 2014). Despite the direct 
connection of the striatum as injection site and the SN, a significant loss of dopaminergic 




dpi (Luk et al., 2012a). Therefore, pathological abnormalities other than α-syn spreading 
pathology occur rather late in this model.  
1.7 The usage of X-ray-based techniques for analyses of human samples 
One common X-ray-based analytical technique is the detection of X-ray fluorescence 
(XRF). XRF allows to identify several elements simultaneously so that an exact 
composition of an analyzed matter can be defined. The photoelectric absorption is the 
underlying principle of XRF which enables to identify the available elements (Figure 2). 
Accordingly, an incoming X-ray photon interacts with an electron of an inner orbital shell 
of an atom. The absorption of the photon energy of this electron leads to the ejection of the 
photoelectron from the inner shell of the atom causing a state of instability. To regain its 
stability, an electron from an outer orbital shell fills the vacancy of the ejected 
photoelectron. Since this electron drops from a higher energy level to a lower energy level, 
it releases another X-ray photon with lower energy compared to the incoming X-ray 
photon, which can be detected and assigned to a specific element (Seibert and Boone, 
2005).  
 Figure 2. Scheme of the photoelectric 
absorption as elementary principle of 
XRF. An incoming X-ray photon 
induces the ejection of a photoelectron of 
the inner shell of the atom. A 
photoelectron from an outer shell 
releases an X-ray photon by replacing 
the vacancy. The released X-ray photon 
is specific for the present element. 
Illustration designed based on (Seibert 
and Boone, 2005). 
 
For the sake of completeness, except the photoelectric absorption the incoming X-
ray photon can also interact in two other ways with an electron of the atom which are called 
Rayleigh scattering and Compton scattering. Therefore, an X-ray detector can additionally 
measure the energy released by Rayleigh scattering and by Compton scattering. The 
Rayleigh scattering describes the case that the incident X-ray is just scattered caused by an 




ejected so that energy of both scattered and incoming X-ray photons are equal. According 
to the Compton scattering, the incoming beam loses some energy since it leads to an 
ejection of an electron from an outer shell and this event effects the scattering of the beam 
(Seibert and Boone, 2005).  
XRF enables both a spatial resolution and quantification of trace elements. Already 
some years ago, both XRF and scanning transmission X-ray microscopy (STXM) have 
been described as well-established and useful techniques to perform a microanalysis on 
neuronal tissue or more specific structures such as cells (Fahrni, 2007; Salditt and Dučić, 
2014). Many studies exist which used XRF-based techniques to analyze the trace element 
content either in human brain tissue (Popescu et al., 2009; Surowka et al., 2015; 
Szczerbowska-Boruchowska et al., 2004, 2012), or brains of rodents (James et al., 2011; 
Tian et al., 2015) or in cell culture (Ortega et al., 2016; Vogt et al., 2003). One study 
indicated that different fixation procedures potentially alter the elemental content of 
samples (James et al., 2011). This implicates the favored usage of native tissue for trace 
element measurements. Next to the mapping and quantification of trace elements, XRF was 
also used to further analyze cell signaling. In this context of cell signaling, one study 
combined XRF microscopy with a fluorescent copper sensor and revealed that neuronal 
cells show a calcium-dependent copper redistribution (Dodani et al., 2011). With a limit of 
approximately 0.1 µg g-1 to 1 µg g-1 the sensitivity of XRF to map absolute concentrations 
of trace elements is similar to electron-based microanalysis (Bourassa and Miller, 2012). 
XRF is only one of many methods which enable to analyze the elemental composition 
of brain samples. In previous studies, methods such as ICP-MS, atomic absorption 
spectroscopy (AAS), analytical electron microscopy or Nano-secondary Ion mass 
spectrometry were also used for a quantification approach of trace element within SN 
neurons or in the extracellular space (Biesemeier et al., 2016; Fernández et al., 2017; 
Genoud et al., 2017). As a promising approach, high spatial resolution in XRF cannot only 
be used for an elemental quantification in cells but also in subcellular structures. 
Furthermore, XRF approaches are advantageous since they are non-destructive compared 
to other mentioned techniques which lead to a destruction of the analyzed tissue 
(Grochowski et al., 2019). 
In addition to XRF, X-ray diffraction (XRD) measurements can be performed. XRD 




the analyzed matter (Bunaciu et al., 2015). The XRD measurements can be performed in 
combination with XRF using different detectors. The scattering signal is generated when 
the focused X-ray beam raster-scans the tissue. Two-dimensional maps can be generated 
including structural parameters such as tissue density, presence of crystalline components 
or short range order. In a previous study investigating human SN tissue, the XRD analysis 
could determine an increased amount of crystallized cholesterol in one PD sample 
compared to a control sample, whereas the XRF measurement showed PD-specific 
alterations in concentrations of trace elements (Carboni et al., 2017b).  
1.8 Aims of this doctoral thesis 
The spreading of α-syn aggregates in the brain is an essential part of the multifaceted 
PD pathology, but its causes and triggers still remain elusive. Unraveling pathomechanisms 
which cause or influence α-syn propagation is aimed to identify novel treatment strategies 
for PD to stop the disease progress. Since iron and other trace elements are known to 
interact with α-syn in particular in its aggregation process, trace element dyshomeostasis is 
a possible pathogenic event reinforcing the disease progression. X-ray techniques are 
powerful tools to detect trace elements and to perform a structural characterization of tissue. 
In this thesis, X-ray techniques were used in order to complement the conventional 
biochemical methods to analyze α-syn pathology.  
The aim of this doctoral thesis was to identify PD-related changes of trace elements 
in dopaminergic neurons and subcellularly in LBs to link the role of trace elements to α-
syn pathology. In vivo and in vitro, specifically the influence of iron on PFFs-induced α-
syn spreading was investigated. Beyond that, this thesis contained a second approach to 
modulate α-syn fibrils propagation investigating the effect of ROCK inhibition by fasudil 
as a therapeutic approach.  
In the following, I will point out the central questions of this thesis:  
1. Is it possible to depict PD-related trace elemental changes in neuromelanin-
positive neurons of patients by XRF? Can X-ray-based techniques be applied to 
visualize LBs due to the presence of partially crystalline structures and to reveal 
their elemental profile?  
XRF was used to analyze midbrain tissue sections of PD and control patients with 




neurons. We aimed to compare these microscopic data from neurons with the elemental 
profile in LBs to verify, which dysregulated trace elements accumulate in LBs. XRD was 
used to attempt a structural characterization of LBs, whereas the distribution of different 
trace elements within LBs was measured by XRF. 
2. Does postnatal iron treatment modulate PFFs-induced α-syn spreading in a 
mouse model? Do intrastriatal PFFs injections and iron supplementation affect 
motor or cognitive behavior of mice? 
To address these questions, postnatal iron treatment of mice was combined with 
intrastriatal PFFs injections. The cognitive and motor performance of the mice was 
monitored to find treatment-related changes and the α-syn spreading pathology was 
analyzed to gain a better understanding, which role iron plays within mechanisms 
underlying α-syn spreading. 
3. Can iron treatment change α-syn PFFs spreading in vitro and do the results 
mimic changes in the in vivo model? 
To investigate α-syn PFFs transmission in vitro, a microfluidic chamber model was 
used and the effect of iron on α-syn spreading in cortical neurons was analyzed. 
4. Does ROCK inhibition by fasudil treatment prevent or reduce α-syn PFFs-
induced pathology in a PD mouse model? 
The α-syn PFFs injection mouse model was used to investigate the effect of ROCK 
inhibition by fasudil on α-syn spreading to get a better understanding of the underlying 
pathomechanism and to assess the therapeutic potential of fasudil in the context of PD.  
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2 Materials and Methods 
2.1 Material 
2.1.1 Equipment 
6-, 12- and 24-well cell culture plates Sarstedt (Nümbrecht, Germany) 
96 well micro test plate Sarstedt (Nümbrecht, Germany) 
Blades Teflon-coated DB80 LX, 
#14035843496  
Leica Biosystem (Nussloch, Germany) 
Cage incubator Okolab (Pozzuoli, Italy) 
Camera Legria HFM36 Canon (Krefeld, Germany) 
Capillary puller P-97 Sutter Instruments (Novato, CA, USA) 
Cover slide Ø 18 mm Menzel (Braunschweig, Germany) 
Cover slides 24 × 60 mm Menzel (Braunschweig, Germany) 
Cover slides Ø 12 mm Menzel (Braunschweig, Germany) 
Cover slips 24 × 55 mm #1 Menzel (Braunschweig, Germany) 
Cryomatrix Thermo Scientific (Waltham, CA, USA) 
Cryomatrix 3801480S Leica Microsystems (Mannheim, Germany) 
Cryomold (Tissue-Tek, Intermediate, 
15 × 15 × 5 mm) 
Sakura Finetek (Torrance, USA) 
Cryostat CM 3050S Leica Microsystems (Mannheim, Germany) 
FluoroDishTM, dish Ø 35 mm, glass 
Ø 3 mm 
World precision instruments  
(Berlin, Germany) 
Gilson pipettes Gilson (Villiers de belle, France) 
Glass capillaries World Precision Instruments (Berlin, 
Germany) 
IVC animal cages Tecniplast (Hohenpeißenberg, Germany) 
Micro Injector Nanoliter 2000 Pump 
Head 
World Precision Instruments (Berlin, 
Germany) 
Micro-centrifuge 5415R Eppendorf (Hamburg, Germany) 
Microfluidic chambers, round device 
450 µm 
Xona (Temecula, CA) 
Microtome blades Feather Safety Razor Co. (Seki, Japan) 
Mini drill with 0.8 mm drill head Dremel (Leinfelden-Echterdingen, Germany) 
Mouse jaw holder with ear bars World Precision Instruments (Berlin, 
Germany) 
Parafilm sealing film Starlab International GmbH (Hamburg, 
Germany) 
Peristaltic perfusion pump Idex (Wertheim, Germany) 
Plastic feeding tubes, 22 ga × 25 mm Instech Laboratories (Plymouth Meeting, PA, 
USA) 
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Rotarod 47600 Ugo Basile (Gemonio, Italy) 
Spark 10M multimode microplate reader Tecan (Männedorf, Switzerland) 
Stereotactic frame David Kopf Instruments (Tujunga, CA, USA) 
SuperFrost Plus Microscope Slides Menzel (Braunschweig, Germany) 
SYS Micro4 controller World Precision Instruments (Hamburg, 
Germany) 
2.1.2 Reagents 
2-Methylbutane Honeywell (Offenbach, Germany) 
4′,6-Diamidin-2-phenylindole (DAPI) Sigma Aldrich (Taufkirchen, Germany) 
B-27 Supplement Gibco (Karlsruhe, Germany) 
Bepanthene Braun (Melsungen, Germany) 
Sodium Bicarbonate solution Gibco (Karlsruhe, Germany) 
Bovine serum albumin (BSA)  Applichem (Darmstadt, Germany) 
Carbonyl iron Sigma Aldrich (Taufkirchen, Germany) 
Citric acid Roth (Karlsruhe, Germany) 
cytosine arabinoside (AraC) Sigma Aldrich (Taufkirchen, Germany) 
DEPC water Sigma Aldrich (Taufkirchen, German 
Dermabond Ethicon (Norderstedt, Germany) 
DNAse Sigma Aldrich (Taufkirchen, Germany) 
D-Sorbitol Sigma Aldrich (Taufkirchen, Germany) 
Enthellan Merck Millipore (Darmstadt, Germany) 
Ethanol absolute Applichem (Darmstadt, Germany) 
Fasudil LC Laboratories (Woburn, USA) 
Fetal calf serum (FCS) Biochrom; PAA (Berlin; Pasching, Germany) 
Glucose 45 % Merck (Darmstadt, Germany) 
Glutamax Gibco (Karlsruhe, Germany) 
Glycerol Roth (Karlsruhe, Germany) 
Glycine Applichem (Darmstadt, Germany) 
Hank's Balanced Salt Solution (HBSS) Gibco (Karlsruhe, Germany) 
Hemalum solution Roth (Karsruhe, Germany) 
Hydrochloric acid 37 % Applichem (Darmstadt, Germany) 
Iron(II) chloride tetrahydrate  Sigma Aldrich (Taufkirchen, Germany) 
Isopropanol Applichem (Darmstadt, Germany) 
Ketamine Medistar (Ascheberg, Germany) 
Levamisol hydrochloride Sigma Aldrich (Taufkrichen, Germany) 
Metamizole Zentiva (Frauenfeld, Switzerland) 
Methanol Applichem (Darmstadt, Germany) 
Mineral oil Sigma Aldrich (Taufkirchen, Germany) 
Mowiol - 488 Sigma Aldrich (Taufkirchen, Germany) 
Naphtol As-BI phosphate Sigma Aldrich (Taufkirchen, Germany) 
Neurobasal medium Gibco (Karlsruhe, Germany) 
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New fuchsin Sigma Aldrich (Taufkirchen, Germany) 
Normal goat serum (NGS) Cedarlane (Burlington, NC, USA) 
Normal horse serum (NHS) PAA (Berlin; Pasching, Germany) 
Hydrogen peroxide 30 % (H2O2) Applichem (Darmstadt, Germany) 
Para-formaldehyde (PFA) Roth, Applichem (Darmstadt, Germany) 
Pen-Strep-Neomycin Gibco (Karlsruhe, Germany) 
Phosphate buffer solution (PBS) Applichem (Darmstadt, Germany) 
Poly-L Lysine Hydrate 100 mg (PLL) Sigma Aldrich (Taufkirchen, Germany) 
Potassium ferricyanide (II) Honeywell (Offenbach, Germany) 
Roti-Histokitt Roth (Karlsruhe, Germany) 
Sodium azide (NaN3) Sigma Aldrich (Taufkirchen, Germany) 
Sodium dodecyl sulphate (SDS) Applichem (Darmstadt, Germany) 
Sodium hydroxide (NaOH) Applichem (Darmstadt, Germany) 
Sodium nitrite, 67398-1G Sigma Aldrich (Taufkirchen, Germany) 
Sterofundin Braun (Melsungen, Germany) 
Sucrose Applichem (Darmstadt, Germany) 
Sudan black Applichem (Darmstadt, Germany) 
Thionine acetate Sigma Aldrich (Taufkirchen, Germany) 
Tris base Applichem (Darmstadt, Germany) 
TritonX 100 Applichem (Darmstadt, Germany) 
Trypsin Sigma Aldrich (Taufkirchen, Germany) 
Tween20 Applichem (Darmstadt, Germany) 
Xylazine Ecuphar (Greifswald, Germany) 
Xylene Sigma Aldrich (Taufkirchen, Germany) 
2.1.3 Buffer and solutions 
Blocking solution for immunohistochemistry (IHC): 10 % NHS, 5 % BSA (IgG free), 
0.3 % TritonX, 25 mM glycine in PBS 
Borate buffer: 0.927 g boracic acid (150 mM) diluted in < 100 ml H2O with NaOH 
adjusted to pH 8.4, filled up to 100 ml with H2O, sterile filtered 
Citrate buffer (100 ml): 10mM citric acid (monohydrate 0.21 g) in H2O, pH-value of 6.0 
adjusted with 1N NaOH, 0.05 % Tween 20 
Calcium-magnesium-free medium (CMF): 450 ml H2O, 50 ml of 10x HBSS, 600 µl 
sodium bicarbonate solution 7.5 % 
Cortex cell culture medium: 660 µl 45 % glucose, 500 µl 100x glutamax, 500 µl 100x 
Pen/Strep, 1 ml 50x B27 diluted in 47,34 ml Neurobasal medium  
DAPI solution: 1 μg/ml DAPI in PBS 
DNAse: 25 mg/ml in CMF 
Mowiol: 6 g glycerin, 2.4 g Mowiol, 6 ml H2O, 12 ml 0.2 M Tris pH 7.2 
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PBS: 9.55 g/L PBS salt solution in distilled H2O 
PFA (4 %) solution: 40 mg/ml PFA, 9.5 mg/ml PBS, 1-3 pellets NaOH in distilled water 
PLL: Hydrate 100 mg PLL in 50 ml 0.1 M borate buffer, sterile filtered (stock of 
2 mg/ml). Stock diluted 1:4 in distilled H2O  
Sudan black: 0.1 g per 100 ml 70 % ethanol 
TBS: 10 mM Tris HCl, 150 mM NaCl in distilled water 
TBS-T: 0.1 % Tween20 in TBS, pH 7.6 
Tris: 10 mM Tris-buffered saline pH 8.0 
Trypsin solution: 50 mg trypsin diluted in 26.7 HBSS pH 7.4, sterile filtered  
2.1.4 Primary antibodies  
Anti-α-syn (LB509) from mouse Covance (Princeton, NJ, 
USA) 
Anti-α-syn (phospho S129; EP1536Y) from rabbit Abcam (Cambridge, United 
Kingdom) 
Anti-MAP2 from mouse Merck Millipore 
(Darmstadt, Germany) 
Anti-mouse CD3 conjugated with Alexa Fluor 
488 
from rat Biolegend (San Diego, CA, 
USA) 
Anti-mouse CD11b from rat Bio-Rad Laboratories 
(Hercules, CA, USA) 
Anti-tyrosine hydroxylase  from rabbit Zytomed (Berlin, Germany) 
2.1.5 Secondary antibodies  
Anti-mouse alkaline phosphatase from goat Dako (Hamburg, Germany) 
Anti-rabbit Cy3 from goat Dianova (Hamburg, Germany) 
Anti-rabbit biotinylated from goat Dianova (Hamburg, Germany) 
Anti-mouse  Cy5 from goat Jackson ImmunoResearch 
(Cambridge, United Kingdom) 
2.1.6 Kits 
Vectastain ABC PK-4000 Peroxidase Kit Vector Laboratories (Burlingame, USA) 
DAB Peroxidase SK-4100 substrate kit Vector Laboratories (Burlingame, USA) 
ToxiLight bioassay kit  Lonza (Cologne, Germany)  
2.1.7 Software 
AxioVision SE64 Rel. 4.9 Carl Zeiss 
CorelDraw Graphics Suite 2019 Corel Corporation 
EthoVision XT 8.5 Noldus 
Graphpad Prism 5.04 and 8.2.1  GraphPad software Inc. 
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Inkscape 0.92  The Inkscape Team 
PyMCA 5.3.1  Sourceforge.net 
SparkControl V1.2  Tecan 
SPSS Statistics 25.0  IMB Statistics 
Stereo Investigator 9.0  Micro Bright Field Inc. 
ImageJ 1.50b  N.I.H. 




2.2.1 Analysis of human midbrain tissue from PD and control patients 
Human midbrain samples were used to analyze the elemental composition of 
neuromelanin-positive cells and the elemental distribution in LBs of PD patients. The X-
ray-based analyses of the human tissue were performed in collaboration with Prof. Dr. Tim 
Salditt and Dr. Jan-David Nicolas (Institute for X-ray Physics, Göttingen, Germany). Also 
Kilian Frank, Marina Eckermann and Tilman A. Grünewald were involved in the 
measurements of the samples at the European Synchrotron Radiation Facility (ESRF) in 
Grenoble, France (Joppe et al., 2020). For an overview on these X-ray experiments, Figure 
3 illustrates the processing of the human midbrain tissue and the procedure of the 
consecutive analyses. MATLAB and Python analyses for XRD and XRF data were also 
performed in collaboration with the Institute for X-ray Physics in Göttingen.  
In a parallel study, human midbrain samples were analyzed regarding their 
cholesterol amounts. The lipid extraction and cholesterol analysis were performed in 
collaboration with Dr. Cornelia Herrfurth and Sabine Freitag from the Lab of Prof. Dr. Ivo 
Feußner (Department for Plant Biochemistry, Göttingen, Germany). 
2.2.1.1 Tissue preparation for X-ray analyses 
Human tissue was obtained from the UK Brain Bank (Parkinson's UK, London, 
England). The Multicenter Research Ethics Committee granted the ethical approval 
(07/MRE09/72). In order to analyze the elemental profile of PD patients with XRF, brain 
sections of four PD patients and four controls (three cancer patients and one multiple 
sclerosis (MS) patient) were prepared (Table 1).  
 






Snap frozen midbrain tissue blocks of PD and control (CO) patients were used as 
starting material (Figure 4A). The samples were transferred from −80 °C to the cryostat 
(−21 °C) at least one hour before sectioning. Tissue blocks were cut into 30 µm thick tissue 
sections using iron-free teflon-coated blades to avoid friction-dependent particle 
contamination. Two adjacent sections were prepared for each patient. The first section was 
Figure 3. Processing of human 
midbrain tissue and the analysis 
procedure. Frozen human tissue 
blocks received from the UK PD 
brain bank were transferred to the 
cryostat and sectioned into 30 µm 
thick slices. The sections were 
mounted on rings covered with 
polypropylene (PP) or Kapton foil. 
Sections on PP rings were not further 
processed, whereas tissue sections on 
Kapton rings were immunolabelled 
for α-syn. Microscopy was used to 
identify neuromelanin-positive 
neurons on native tissue and LBs on 
immunostained tissue. Trace 
elements were measured in both 
preparations using XRF. XRF data 
were processed with the software 
PyMCA and statistically analyzed 
with MATLAB and Python. 
Structural analysis of the tissue was 
performed by using XRD 
measurements.  
MATERIALS AND METHODS 
 
31 
mounted on a ring covered with Kapton foil (ring diameter 50 mm; Kapton thickness 30 
µm); the second section was mounted on a PP-covered ring (diameter 25 mm, PP thickness 
1 µm). Sections mounted on PP foil were dried at 60 °C for 15 min and afterwards another 
PP ring was put on top of each section. Both rings covering one section were sealed with 
nail polish. The sections on Kapton rings were dried for 3 min at 60 °C and fixed with 
methanol for 10 min at −20 °C. These sections were kept at room temperature (RT) for 
immunohistochemical staining.  
The sections on Kapton rings used for the α-syn staining were rehydrated in tris-
buffered saline (TBS) for 20 min. Afterwards, the tissue underwent antigen retrieval in a 
citrate buffer made of sodium citrate at pH 3 for 1 h at 60 °C. After 30 min of cooling down, 
the citrate buffer was removed and the sections were washed 3 × 5 min in TBS. Blocking 
was done in 5 % NGS in TBS with 0.1 % Tween 20 (TBS-T) for 1 h. Afterwards, the 
sections were incubated over night at 4 °C with the first antibody (mouse anti α-syn, 
LB509), 1:250 diluted in 5 % NGS dissolved in TBS. On the next day, the sections were 
washed (3 × 10 min in TBS) and were then incubated with a secondary antibody conjugated 
with alkaline phosphatase (goat anti-mouse IgG/alkaline phosphatase), 1:150 diluted in 
TBS for 45 min. Sections were washed again (3 × 10 min in TBS). Adding Naphthol As-
BI phosphate to the alkaline phosphatase, the fission product reacts with the added 
triphenylmethane dye new fuchsin (0.1 mg/ml) effecting a red staining of α-syn. After an 
incubation with the new fuchsin for around 20 min, a washing step followed (5 min in 
distilled H2O) to rinse any unbound new fuchsin from the tissue. The sections were dried 
at RT. On the next day, distilled H2O was used to rehydrate the tissue (5 min). Afterwards, 
the sections were incubated for 8 s in hemalum solution to stain cell nuclei. After blueing 
of the samples (10 min in H2O), the tissue dried at RT. Due to the yellow color of the 
Kapton foil, the nuclei staining (hemalum) of the sections mounted on Kapton was not 
visible in recorded optical micrographs. After covering the section with another Kapton 
ring, both rings were sealed with nail polish. The Axio Imager.Z2 microscope (Zeiss, 
Göttingen, Germany) was used to identify and document LB-like structures within sections 
from PD patients (Figure 4B) (Joppe et al., 2020). 
 
Table 1. Characterization of the used human samples for X-ray analyses. Samples and detailed information were provided by the UK brain bank. The column ‘analysis 
target’ describes if a section of the sample was used for the analysis of neuromelanin-positive cells (cells) or for the Lewy body (LB) analysis. For PD2, one native section was 
used for the cell analysis and a stained section was used for the LB analysis. CO: control patient, PD: Parkinson’s disease, MS: multiple sclerosis, F: female, M: male, postmortem 





















PD1 PD50 PD PD cells 5 82 F 6 14 18 
PD2 PD334 PD PD cells/LB 8/1 87 M N/A 9 21 
PD3 PD458 PD PD cells 8 73 M 6 19 10 
PD4 PD153 PD PD cells 6 76 F 6 7 12 
LB  PD29 PD PD LB 1 76 M 6 7 15 
CO1 CO46 CO cancer cells 5 75 M N/A N/A 24 
CO2 CO28 CO cancer cells 7 60 F N/A N/A 13 
CO3 PDC35 CO cancer cells 6 89 F N/A N/A 13 

























Figure 4. Human tissue description and microscopic images of a LB as guidance for X-ray-based analyses. 
(A) Schematic anatomical representation of the SN within the midbrain as region of interest (ROI). (B) 
Microscopy images of different magnifications focused on an immunostained LB inside a neuromelanin-
positive neuron of the SN. Tissue was immunostained against α-syn with an alkaline-phosphatase-based new 
fuchsin staining. Holes inside the tissue originated from biopsy punches used for another project. Red squares 
are used to highlight the position of the LB in lower magnifications. Adapted with permission from (Joppe et 
al., 2020) © The Optical Society.  
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2.2.1.2 X-ray-based measurements of human midbrain sections 
Data were recorded at the ESRF (Grenoble, France) using the nanofocus experiment 
endstation (EH3) of the beamline ID13. We aimed at analyzing neuromelanin-positive 
neurons and LBs in these cells and used an in-line microscope for identification. The 
experimental configuration is depicted in Figure 5. 
 
Figure 5. Principle of XRF measurements. 
Experimental setup for XRF measurements. 
The detector records an electrical signal 
proportional to the energy of an absorbed 
photon. With proper calibration, the number of 
photons per energy interval can be calculated, 
which can be visualized in a spectrum. 
 
For the experiment, a photon energy of 14.8 keV with an energy spread of 
ΔE/E = 0.1 % defined by a Si(111) channel-cut monochromator was used. A two-
dimensional single-photon counting X-ray detector (Eiger 4M, Dectris) was used to capture 
XRD. An energy-sensitive silicon-drift X-ray detector recorded XRF photons (Vortex EM, 
SII NanoTechnology Inc.).  
A standard reference material and the pyFAI-calib software (Ashiotis et al., 2015) 
were utilized to calibrate the detector distance of the Eiger detector. At distances 
zEiger = {303.194, 503.067, 901.188, 1298.137} mm, the Eiger detector distance and 
position of the primary beam (and detector tilt) was calibrated. Two different distances for 
the XRF detector were chosen, zVortex = 25.5 mm and 35.5 mm, depending on the size of 
the sample holder. All other relevant parameters for the configuration of the XRF detector 
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Table 2. Parameters used for the configuration of the Vortex EM silicon drift detector. An aluminum 
cap with a circular aperture was used as a collimator by placing it on the detector. Adapted with permission 
from (Joppe et al., 2020) © The Optical Society. 
Parameter Value 
Sample − collimator aperture (mm) 15.5 ± 1 (PP foils) 
 20.5 ± 1 (Kapton foils) 
Distance aperture − entrance window (mm) 10 
Aperture opening diameter (mm) 3.6 
Entrance window − Si chip (mm) 3 
Thickness Si chip (µm) 500 
Thickness Be window (µm) 8 
Active area (mm2) 40 
Tilt angle (degrees) 15.62 
 
A stack of compound refractive lenses was used achieving X-ray focusing. Due to 
the usage of two sets of nanofocusing Si compound refractive lenses, a focal spot of 
240 × 250 nm2 was generated. We assumed a constant photon flux at I0 = 8.4 × 109 photons 
s-1. Fluorescence spectra were calibrated to the amplitude of the Argon Kα fluorescence line 
(Joppe et al., 2020). 
2.2.1.3 Analysis of XRF data 
In order to analyze the elemental composition of cells and LBs in PD and CO 
samples, each sample was placed directly into the focus of the X-ray beam. Regions of 
interest (ROIs) on each section were raster scanned. The detector generated a spectrum of 
the recorded XRF photons at each scan point. Afterwards, spectra could be averaged over 
specific areas within the raster scanned ROIs (Figure 6A). In order to quantify intra- and 
extracellular levels of recorded trace elements separately and to generate area-specific 
mean spectra for analysis, measured cells within the ROIs had to be contoured in a next 
step. The intensity image of XRF data and fluorescence maps from specific elements were 
therefore compared with an optical micrograph. Selenium was relatively homogeneous 
distributed within the measured cells, therefore, the selenium Kα fluorescence intensity 
map was used to delimit the neuron from surrounding tissue (Figure 6B). 




Figure 6. Processing of XRF data and intracellular area delimitation. (A) A ROI which contained at 
least one neuromelanin-positive neuron was defined at the brain section and was raster scanned with a 
focused X-ray beam. At each scan point a single fluorescence spectrum was recorded, which were averaged 
for subsequent analyses. (B) For quantification, the intracellular area was delimited from the extracellular 
region at the ROI. The map of the selenium Kα fluorescence intensity was used to delimit the cell. Using 
MATLAB, the selenium fluorescence map was filtered with a Gaussian and a manual threshold was 
applied to divide each image into an intra- and extracellular area. By slightly enlarging and inverting the 
intracellular area, the extracellular compartment could be identified. Adapted with permission from (Joppe 
et al., 2020) © The Optical Society. 
 
In a next step, PyMCA (Solé et al., 2007) was used to identify which trace elements 
were detected in our sample based on the spectral line intensities. For energy calibration 
and fitting the peaks of the spectral lines to the corresponding elements, the averaged 
spectrum of a cell in each scan or the extracellular area of a scan was analyzed by using 
PyMCA. In addition, the NIST Standard Reference Material 1577b (bovine liver) was fitted 
in PyMCA. The bovine liver served as a calibration standard to determine absolute element 
concentrations (area density in g cm-2) in human tissue sections (Table 3).  
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Table 3. Elemental composition of the NIST Standard Reference Material 1577b bovine liver. The area 
density of each element within the bovine liver was used to calculate the element concentration in human 
tissue. X-ray emission energies were obtained from (Thompson et al., 2009). Adapted with permission from 
(Joppe et al., 2020) © The Optical Society. 
Elements Kα1 (keV) Mass fraction (g [100 g]-1) Area density (g cm
-2) 
K 3.31 0.994 1.12 × 10-8 
Ca 3.69 160 1.31 × 10-12 
Mn 5.90 10.5 1.19 × 10-13 
Fe 6.40 184 2.08 × 10-12 
Cu 8.05 160 1.81 × 10-12 
Zn 8.64 127 1.44 × 10-12 
As 10.54 0.05 5.65 × 10-16 
Se 11.22 0.73 8.25 × 10-15 
Br 11.92 9.7 1.10 × 10-13 
 
To calculate the absolute concentration ci of a specific element i, the following 
formula was used: 















� means the fit area ratio of the Argon Kα line of both the bovine liver 
and the sample and c𝑖𝑖bov abbreviates the certified reference concentration of the element in 
the bovine liver. While A𝑖𝑖bov expresses the fit area of the element in the bovine liver 
spectrum, Ai contains the fit area of the element in the midbrain sample spectrum. The 
actual thickness of the bovine liver of 150 µm is termed d and the exposure time t. tref is the 
rescaled exposure time of the bovine liver to 1 s and dref an effective thickness of 30 µm to 
match the midbrain sample thickness. Figure 7 shows the fitted spectrum of the averaged 
bovine liver (A) and an averaged spectrum of a cell of a control sample (B) containing all 
detectable elements. The continuum background was determined with PyMCA using 
manually chosen parameters for the ‘strip’ filtering algorithm (Joppe et al., 2020). 
2.2.1.4 Tissue preparation for cholesterol analysis 
Midbrain tissue from nine PD and ten CO patients (three cancer and seven MS 
patients) was used to compare the amount of cholesterol between these two groups (Table 
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4). Therefore, on dry ice small pieces were cut out of the tissue block. For each patient three 
tubes were prepared with approximately 30 mg of tissue inside to have both technical and 
biological replicates for the lipid extraction. The tissue was stored at −80 °C until further 
preparation for the lipid extraction, accomplished by our collaboration partners Dr. 
Cornelia Herrfurth and Sabine Freitag (Department for Plant Biochemistry in Göttingen). 
 
Figure 7. XRF spectrum of a bovine liver and a control sample. For both XRF spectra, PyMCA was 
used to fit the data. A red line indicates the averaged fit, whereas the spectrum of the measured material is 
shown in black and the continuum background is indicated by a blue line. (A) Average spectrum of over 
10000 individual spectra obtained from the measurement of a 150 µm thick section of a bovine liver. The 
continuum background was determined with PyMCA using manually chosen parameters for the ‘strip’ 
filtering algorithm. (B) An exemplary average spectrum of a control patient (intracellular region). The 
instrumental settings did not allow to resolve the Compton and elastic scattering peak. Minimum amounts 
of titanium found in both spectra are probably caused by contamination within the collimation system of 
the fluorescence detector. Adapted with permission from (Joppe et al., 2020) © The Optical Society. 
Table 4. Characterization of the used human samples for cholesterol analysis. Samples and detailed information were provided by the UK brain bank. CO: control patient 
group, PD: Parkinson’s disease, MS: multiple sclerosis, F: female, LBDBS: Lewy Body disease (α-synucleinopathy) brain-stem predominant, LBDN: Lewy Body disease (α-
synucleinopathy) neocortical predominant, M: male, post mortem interval: the time in hours (h) between death and tissue freezing, N/A: not available, y: years. 
Case ID Disease 
type 








PD29 PD PD 76 M 6 LBDBS 7 15 
PD39 PD PD 82 F 5 LBDBS 15 12 
PD50 PD PD 82 F 6 LBDBS 14 18 
PD74 PD PD 85 M 6 LBDBS 9 17 
PD153 PD PD 76 F 6 LBDN 7 12 
PD268 PD PD 72 M 6 LBDN 20 8 
PD458 PD PD 73 M 6 LBDN 19 10 
PD334 PD PD 87 M N/A LBDN 9 21 
PD666 PD PD 93 F 6 LBDN 15 24 
MS506 MS CO 61 F N/A N/A 50 21 
MS517 MS CO 48 F N/A N/A 25 12 
MS520 MS CO 74 M N/A N/A 42 21 
MS523 MS CO 63 F N/A N/A 32 20 
MS528 MS CO 45 F N/A N/A 25 17 
MS530 MS CO 42 M N/A N/A 21 15 
MS536 MS CO 47 F N/A N/A 21 30 
CO28 cancer CO 60 F N/A diffuse hypoxic 
damage 
N/A 13 
CO46 cancer CO 75 M N/A N/A N/A 24 
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2.2.1.5 Lipid extraction and cholesterol analysis 
The following procedure of lipid extraction was performed using an adapted protocol 
for extraction of cholesterol from the brain samples. The protocol was provided and 
performed by the Department for Plant Biochemistry in Göttingen. First, the samples were 
grinded using the Mixer Ball Mill MM200 with stainless steel grinding jars (Retsch GmbH, 
Haan, Germany). From approx. 30 mg gross weight of the tissue, 10 mg were extracted as 
previously described applying some modifications (Matyash et al., 2008). Sample 
extraction was performed using 0.75 ml of methanol, which contained 3.1 µmol ergosterol 
as internal standard. Samples were vortexed, 2.5 ml of methyl-tert-butyl ether (MTBE) 
were added and the extract was shaken for 1 h at RT. Phase separation was initiated by 
adding 0.6 ml of distilled water. Afterwards, an incubation of the mixture for 10 min at RT 
and centrifugation at 450 x g for 15 min followed. While the upper phase was collected, 
the lower phase was re-extracted with 0.7 ml methanol/water (3:2.5, v/v) and 1.3 ml MTBE 
as described above. Streaming nitrogen was used to dry the combined upper phase. Then, 
it was resuspended in 0.5 ml of hexane.  
Prior the analysis, a 20-fold dilution of the sample in hexane was performed and 5 µl 
of pure N,O-bis(trimethylsilyl)trifluoroacetamide (Sigma, Germany) were added to 10 µl 
of each sample. For analysis, an Agilent 5977B mass selective detector connected to an 
Agilent 7890B gas chromatograph equipped with a capillary HP-5MS UI column (30 
m × 0.25 mm; 0.25 µm coating thickness; Agilent) was used. Helium served as carrier gas 
(1 ml/min) and the injection port temperature was 280 °C. The temperature gradient 
reached 180 °C for 1 min, 180 – 320 °C at 5 K/min and 320 °C for 5 min. For the transfer 
line, the following set up was used: electron energy of 70 eV, an ion source temperature of 
230 °C, and a temperature of 280 °C. Under the mentioned conditions, the retention times 
of the trimethylsilyl ether derivatives of cholesterol and ergosterol were detected at 23.9 
and 25.0 min, respectively. Using a mass range of m/z 50-650, the mass spectrometer was 
operated in the scan mode. Gas chromatography-mass spectrometry (GC-MS) data analysis 
was performed using the Agilent ChemStation data analysis software. 
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2.2.2 Animal handling and tissue processing 
2.2.2.1 Animals 
Wild-type C57BL/6J mice were used for the experiments of this thesis, which were 
obtained from Charles River (Sulzfeld, Germany). During ongoing experiments, the 
animals were kept in the mouse room of the Neurology department with standard ad libitum 
feeding and 12 hours dark/light cycle. Five animals were maximally housed in one 
individual ventilated cage. For experiments using animals of an age of 10 weeks and older, 
the mice were resettled to our animal facility two weeks before starting the experiment to 
allow habituation to the new environment. For experiments with mouse pups, mice (wild-
type C57BL/6J) were paired in the central animal facility, University Medical Center 
Göttingen. The pregnant mother animals were transferred to the mouse room of the 
Neurology department some days before the delivery of the pups. All animal experiments 
were governed by the national German animal protection law listed under the grant no. 
33.9-42502-04-15/1982 (LAVES Niedersachsen) and the approval was given by the local 
authorities. For preparation of primary cortex neuron cultures, pregnant C57BL/6J mice 
(central animal facility, University Medical Center Göttingen) were used as donor animals 
for embryos of embryonic day (E) 18.5. 
2.2.2.1.1 Overview on the used animal models  
Animal models were used to analyze the impact of iron as well as fasudil on the α-
syn spreading pathology in the brain. Both study models are used to understand and clarify 
the effect mechanism of the α-syn propagation as one of the major characteristics in PD. In 
a first study, mouse pups were treated with carbonyl iron between p10 and p17 per gavage. 
At an age of approximately 12 weeks, mice were injected with α-syn PFFs or monomers to 
analyze the mutual effect of iron and α-syn on motor and cognitive behavior as well as the 
effect on α-syn propagation at 90 dpi (Figure 8A). In a parallel experiment, uninjected 
animals were used to analyze the iron enrichment in mouse brains.  
In a therapeutic approach, mice were injected with α-syn PFFs or monomers and 
additionally treated with fasudil via drinking water between the injection and their sacrifice 
(Figure 8B). An overview on the used animal models is given in Table 5. The model-based 
treatment and injection method will be described in the following chapters.  




Figure 8. Experimental layouts of the main in vivo studies. (A) Experimental procedure of a study 
investigating the influence of iron on PFFs-induced α-syn spreading. Iron was treated per gavage, α-syn 
was injected intrastriatally. Novel object recognition test (NOR) and rotarod test were performed to assess 
the behavior. (B) Experimental procedure of a study investigating the influence of fasudil on PFFs-induced 
α-syn spreading. Mice were injected with α-syn PFFs intrastriatally and received fasudil via drinking water. 
In both studies animals were sacrificed at 90 days post injection (dpi). Doi: day of injection, d: days, IHC: 
immunohistochemistry, mo.: months. 
 
2.2.2.2 Treatment of mice 
2.2.2.2.1 Iron intoxication 
Mouse pups (C57BL/6J) were fed with iron or sorbitol (control condition) between 
p10 and p17 by oral gavage. Within this time frame, the blood brain barrier is still open, so 
that iron treatment should lead to an increased iron load inside the brain. Based on the 
weight of the pups they were fed with between 50 and 80 µl of iron or control solution. 
Before applying, carbonyl iron was dissolved in 5 % aqueous sorbitol solution, which 
served as vehicle. Iron was fed in three different concentrations: 60 mg iron per kg body 
weight, 120 mg iron per kg body weight and 240 mg iron per kg body weight. For 
convenience only, from now on the iron treatment groups are mentioned as 60 mg/kg Fe, 
120 mg/kg Fe and 240 mg/kg Fe. The control group was treated with 5 % aqueous sorbitol 
solution. Between p10 and p14 plastic feeding tubes were used for the gavage while metal 
tubes had to be used between p14 and p17. During the whole iron treatment time frame, 
pups were still in the cage with the mother animal. Since pups ingest their own excrements, 
which could thus contain different iron amounts (due to gavage with different iron 
dosages), pups from the same litter were treated with the same iron dosage. All animals 
respectively both sexes were included in the experiment. 
MATERIALS AND METHODS 
 
43 
Table 5. Overview on the used mouse models. In an iron intoxication model, the treatment with sorbitol is 
a vehicle/control condition for iron treatment. Iron was prepared in three different dosages diluted in 5 % 
sorbitol. Iron and fasudil concentrations were stated as mg/kg body weight (bw). As injection solution either 
human (hum) or mouse (ms) α-syn was used. Mice were injected with either α-syn monomers or preformed 
fibrils (PFFs) diluted in PBS. F: female, Fe: iron, ICP: inductively coupled plasma, IHC: 
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2.2.2.2.2 Fasudil application 
In a therapeutic approach, the ROCK inhibitor fasudil was tested in regard to its 
effects on α-syn spreading. Fasudil treatment started directly after the injection of mouse 
α-syn PFFs and the treatment was continued until mice were sacrificed. Mice were treated 
with fasudil daily via drinking water with a dosage of 30 mg/kg bw per day, adjusting the 
application of fasudil to previously published studies of our lab (Tatenhorst et al., 2014, 
2016). 
2.2.2.3 Intrastriatal injection of α-syn 
2.2.2.3.1 α-syn PFFs production 
Monomeric and fibrillized α-syn solutions were provided by Dr. Stefan Becker (Max 
Planck Institute for Biophysical Chemistry, Göttingen, Germany). Both human and mouse 
α-syn were expressed recombinantly in E. coli and purified as described before (Hoyer et 
al., 2002). For the preparation of pure monomeric α-syn (aggregate-free), the protein was 
dialyzed against PBS buffer (pH 7.4), centrifuged at 106.000 x g for 1 h at 4 °C and filtrated 
through 0.22 µm ULTRAFREE-MC centrifugal filter units (Millipore). The protein 
concentration of α-syn monomers diluted in PBS was finally adjusted to 5 mg/ml. 
For fibrillization, both monomeric human and mouse α-syn were incubated in PBS 
buffer at RT and 37 °C, respectively, with constant stirring at 200 rpm. The fibrillization 
progress was monitored with a thioflavin T fluorescence assay (Hoyer et al., 2004). The 
steady state of fibrillization of human α-syn was reached after 7-9 days, while fibrillization 
of mouse α-syn took up to 11 days until it reached steady state. After preparation, 
monomeric α-syn and PFFs were shock frozen in liquid nitrogen and were stored at −80 °C. 
2.2.2.3.2 Preparation of α-syn PFFs for injection 
α-syn PFFs were defrosted at RT immediately before use whereas α-syn monomers 
were kept on ice. Directly before the injection, the PFFs solutions (PFFs amounts in stock 
solution: 3.4704 mg/ml) were diluted with PBS to achieve the desired dosage (5 µg in 2 μl) 
and were sonicated (30 sec, 1 cycle, 10 % power; Volpicelli-Daley et al., 2014). The 
sonication ensures that long-chain molecule fibrils are shortened, which is a crucial step to 
generate small seeds. 
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2.2.2.3.3 Anesthesia and surgical procedure 
C57BL/6J mice received an analgesic treatment with Metamizole (1.5 mg/ml) in 
drinking water, starting two days before surgery and ending two days after the injection of 
α-syn. Mice were anesthetized with an intraperitoneal injection of ketamine (150 mg/kg 
bw) and xylazine (10 mg/kg bw) solution. In order to verify the depth of the anesthesia, the 
toe pinch reflex and eyelid reflex were checked before the surgery. 
Under anesthesia, the skull of the mouse was fixed within a stereotactic frame (Figure 
9A). The skin was opened with a longitudinal cut to determine the Bregma and Lambda 
coordinates at the cranial roof. Measuring coordinates of both anatomical points, the 
coordinate in the dorsoventral axis should not vary more than 0.3 mm, otherwise the skull 
position was corrected. The stereotactic injection was performed into the striatum at the 
right hemisphere for every mouse and the injection coordinates were calculated based on 
the Bregma point of each mouse by means of the following information taken from the 
Paxinos Mouse Brain Atlas (Paxinos & Franklin, 2003): Anteroposterior axis + 0.4 mm; 
mediolateral axis −1.8 mm; dorsoventral axis −3.5 mm. 
The injectional plane and injection site are visualized in Figure 9B. A drilled hole 
into the skull enabled a slow insertion of a thin glass capillary into the brain tissue until the 
target coordinate of depth (dorsoventral axis) was reached. After the injection (injection 
volume 2 μl, injection rate 500 nl/min) the needle was left in place for 4 minutes to prevent 
reflux of the injected substance via the injection pathway. The capillary was slowly 
removed, the skin above the skull was closed with DermaBond (tissue glue) and the mouse 
received an injection of 1 ml of the sterofundin electrolyte solution (warmed up at 37 °C) 
into the nuchal fold to prevent from dehydration. Under observation, the mice were sleeping 
at a warming pad under a thermal lamp until they woke up from anesthesia.  
2.2.2.4 Behavioral tests 
After the stereotactic injection, the weight of the mice was weekly controlled as an 
indicator for recovery and physical health of the mice until the sacrifice. In order to detect 
treatment-related behavioral changes or pathological abnormalities, behavioral tests were 
conducted during both the iron α-syn study and the fasudil α-syn study. Animals performed 
the rotarod test weekly (once a week). Mice included in the study analyzing the contribution 
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of iron on α-syn spreading were additionally tested with the novel object recognition test 
(NOR) starting two days before the α-syn injection and two days before sacrifice at 90 dpi. 
 
Figure 9. Illustrations on the stereotactic injection procedure and used behavioral tests. (A) 
Stereotactic injection. The skull of the mouse is fixed with ear bars and a teeth holder. A glass capillary is 
inserted inside the brain to inject α-syn. (B) The scheme illustrates the coronal view on the injection site 
in the striatum (adapted from Paxinos and Franklin, 2003). (C) Rotarod device. In parallel, up to five mice 
are running on the rotarod with accelerating speed from 5 to 40 rpm for maximum 300 seconds. (D) The 
procedure of the NOR. After a habituation phase inside the empty arena, the mouse is placed inside the 
arena with two identical objects for 5 min to get used to these objects. After a recovery phase, the short-
term memory (STM) is tested by recording the mouse while exploring a familiar and one novel object. 
The long-term memory (LTM) is tested after 24 h. The Ethovision XT 8.5 software determines the head 
direction to the object within 2 cm of the object’s diameter, which is hereby called the zone of interest. (E) 
Exemplary images on the movement of the mice within the experimental cage with two different objects 
– one familiar and one novel object. The exemplary images represent mice belonging to the four different 
treatment groups (sorbitol = vehicle, 60 mg/kg Fe, 120 mg/kg Fe, 240 mg/kg Fe) before α-syn injection. 




The rotarod test was used to analyze motor behavior. Motor coordination, balance 
ability and endurance are required to complete the rotarod test properly. Up to five mice 
can be tested simultaneously on the rotating rod, which has a diameter of 3 cm (Figure 9C). 
Large disks separate the mice from each other. Placing the mice on the rod, a constant speed 
of 5 rpm is kept. In order to familiarize the mice to the test and to reach stability in the test 
performance, the mice were pretrained on the rotarod at a constant speed of 15 rpm (three 
trials for 5 min) on two consecutive days before the first official assessment. 
During the experiment, the spin speed of the rotating rod was automatically 
accelerating from 5 rpm to 40 rpm within 5 min of testing and the time was recorded after 
how many seconds the mouse fell from the rod (between 0 and 300 sec). At each testing 
day, mice performed three times on the rotarod with an intertrial interval of 30 min to 
reduce stress and fatigue. The test was performed at a similar time of day.  
2.2.2.4.2 Novel object recognition test  
One mouse was placed into an arena of 48 cm × 35 cm. After a 3-minute habituation 
phase within the empty arena, two identical objects were put inside the arena for 5 min. 
This phase aimed to familiarize the mouse with the objects. Afterwards, the mouse was 
transferred back into its cage for 10 min. Subsequently, the mouse was placed again into 
the arena with one of the familiar objects and one novel object for 5 min, meanwhile the 
mouse behavior was recorded with a camera placed above of the arena. With this 10-minute 
interval between habituation and recording phase, short-term memory (STM) of the mouse 
was assessed. In order to assess the long-term memory (LTM) of the mice, 24 h after the 
habituation phase, the mouse was again exposed to one familiar object and one novel object 
for 5 min. Figure 9D illustrates the NOR procedure measuring STM and LTM. The short-
term and long-term experimental setup were analyzed with the Ethovision XT 8.5 software 
from Noldus. The software measured the duration (s) of the head direction to the object 
within 2 cm of the object’s diameter, which is hereby called the zone of interest (indicated 
in Figure 9D). For the analysis, a discrimination ratio was generated relativizing the time 
spent with the novel object to the time spent with both objects, as previously described 
(Bevins and Besheer, 2006; Tatenhorst et al., 2016). The software could also give an output 
on the explorative behavior within the arena. Mice of all iron treatment groups showed 
explorative behavior, which is demonstrated by exemplary images in Figure 9E. To gather 
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information on the mobility of the mice, the distance moved was recorded for each mouse 
during 5 min of testing. 
2.2.2.5 Transcardial perfusion and brain processing 
In order to histologically analyze brain tissue of mice injected with α-syn, a 
transcardial perfusion was performed. Deeply anesthetized mice were transcardially 
perfused with ice-cold PBS for 5 min and afterwards with 4 % ice-cold PFA in PBS for 5 
min. The brains were removed and post-fixed with 4 % PFA in PBS for 24 h at 4 °C. On 
the next day, the brains were transferred to 30 % sucrose in PBS and stored at 4 °C for two 
days for tissue dehydration as cryo-protection. Finally, the dehydrated brains were stored 
at −80 °C until cryo sectioning. 
For the quantification of iron within whole mouse brains via inductively-coupled 
plasma (ICP) spectrometry, 6 month-old iron-treated mice were sacrificed, PBS perfused, 
and their extracted brains were frozen at −80 °C. Each brain was put in a tube with 500 µl 
Milli-Q water and homogenized (3 × 45 sec). Hyphenated ICP spectrometry analysis was 
accomplished by Prof. Dr. Bernhard Michalke (Helmholtz Institute, Munich, Germany).  
For XRF analysis, 6 month-old iron (60 or 120 mg/kg Fe) treated mice and control 
mice were sacrificed and PBS perfused. Mice of the control group were not treated with 
iron. Brains were extracted, the hemispheres were divided and cut into 5 mm thick slices. 
These single blocks were mounted in cryo matrix and were cryofixed for 2 min in −160 °C 
cold 2-methyl butane to avoid ice crystal formation. Samples were stored in liquid nitrogen 
until usage. 30 µm cryosections were cut, freeze-dried and mounted between two layers of 
4 µm ultralene foil (SpexSamplePrep) (Vogel-Mikuš et al., 2014). 
2.2.2.6 Cryosectioning 
For the analysis of fixed mouse tissue, brains were covered with a cryo matrix at 
−20 °C directly before cutting. 30 µm thick sections of the brain were cut. Half of all cut 
sections of the SN were directly mounted on Superfrost object slides whereas the other half 
was stored in 24-well plates filled with PBS. Sodium azide solution was added to each well 
of the plate (0.1 % sodium azide in PBS) to conserve the free-floating sections, and the 
plates were stored at 4 °C. Slices on object slides were stored at −20 °C until usage.  
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2.2.3 Cell culture 
Cell culture experiments were performed to investigate the contribution of iron to α-
syn spreading in vitro mimicking the in vivo model. Cortical cultures were used to establish 
iron treatment. To analyze spreading of α-syn, neurons were seeded into microfluidic 
chambers. Cells were treated with iron and α-syn on consecutive days. 
2.2.3.1 Coating of culture plates and imaging dishes  
Cell culture 24-well plates were coated with PLL and stored at 37 °C overnight. The 
plates were washed two times with PBS and once with Neurobasal and were stored at 4 °C 
until usage. For microfluidic chamber experiments, petri imaging dishes were coated with 
PLL over night at 37 °C. Afterwards, the dishes were washed twice with distilled water and 
the chambers were assembled with the dishes as described in chapter 2.2.3.2. 
2.2.3.2 Preparation of microfluidic chambers 
The microfluidic chambers were constantly reused for the experiments. Therefore, a 
precise cleaning procedure was applied prior to new cultures. Directly after use, the 
chambers were carefully cleaned with soap water. Afterwards, chambers were rinsed with 
distilled water (milliQ) and were kept overnight in a jar filled with distilled water at 37 °C. 
For the whole cleaning procedure, the microgroove side of the chamber has to face up. On 
the next day, chambers were transferred into a plastic dish and dried in the 60 °C warm 
incubator. Debris was removed from the chambers using scotch tape. In order to sterilize 
the chambers, they were incubated for at least 15 min in sterile 70 % ethanol under the cell 
culture hood. Afterwards, the chambers were dried for 1 h. In parallel, distilled H2O was 
removed from PLL-coated imaging dishes and they were dried for 1 h, and then the 
chambers and imaging dishes were assembled. 200 µl warm cortex medium was filled 
inside one compartment of the chambers. After approximately 3 h, the other compartment 
was also filled with 200 µl medium. These ready-to-use chambers were left in the 37°C 
incubator until cell culture preparation.  
2.2.3.3 Primary cortex neuron culture 
C57BL/6J embryos (E 18.5) were used for primary cortex neuron cultures. All 
embryos were transferred to ice-cold CMF. Under aseptic conditions, meninges were 
removed, and the cortices were isolated. Cortex tissue was collected in ice-cold CMF and 
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centrifuged at 1 rcf for 2 min at RT. CMF was removed, and the pellet was incubated with 
1 ml trypsin (≥ 9,000 U/mg; 1.87 mg/ml) in 37 °C for 12 min under occasionally shaking 
movements. 100-150 µl DNAse (~400 U/mg) was added and the cell suspension was 
centrifuged for 1 min at 1 rcf. The supernatant liquid was exchanged with 1 ml FCS to 
inactivate the remaining trypsin. Under trituration with fire polished Pasteur pipettes, cells 
were dissociated and afterwards centrifuged for 4 min at 1 rcf at RT. The remaining pellet 
was resuspended in cell culture medium. A Neubauer counting chamber was used to 
quantify the number of cells within the solution. 250,000 cells/well were plated on PLL-
coated coverslips inside a 24-well plate in 500 µl medium. 120,000 cells were seeded into 
the primary cell compartment of the microfluidic chambers and 250,000 cells at the 
opposing secondary cell compartment exactly one week later. All cells were stored in an 
incubator at 37°C with 5 % CO2 and 95 % humidity. One day after preparation, half of the 
medium was replaced with 4 µM cytosine arabinoside containing medium (AraC; stock 
1 mM) to reach a final concentration of 2 µM AraC within each well. AraC is an inhibitor 
of the DNA synthesis and is therefore used to control the proliferation and to decrease the 
amount of glia cells within the cultures. Every 2-3 days half of the medium in each well 
was replaced with fresh medium containing 2 µM AraC. 
2.2.3.4 Iron treatment of cortex cells 
A stock solution of 5 mM iron(II) chloride (FeCl2) was prepared by dissolving FeCl2 
in 5 % glucose in distilled H2O (sterile solution). For neuron cultures in 24-well plates, iron 
stock solution was diluted in cell culture medium to gain final treatment concentrations of 
10, 50, 100 and 200 µM FeCl2. As a control/vehicle condition, 5 % aqueous glucose was 
added to the medium in the same amount as in the iron conditions. Cells were incubated 
with iron or vehicle for 24 h. After treatment, cells were washed three times with medium. 
For the microfluidic chamber model, stock solution was diluted in warm cortex medium 
containing 2 µM AraC to obtain a treatment solution of 100 µM FeCl2. At day in vitro (div) 
2, the existing medium was removed from the cell side of the microfluidic chambers and 
200 µl of the iron solution was added. As a control condition, the same amount of 5 % 
aqueous glucose was mixed with cortex medium as in the iron condition. After 24 h, the 
whole chambers were washed two times with fresh medium and were treated with α-syn.  
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2.2.3.5 PFFs treatment of cortex cells 
Mouse α-syn monomers and PFFs stored at −20 °C were thawed – monomer at 4 °C 
and PFFs at RT – and both protein solutions were diluted 1:10 in sterile PBS. Then, α- syn 
PFFs were sonicated for 30 sec at RT at cycle 1 and with 10 % power. In microfluidic 
chambers, cells were treated with 1 µg PFFs or monomers diluted in 200 µl fresh cell 
culture medium. After 24 h of treatment starting at div3, the cells were washed three times 
with fresh medium. As a separate control condition, cells were treated with PBS instead of 
α-syn.  
2.2.3.6 Fixation of cells 
Cells in 24-well plates were rinsed with PBS and then fixed with 4 % PFA in PBS 
for 10 min at RT. Afterwards, PFA was replaced by PBS and the cell-containing coverslips 
were stored in PBS at 4 °C until staining. For longer storage of the unstained cells, PBS 
was replaced by 0.1 % sodium azide diluted in PBS. 
The fixation procedure of cells within microfluidic chambers differs marginally from 
the above-mentioned procedure. First, the whole imaging dish, where the chamber was 
placed in, was filled with PBS to facilitate detaching of the chamber to the coverslip. After 
removing the chamber, PBS was replaced by 4 % PFA in PBS for 10 min. The following 
step was the same as above mentioned for 24-well plates.  
2.2.4 Molecular biology and biochemical techniques 
For the analyses of mouse tissue, immunohistochemical methods were applied. 
Depending on the evaluation method, the following antibody-based staining protocols were 
used: either fluorescence-based or peroxidase-based staining. An immunocytochemical 
approach, a modified Prussian blue staining and a ToxiLight Assay were used to analyze 
cortex neurons. 
2.2.4.1 Immunohistochemistry 
2.2.4.1.1 Fluorescence-marked antibody staining 
In order to analyze α-syn spreading pathology through coronal mouse brain sections, 
a fluorescence-based antibody staining of α-syn was applied. For this staining, 30 µm thick 
sections, already mounted on object slides and stored at −20 °C, were used. The tissue was 
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rehydrated in PBS for one hour and afterwards incubated in citrate buffer (pH = 6.0) at 
80 °C for 30 min. The sections were cooled down to RT within 30-60 min and then washed 
in PBS 2 × 5 min. The tissue was incubated for 20 min in 25 mM glycine in PBS and 
washed in PBS twice for 5 min. After incubation with 0.1 % Sudan black for 15 min, the 
sections were rinsed with water and washed with PBS 2 × 5 min. In order to block 
unspecific antibody binding, sections were incubated for 1.5 h at RT in a blocking solution 
inside a moist chamber. Afterwards, the tissue was incubated with the first antibody over 
night at 4 °C. Rabbit anti-phospho S129 α-syn antibody (EP1536Y, #ab51253, Abcam) was 
utilized to recognize α-syn aggregates in a dilution of 1:1000 in blocking solution.  
On the following day, slides were washed 3 × 15 min in PBS and incubated with the 
second antibody in a moist chamber for 1.5 h at RT (Cy3 goat anti-rabbit, 1:500, #111-165-
006, Dianova). Another washing step 3 × 10 min followed, and the sections were incubated 
in DAPI solution for 2 min to achieve staining of the nucleus since DAPI is known to bind 
to adenine-thymine rich regions in the DNA. The slides were washed with PBS 2 × 10 min 
and dried at 37 °C for 10 min. The sections were embedded with Mowiol and then dried at 
60 °C for 10 min for a better expansion of the Mowiol. The slides were kept at RT overnight 
and were stored afterwards at 4 °C. 
CD3-positive (CD3+) T cell stainings were performed by our collaboration partner 
PD Dr. Chi Wang Ip (University Hospital Würzburg, Germany). 30 µm thick brain sections 
of SN (pars compacta and pars reticulata) and the pre-commissural, commissural and post-
commissural parts of the striatum of iron-treated mice were stained. Free floating sections 
were preincubated for 3 h at RT on a shaker with 5 % BSA / 5 % NGS in 0.01 M PBS. 
Afterwards sections were incubated for 2 h at RT with primary rat anti mouse CD3 antibody 
conjugated with Alexa Fluor® 488 (Biolegend, #100210) diluted in 1 % BSA / 1 % PBS 
in 0.01 M PBS. DAPI was used to label cell nuclei. 
2.2.4.1.2 Peroxidase-based antibody staining 
In order to stereologically quantify the dopaminergic neuron population in SNpc, 30 
μm thick brain sections were stained free floating against tyrosine hydroxylase (TH) 
followed by an on-slide Nissl staining. Every fourth section of SNpc was washed 3 × 5 min 
with TBS in net tubes. The following quenching of endogenous peroxidase was performed 
by a 15 min incubation in 40 % methanol and 1 % H2O2 dissolved in TBS. After another 
washing step with TBS, sections were incubated in 5 % NGS in TBS for 60 min at RT to 
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block unspecific antibody binding. The incubation with the primary rabbit anti-TH 
antibody, diluted 1:1000 in 2 % NGS in TBS, took place for 48 h on a shaker at 4 °C.  
The antibody solution was decanted, and the sections were washed three times in 
TBS. The secondary anti-rabbit (biotinylated) antibody was diluted 1:200 in TBS and 
stayed on the sections for 2 h at RT, followed by three times washing in TBS. For enhancing 
the signal power, the sections were incubated with the VECTASTAIN Elite ABC 
Peroxidase Standard kit (Vector Laboratories) for 2 h at RT. After washing with TBS (three 
times), the diaminobenzidine-HCl (DAB) Peroxidase Substrate kit was used to visualize 
TH staining through the chromogen DAB. Sections were incubated for about 20 min and 
the DAB reaction was stopped by an incubation in distilled water for 5 min. Subsequently, 
sections were transferred to Superfrost object slides and were dried for 5 days at RT.  
Afterwards, the Nissl staining was performed. The tissue was rehydrated in distilled 
water for 5 min and stained with thionine acetate solution for 7 min, followed by another 
washing step in distilled water for 5 min. Dehydration of the tissue was reached by a step-
by-step incubation in 70 % (2 min), 90 % (2 min) and 95 % (5 min) ethanol. After repeating 
all previously performed staining steps, sections were incubated in 100 % isopropanol for 
5 min and then 3 times in xylene respectively for 5 min. Finally, slides were mounted with 
Entellan and stored at RT until stereological counting. 
For the analysis of CD11b+ cells in brains of iron-treated animals, the related staining 
procedures were performed by our collaboration partner PD Dr. Chi Wang Ip (University 
Hospital Würzburg, Germany). 30 μm coronal cryo-sections of the SN (pars compacta and 
pars reticulata) and the pre-commissural, commissural and post-commissural parts of the 
striatum were used. Sections were preincubated free floating for 3 h at RT on a shaker with 
5% BSA / 5 % NGS in 0.01 M PBS. Afterwards, they were incubated on a shaker overnight 
at 4°C with the primary rat anti mouse CD11b antibody (Bio-Rad Laboratories, 
#MCA74G), diluted in 1 % BSA / 1 % PBS in 0.01 M PBS. Sections were then incubated 
for 2 h with the biotinylated secondary antibody against rat Igs (Vector Laboratories), 
which was diluted in 1 % PBS / 1 % NGS in 0.01 M PBS, followed by an incubation with 
the avidin/biotin reagent (Thermo Fisher Scientific). In a next step, tissue was incubated 
and stained with DAB and H2O2. Cells were additionally stained with Hematoxylin.  
 




In order to analyze the α-syn PFFs pathology in cortex cells, an antibody-based 
fluorescence staining was applied. Cells were washed twice in PBS and were incubated 
with 25 mM glycine in PBS for 20 min. After another step of 2 × 5 min washing in PBS, 
cells were incubated with blocking solution for 1.5 h at RT. The primary antibodies (rabbit 
anti-α-syn pS129, 1:1000, #EP1536Y; mouse anti-MAP2, # MAB3418) were diluted in 
blocking solution and cells were incubated with first antibodies over night at 4 °C. At the 
second day of staining, the cells were washed 3 × 15 min with PBS. Afterwards, cells were 
incubated with the secondary antibodies for 1.5 h at RT (Cy3 goat anti-rabbit, 1:500, #111-
165-006; Cy5 goat anti-mouse, #111-175-146). The cells were washed with PBS for 
3 × 10 min and incubated with DAPI for 2 min for nucleus staining. After another washing 
step for 2 × 10 min with PBS, cells were mounted with Mowiol and stored at 4°C.  
2.2.4.3 Modified Prussian blue staining  
In order to stain Fe3+ ions, a previously reported protocol was adapted (Höpken, 
2005). The protocol is based on the classical known Prussian blue staining from Perls 
(1867) detecting Fe3+ combined with a DAB approach to intensify the iron signal (Nguyen-
Legros et al., 1980). 
Cells were washed 2 × 10 min in PBS with 0.3 % Triton and afterwards incubated 
with 5 % potassium ferricyanide(II) dissolved in distilled H2O for 30 min at RT. Following, 
the cells were incubated with 2 % potassium ferricyanide(II) dissolved in distilled H2O in 
a 1:1 dilution with 2 M HCl for 30 min at RT. The addition of potassium ferricyanide(II) 
to iron in an acidic environment resulted in a blue staining of iron. To intensify the signal 
of iron, cells were incubated with DAB and nickel, mixed according to the description in 
the DAB kit (2.5 ml H2O, 1 drop buffer, 1 drop nickel, 2 drops DAB) for 15 min at RT. 
Afterwards, an incubation for 15 min at RT in DAB, nickel and H2O2 followed (2.5 ml 
H2O, 1 drop buffer, 1 drop nickel, 2 drops DAB, 1 drop H2O2). Cells were washed twice in 
PBS with 0.3 % Triton for 10 min. For slight staining of the nuclei, nuclear fast red was 
used (15 min). After another washing step of 2 × 2 min in PBS, coverslips were dipped in 
100 % ethanol for 2 min and mounted with Histokit on an object slide. 
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2.2.4.4 ToxiLight Assay  
To assess if iron treatment provokes toxicity in cortical neuron cultures, cell medium 
was collected from different time points prior and post iron treatment: directly before iron 
treatment (div 2), at the end of iron treatment (24 h post treatment start, div 3), 5 days post 
treatment start (div 7) and 12 days post treatment start (div 14). Medium was stored at 
−80 °C until usage. The cells were previously treated with 10, 50, 100 or 200 µM FeCl2 or 
vehicle (only with 5 % Glucose). ToxiLight Assay was performed using the kit from Lonza. 
Medium was defrosted and 30 µl of each sample was pipetted into a 96-well plate (three 
replicates per condition). An equal amount of the kit solution was added to the sample and 
after 5 min of incubation the luminescence was monitored for each well with the Tecan 
Spark 10M multimode microplate reader (SparkControl software). The release of adenylate 
kinase from damaged cells was quantitatively measured. A mean value of the three 
replicates per condition was calculated and a negative control (medium from a blank well, 
without cells inside) was subtracted from all other conditions.  
2.2.5 Microscopy and analyses of in vivo and in vitro experiments 
2.2.5.1 Image processing and analyses of α-syn PFFs of the in vivo model 
For the analysis of PFFs-induced α-syn pathology in mouse brain tissue, 
immunostained sections were imaged with a Zeiss Axioplan microscope (Zeiss, Göttingen, 
Germany). The MosaiX module of the AxioVision SE64 Rel. 4.9 software was used to 
generate images of whole brain sections (magnification of 10x). The same exposure time 
was used for all images in one experiment. For the evaluation of the images of one 
experiment, the same color intensities were used. Afterwards, only α-syn phosphorylated 
at S129 was quantified. From now on α-syn phosphorylated at S129 will be referred to as 
pS129-α-syn. The quantification of pS129-α-syn in whole sections was realized using two 
different methods: manual counting or threshold-based particle quantification. Both 
methods are separately described in the following chapters. In order to compile pS129-α-
syn spreading maps and to assess the spread amounts of α-syn in specific brain regions per 
section, another manual rating approach was established, described in chapter 2.2.5.1.3. 
Using the three above-mentioned approaches to investigate α-syn spreading in the 
mouse brain, six different coronal brain sections were analyzed. According to the Paxinos 
mouse brain atlas (Paxinos and Franklin, 2003) the following sections were analyzed 
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named after their distance to the Bregma point: 1.54 mm, 0.38 mm, 0.02 mm, -1.58 mm, -
3.08 mm, -3.28 mm. 
2.2.5.1.1 Manual α-syn spreading analysis  
For a manual quantification of pS129-α-syn, merged images of both channels DAPI 
(nuclei staining) and Cy3 (pS129-α-syn) were imported to the vector graphics software 
Inkscape 0.92. Merged images (scale 0.65 µm / pixel) were overlaid with a grid. Each box 
of the grid covered an area of 150 µm × 150 µm (230.8 pixel × 230.8 pixel). The whole 
section was manually raster scanned by the investigator on a subjective perception. Signal 
within each box was rated as follows:  
Low signal amounts: 1-5 α-syn-positive structures  
Medium signal amounts: 6-10 α-syn-positive structures 
High signal amounts: >10 α-syn-positive structures 
To illustrate the rating, boxes in the grid were marked with dots in yellow (low 
signal), orange (medium signal) or red (high signal). The procedure is exemplarily depicted 
in Figure 10. For further analysis, both ipsilateral hemisphere (injected hemisphere) and 
contralateral hemisphere were individually examined. The total count of yellow, orange or 
red marked boxes was relativized to the total number of boxes covering the respective 
hemisphere to provide the percentual affected area. Graphs based on this 3-stage method 
give an idea on how much area of the hemisphere is highly affected by α-syn or how much 
area of the hemisphere is marginally affected.  
In order to illustrate how much area of the whole brain section is generally affected 
(independent on the quantity evaluated in each counted box) a sum of all rated boxes (low, 
medium, high signal amounts) on both hemispheres was calculated, relativized to the box 
numbers of the total section and given as percentage (%).  
 




Figure 10. The procedure of the manual quantification analysis of α-syn spreading. Brain sections 
were covered with a grid. Immunolabeled α-syn structures were counted within each box of the grid using 
a 3-stage rating.  
 
 
2.2.5.1.2 Threshold-based α-syn spreading analysis 
The aim was to quantify pS129-α-syn signal in different brain sections of mice 
injected with α-syn PFFs. The threshold procedure is illustrated in the upper part of Figure 
11. Therefore, processed microscopy images as described earlier in 2.2.5.1 were used. 
Images of the Cy3 channel were imported to the ImageJ software and converted to 8-bit 
images. The threshold function of ImageJ was used (default mode) and the threshold of 
interest was manually adjusted for each single image due to individual background signal 
(noise) (threshold of greyscale 231-250). After applying the selected threshold, the 
corresponding image of the DAPI channel was considered to surround and calculate the 
area of the injected and contralateral hemisphere separately. In another step, both contours 
were assigned to the threshold image and a tool named ‘analyze particles’ calculated the 
area of the α-syn-positive signal within each contour. Results were given as percentage 
resulting from the observed signal area divided by the total area of the corresponding 
hemisphere.  
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Figure 11. Quantitative analysis of α-syn distribution after PFFs injections in mice. α-syn 
immunostained mouse brain sections were imaged and analyzed with ImageJ threshold-based particle 
analysis tool. For a quantitative analysis, α-syn signal was quantified within the ROI, which is either the 
injected or contralateral hemisphere. For a distributional analysis of pS129-α-syn, an overlay image of the 
threshold image and DAPI channel in grey-scale was generated. Comparing the overlay image with the 
Paxinos atlas figure (Paxinos and Franklin, 2003), α-syn signal was rated per brain region (rating scale 
from 0 to 4) using the cell counter function as aid. One marker represented one animal and per region 0 to 
4 counts of each marker were set demonstrating the α-syn signal in the specific brain region of each animal. 
To visualize the group-specific average distribution of α-syn in different brain sections, the rating scale 
was translated into a color code. For a better overview, average values of the groups within the rating scale 
from 0 to 4 were translated into: −, +, ++, +++ and ++++. 
 
Since the threshold was manually adjusted for each image in this quantification 
analysis, it was tested if the underlying thresholds per mouse differ significantly from each 
other. The analysis showed that the used threshold values did not vary significantly between 
the investigated groups (240 mg/kg Fe vs. control; one-way ANOVA; Figure 12). 
 
Figure 12. Manual threshold variance. 
The averages of the manually selected 
thresholds per group do not differ 
significantly between the four treatment 
groups. One-way ANOVA; n = 6-8 
(average of 4-6 sections per mouse), data 
given as mean ± SEM. 
2.2.5.1.3 Region-specific rating analysis of α-syn spreading and a connectome-based 
analysis 
A region-specific rating analysis was performed to show an overview on affected 
brain regions and an estimation on the severity of the pathology within the regions. The 
analysis procedure is illustrated in the lower half of Figure 11. The same six sections per 
animal were analyzed as used for the quantitative threshold-based analysis described in the 
previous chapter. In the aforementioned analysis, the whole hemispheres of the sections 
were analyzed in a threshold-based quantification manner, which provides the difference 
MATERIALS AND METHODS 
 
60 
compared to this analysis. In this analysis, we aimed to visualize the distribution of α-syn 
through the brain and the amount of α-syn per brain region to compare this signal between 
groups in spreading maps. Therefore, we manually classified the observed α-syn signal per 
brain regions in a 5-stage rating scale as described below. 
ImageJ was used to overlay the generated threshold image from 2.2.5.1.2 with the 
image of the DAPI channel showing the brain structures on the section due to the stained 
nuclei. The related Paxinos atlas figure of the identical section was opened with ImageJ 
and brain regions on the Paxinos figure were marked using the cell counter tool where the 
overlay-images showed α-syn signal. In addition, the occurrence of pS129-α-syn signal was 
graded in each different brain region as follows: − no positive signal, + sparse (few positive 
structures), ++ mild (minor clusters of positive structures), +++ moderate (dense signal 
covering a big area of the brain region) or ++++ severe (huge clusters of positive signal 
throughout the whole region). Exemplary micrographs are shown in Figure 13. Per group 
6-8 animals were evaluated and a mean signal amount was calculated for each positively 
graded brain region. A color code was assigned to the scale and the results were illustrated 
as heat maps.  
 
Figure 13. Exemplary images for spreading of α-syn using the 5-stage rating scale. Threshold images 
indicating pS129 signal (green) were overlaid with DAPI images (black) to visualize the presence of α-syn 
per region. From left to right the images show increased amounts of α-syn pathology visualized in green. 
Scale bar 200 µm. 
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In order to assess whether pS129-α-syn pathology spreads according to the 
anatomical connectivity starting from the injection site, the Allen Mouse Brain 
Connectivity Atlas (©2020 Allen Institute for Brain Science. Allen Mouse Brain 
Connectivity Atlas, available from: https://connectivity.brain-map.org/) was used (Oh et 
al., 2014). This platform includes mouse EGFP injection experiments and indicates its 
specific injection sites and volumes.  
For the current study, the injection radius was computed based on the volume of 2 µl. 
Experiments included in the mentioned software were selected which used injection sites 
within our radius. Two injection sites (Exp. 158916311: https://connectivity.brain-
map.org/projection/experiment/158916311; Exp. 100142580: https://connectivity.brain-
map.org/projection/experiment/100142580) were selected to reconstruct the anatomical 
connectivity in our experiment. The software illustrated EGFP signal in different sections 
throughout the whole mouse brain. For a better visualization of the EGFP signal in brain 
sections, it was displayed in ‘projection segmentation’ maps showing the signal in front of 
a black background. In six defined brain sections, regions were marked which showed 
EGPF spreading signal and were illustrated in maps. Finally, these connectivity maps were 
compared to α-syn spreading maps of the current study. 
2.2.5.2 Stereological quantification of dopaminergic neurons in mice 
Stereological cell counting was used to assess the cell population of TH-positive 
(TH+) and Nissl-positive (Nissl+) neurons in the SNpc due to intrastriatal α-syn injections 
in mice. The mouse tissue was stained with a DAB-reaction as well as Nissl staining as 
described in chapter 2.2.4.1.2. Immunohistochemistry and evaluation were proceeded as 
previously described (Tatenhorst et al., 2014; Tönges et al., 2012). Using a Zeiss 
microscope and the compatible Stereo Investigator software (Stereo Investigator 9.0; Micro 
Bright Field Inc, Colchester, USA), every fourth section of an animal through the SNpc (8 
- 10 sections in total) was analyzed. Specifically, cell population of TH+ and Nissl+ 
neurons were determined for each mouse in both hemispheres. Therefore, contours of the 
area of SNpc were outlined at 2.5x objective magnification level, while neuron 
quantification was performed at the 40x objective magnification level. A counting frame 
size of 50 µm × 50 µm was set for the optical fractionator application, furthermore a grid 
size of 100 µm × 100 µm, an interval of every fourth section through SNpc and a manual 
focus on top of the 30 µm thick section were chosen. Considering the manually counted 
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Nissl+ and TH+ neurons, the software calculated and projected the absolute cell population 
within the whole SNpc of each animal. The quantification of Nissl+ neurons was performed 
to exclude a mere downregulation of TH-immunoreactivity and to confirm the predominant 
loss of neurons. 
2.2.5.3 CD11b+ and CD3+ analyses 
The analysis of CD11b+ microglia and CD3+ T cells in mouse sections from animals 
treated with iron and α-syn were performed by our collaboration partner PD Dr. Chi Wang 
Ip (University Hospital Würzburg, Germany). At a magnification of 40x, CD11b+ 
microglia were quantified within an ocular grid of a defined area of 0.0625 mm2 using a 
light microscope (Olympus BH2, Olympus, Hamburg, Germany). Axio Imager.M2 
fluorescence microscope (Zeiss, Göttingen, Germany) was used to quantify T cell amounts 
inside the mouse sections. Since T cells were rarely present, the entire regions of the SNpc 
and SNpr, the pre-commissural, commissural and post-commissural parts of the striatum 
were respectively analyzed on each section. For each animal the α-syn injected and 
contralateral hemisphere were investigated separately by quantifying 2-3 grids per region 
and 2 sections per region in average. CD11b+ microglia amounts were calculated per 
square millimeter. 
2.2.5.4 Analyses of iron in mouse brain tissue 
In order to assess the iron amount within whole mouse brains of mice treated with 
different dosages of iron, samples were investigated by Prof. Dr. Bernhard Michalke 
(Helmholtz Institute, Munich, Germany) via ICP spectrometric analysis as previously 
described (Fernsebner et al., 2014). 
To analyze the iron amounts within single sections of SN of mouse brains, Prof. Dr. 
Katarina Vogel-Mikuš performed the XRF imaging and analysis at the XRF beamline of 
Synchrotron Elettra (Karydas et al., 2018). Therefore, frozen hemispheres were cut to 30 
μm slices by CM3060 Leica Cryostat, freeze-dried and mounted between two 4 μm 
ultralene foil layers (SpexSamplePrep) (Vogel-Mikuš et al., 2014). The samples were 
positioned at 45° and afterwards they were scanned by 75 µm × 75 µm beam at excitation 
energy of 10 keV. The silicon drift detector for XRF detection (Bruker, Nano GmbH, 
XFlash 5030) was placed on the incident beam horizontal plane, perpendicular to the 
MATERIALS AND METHODS 
 
63 
primary beam. The silicon drift detector has a 30 mm2 nominal crystal area, exhibits a 
thickness of 450 µm and has a nominal resolution equal to 131 eV (at Mn-K). 
XRF spectra fitting was performed in PyMCA (Solé et al., 2007) and quantification 
was done according to (Kump and Vogel-Mikuš, 2018). Pure metal foils were used to 
calibrate the XRF system (MicromatterTM Technologies Inc., Canada). For validation a 
standard reference material (NIST 1537a Tomato Leaves, Sigma Aldrich) was measured. 
Absorption utilized to determine the sample thickness was detected by a photodiode placed 
behind the sample and the scattering of X-rays on the sample (Kump and Vogel-Mikuš, 
2018).  
2.2.5.5 Imaging and analysis of microfluidic chambers 
Cortex cells cultured inside microfluidic chambers were imaged using the Axio 
Imager.Z2 microscope (Zeiss). The tiles option of the software served to image both cell 
compartments almost completely and the groove area in the middle of the chamber in total. 
The channels Cy3, Cy5 and DAPI were always imaged with the same exposure time for all 
cover slips. Per each tiles image, the focus was adjusted manually for 50 single tiles. The 
threshold function of ImageJ was used to assess the pS129-α-syn signal. One threshold was 
defined for each culture. The secondary cell compartment was contoured and defined as 
ROI. A percentage based on signal area and ROI area was calculated for each microfluidic 
chamber. An average of 1-3 chambers per condition and culture was calculated. The 
relative signal (%) of the PBS condition was subsequently subtracted from the relative 
signal (%) of the monomer or PFFs conditions, respectively. 
2.2.6 Statistical analysis 
Statistical analyses of XRF data from ex vivo human tissue were performed by Dr. 
Jan-David Nicolas (Institute for X-ray Physics, Göttingen, Germany) using MATLAB and 
Python. Python (version 3.6.6.) was used to analyze and display the data (matplotib and 
seaborn modules). The Python package SciPy (version 1.0.0.) was used to perform 
normality tests. For statistical analysis, the Welch test was accomplished by MATLAB 
(R2018b). Scripts of Dowding and Haufe (2018) were used for the sufficient summary 
statistics (SSS) approach. The SSS and the nested ANOVA (nANOVA) approach were 
implemented in MATLAB (R2018b). The cluster analysis was conducted by Scikit-learn 
(version 0.20.1). 
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For statistical analyses of mouse and cell culture experiments, SPSS statistics 25.0 
and Graphpad Prism 5.04 and 8.2 were used. Detailed information about the used statistical 
tests and the sample sizes are indicated in the respective results part. Data were tested for 
normality with Shapiro-Wilk, Kolmogorov-Smirnov or D’Agostino-Pearson omnibus 
normality test and tested for homogeneity of variances with the Levene, Bartlett’s or 
Brown-Forsythe test. For the evaluation of in vivo and in vitro experiments, Fisher’s exact 
test, the ANOVA with repeated measurements, one-way ANOVA, Welch-ANOVA, 
Student’s t-test, Mann-Whitney-U test and Kruskal-Wallis test were calculated. For 
multiple group comparisons, Tuckey’s or Dunn’s post-hoc tests followed. After Welch-
ANOVA, Games-Howell post hoc test followed. Data are given as mean ± SEM and 
statistical differences within the data were considered as significant if p < 0.05 (* p < 0.05, 






3.1 Characterization of human postmortem midbrain tissue of PD 
patients 
In order to analyze the role of trace elements in PD assuming metal dyshomeostasis 
or accumulation as a potential causative factor in PD, neuromelanin-positive neurons of PD 
and CO patients were raster scanned using XRF at the ID 13 (nanofocus experimental 
endstation, EH3) of the ESRF (Grenoble, France) (Joppe et al., 2020). Neuromelanin-
positive neurons degenerate within the SN as one major characteristic of PD, firstly 
described by Tretiakoff in 1912 (Lees et al., 2008). Since neuromelanin is a brown pigment, 
it is easily visible within unstained sections simplifying the identification of these neurons. 
Further studies revealed significant differences in the accumulation of trace elements as 
copper, iron or zinc in cell bodies within the SN from PD patients compared to controls 
(Carboni et al., 2017b; Davies et al., 2014; Szczerbowska-Boruchowska et al., 2012). In 
this study, we used a higher sample size as well as respective neuron count and employed 
higher magnification using a nanofocus beamline to precisely determine trace element 
levels within cell bodies. For the analysis of the metal content in neuromelanin-positive 
neurons, native tissue sections were analyzed to avoid contamination by processing. 
Furthermore, little is known about metal dyshomeostasis within LBs of PD patients which 
could possibly clarify the contribution of trace elements to LB formation or α-syn 
pathology. Therefore, in this study, midbrain sections were immunostained with an 
antibody which recognized α-syn aggregates helping to identify LBs inside neuromelanin-
positive cells. The same sections were used to detect the distribution of trace elements 
within the LBs (Joppe et al., 2020). 
A previous XRD study from our lab suggested that tissue of a PD sample from the 
same cohort showed higher cholesterol amounts compared to a CO sample (Carboni et al., 
2017b). Therefore, in a side project, the cholesterol amount within our patient cohorts (nine 




3.1.1 XRF analysis – the elemental composition of neuromelanin-positive neurons 
of PD patients and controls 
For the element quantification in neuromelanin-positive neurons, tissue of four PD 
and four CO patients were measured. Per patient, five ROIs were raster-scanned with one 
to two neurons located on each ROI. Intracellular trace element amounts (average of five 
to seven cells per patient) or extracellular amounts (cell-surrounding regions in ROIs) were 
detected of the following 12 trace elements: iron (Fe), manganese (Mn), copper (Cu), zinc 
(Zn), arsenic (As), selenium (Se), bromine (Br), calcium (Ca), potassium (K), chlorine (Cl), 
sulfur (S), phosphorus (P). In Figure 14A, the element concentrations inside and outside of 
26 cells from the CO group and 27 cells from the PD group are visualized. Surprisingly, 
the intra- and extracellular levels of bromine exceeded levels of zinc and selenium. Mostly, 
the area density of each element did not differ much comparing the concentration within 
the intracellular and the extracellular space. The relative concentrations were computed 
from the PD (cPD) and CO (cCO) concentrations calculating (cPD – cCO) / cCO. Relative 
changes can be observed in Figure 14B showing that chlorine, manganese, iron and zinc 
concentrations are increased in PD samples compared to CO in both intra- and extracellular 
space, while potassium, copper, arsenic, selenium and bromine amounts are, both intra- and 
extracellularly, decreased in the PD sample cohort. Phosphorus and sulfur levels were 
almost unaltered. For calcium the intracellular level was decreased in PD patients whereas 
the extracellular amount was slightly increased. 
 
Figure 14. Averages of absolute and relative trace element concentrations in neuromelanin-positive 
neurons of PD and CO patients. (A) Absolute trace element concentrations given as area density are shown 




are represented in red, whereas control patient values (CO, n = 26 cells from four patients) are shown in 
blue. Data are given as mean ± SEM. (B) Relative changes in element-specific area density of PD samples 
relative to CO. A value of 1 implies a concentration increase of 100 %. A value of −0.5 corresponds to a 
50 % decrease of a specific element in the PD samples relative to the CO samples. Data are given as 
mean ± SEM. Adapted with permission from (Joppe et al., 2020) © The Optical Society. 
 
For the following analyses, elements with Z < 21 (proton number within the nucleus 
of the specific atom < 21) were omitted, since the nominal concentrations are affected by 
self-absorption in the sample. Probably not all parameters for corrections are sufficiently 
known, in particular the absorption coefficient of the tissue. Therefore, self-absorption 
could erroneously alter the concentrations of elements with Z < 21. Focusing intracellular 
element concentrations, a polar bar chart was used to visualize the results of single cells 
(Figure 15). The used illustration allows deeper insights on intra- and interindividual 
variances and facilitates to identify outliers of single cells which probably distort the group 
average of an element concentration. For example, the overall signal of bromine within the 
CO group is dominated by two single cells from patient CO1. For arsenic, great variability 
was detected for PD3 showing only one cell with high arsenic concentration whereas the 






Figure 15. Polar bar charts of element concentrations in single neuromelanin-positive cells. Polar bar 
charts of Mn, Zn, As, Fe, Se, Cu and Br indicate absolute element concentrations (g/cm2) within cells. Each 
bar represents the absolute concentration (ci) of a specific element in one cell. Bars of the same color belong 
to the same patient. The upper half of the diagram corresponds to the four CO samples whereas the bottom 
part corresponds to the PD patients (n = 4, 5-8 cells per each patient). Adapted with permission from (Joppe 




Above mentioned data on element concentrations were further grouped by patients 
and groups in Figure 16 for a better overview on interindividual differences. For example, 
focusing on iron, PD3 showed a much higher concentration compared to the other PD 
samples. In parallel, this illustration also visualizes the fluctuation of values within a patient 
given by a relatively low number of cells per patient. For example, levels of manganese are 
widely ranging between cells within PD3.  
In order to identify statistical significance between both groups, normality and 
significance tests were calculated based on the pooled data including all neurons of all 
patients per group. A Shapiro-Wilk normality test revealed that for most of the trace 
elements the concentrations within groups were not normally distributed (Table 6). For a 
first impression on statistical group differences, the Welch test for data with unequal 
variances was performed and revealed significantly decreased amounts of copper in PD 
patients. It had to be considered that a normal pooled data analysis obtains wrong results, 
when inter-subject variances are existing but ignored. Since this study showed high 
interindividual differences for some elements (Figure 16), there is a high risk to 
underestimate the variance and obtain smaller p-values. To consider any between-subject 
variance, the following two statistical tests were performed: the SSS approach and 
nANOVA. All results of the used statistical tests are summarized in Table 6. 
Assuming random effects and inverse variance weighting, the SSS was calculated as 
described in (Dowding and Haufe, 2018) with an effect size measured by the mean of each 
sample. For nANOVA, random effects were assumed. For both tests, two layers of the data 
set were modelled. The first layer differentiated between the disease type (PD or CO). The 
second layer considered the individual patients (four patients per group). For all analyzed 
trace elements, no significant results were found. The obtained p-values were orders of 
magnitude larger than results of a Student’s t-test on the pooled data not considering inter-
subject variances. The most discriminant trace element of our analysis was copper, 
however, no significant difference between the two groups was found in SSS and nANOVA 
(p = 0.07 in both analyses; Table 6). Both analyses highlight how important it is to carefully 








Figure 16. Box-Whisker plot analysis of neuromelanin-positive cells of PD and CO samples. (A) Box-
Whisker plots representing intracellular element concentrations for single patients (5-8 cells per patient; n = 4 
per group). Element concentrations are shown for Mn, Fe, Cu, Zn, As, Se and Br. (B) Box-Whisker plots of 
intracellular element concentrations grouped by categories PD (grey; n = 27 cells) and control (CO, blue, 
n = 26 cells). Element concentrations are shown for Mn, Fe, Cu, Zn, As, Se and Br. In both, (A) and (B) values 
of single cells are represented as red dots. Results of SSS / nANOVA are shown. # indicates marginal 
significance of p = 0.07. n.s.: not significant. Adapted with permission from (Joppe et al., 2020) © The Optical 
Society. 
 
In a k-means clustering approach, an unsupervised classification of each data point 
to their a priori known class (PD or CO) was aimed. Outlier showing an element 
concentration of less or more than the interquartile rage of the distribution were excluded 
from this analysis. Running a k-means algorithm for k = 2, only two labels were returned 
from the algorithm which were afterwards compared to the a priori known classes PD and 
CO. Merely, 65.5 % of the cases were classified with the correct label by the algorithm. 
Taken together, the prediction rate was negligible, since high intragroup variances 
disallowed unsupervised automated classification of groups (Figure 17).  
 
Table 6. Statistical tests used for the XRF analysis. Welch test was performed by using total cell counts as 
n per group (PD n = 27, CO n = 26). Bold numbers for Welch test highlight p-values below an α level of 5 %. 
Shapiro-Wilk (SW) test was used to test normality of the data. Normal distribution of data is shown in bold 
within the columns of SW(CO) and SW(PD). Both, the sufficient-summary-statistic approach (SSS) 
described in (Dowding and Haufe, 2018) as well as a nested ANOVA (nANOVA), compute p-values 
considering between-subject variance. Bold numbers indicate the element with the lowest p-value. Adapted 
with permission from (Joppe et al., 2020) © The Optical Society. 
Elements Welch test SW (CO) SW (PD) SSS nANOVA 
Mn 0.40 4.04e-10 1.71e-10 1.00 0.64 
Fe 0.25 1.14e-4 1.32e-10 0.82 0.42 
Cu 0.42e-4 6.20e-3 9.79e-1 0.07 0.07 
Zn 0.20 5.79e-3 2.00e-1 0.51 0.57 
As 0.28 9.94e-8 1.65e-3 0.96 0.45 
Se 0.35 1.67e-1 3.09e-3 0.26 0.34 






Figure 17. k-means clustering approach represented in two-dimensional plots. Seven spectral lines 
were used for the clustering algorithm. Outliers were excluded from further analyses. The algorithm was 
determined to output two labels (k = 2), which were finally compared to the a priori known classes (PD or 
CO). A solid black line indicates matching classes. Black stars indicate the two centroids which are linked 
with a solid black line stating the distance between both centroids. Merely 65.5 % of the datapoints were 
identified correctly by the algorithm (5-8 cells per patient; n = 4 per group). Adapted with permission from 
(Joppe et al., 2020) © The Optical Society. 
3.1.2 X-ray analysis of LBs in PD patients 
Since α-syn aggregation was found to be fostered by various trace elements and α-
syn is one of the major components within LBs in PD patients, XRF was used to analyze 
the elemental content of two LBs from two different patients. For this analysis, sections 
had to be mounted on Kapton foil since this foil allows immunohistochemical staining of 




from cutting neighboring sections of which one is stained and one can be measured with 
XRF. Microscopy-identified LBs were analyzed with XRF and XRD.  
In a first analysis, XRD scattering signal of one LB was compiled in a map. XRD 
was able to detect a signal that was likely a feature that is indicative of the LB (Figure 
18A,B). The averaged background signal was subtracted from the scattering data of the LB 
and the gathered signal was azimuthally integrated. In Figure 18C the scattering signal of 
all scan points is shown plotting the one-dimensional scattering intensity with the scattering 
vector. The scattering vector is defined as q = (4π/λ) sin(θ), where λ is the wavelength of 
the radiation and 2θ the scattering angle between the primary and scattered beam (Joppe et 
al., 2020). The feature of the LB exhibited a prominent intensity peak at 13.6 nm-1. This 
peak is characteristic for dried α-syn pellets but also for secondary structures of proteins as 
especially β-sheet structures. Therefore, it is still pending if α-syn crystals caused the 
scattering signal, in particular, since cells of a CO patient (in green) showed a similar 
diffraction curve with a similar peak as the LB (in blue). 
 
Figure 18. XRD analysis of a LB. (A) 
Microscopy image of a LB-containing 
neuromelanin-positive cell of a PD 
patient. LB is visualized by a new 
fuchsin staining and indicated by a red 
arrow. XRD-scanned region is indicated 
with a dashed square. (B) Visualization 
of XRD scattering intensity representing 
the LB. The background-subtracted one-
dimensional intensity is shown in this 
graph. (C) The q-distribution of 
scattering from the LB resembles the 
distribution of a cell from a CO patient 
(CO1). A prominent peak is observable 
at 13.6 nm-1, which is the scattering peak 
of dried α-syn pellets and also 
characteristic for a secondary structure 
of proteins, in particular β-sheets. Bgr: 
background, extra: extracellular, intra: 
intracellular. Adapted with permission 





Signal gathered from the XRF was analyzed to assess the chemical composition of 
the two measured LBs. For the first LB, which was already described in Figure 18, the main 
fluorescence signal resulted from bromine (Figure 19A,B). Other trace elements as iron, 
arsenic and selenium also correlated well with the feature of the LB whereas the distribution 
of copper anti-correlated with the LB feature. Low-Z elements as potassium and calcium 
were the primary element composition of small features appearing around the cell. In a 
second LB from another patient fluorescence signal from bromine was again highly 
localized with the feature of the LB (Figure 19C,D). The signal of bromine anti-correlated 
once again with the fluorescence signal of copper and it showed no correlation with other 
trace elements. Iron was distributed in the whole cell but rather slightly less in the LB. 
Therefore, both LBs showed quite diverse fluorescence signals of the different trace 





Figure 19. XRF analysis of two LBs. (A) Optical brightfield image of a stained LB (antibody recognizing 
α-syn) and a micrograph of the section recorded before XRF measurements. The LB is marked by a red 
arrow. The black dashed square in the image of the on-axis microscope indicates the XRF scanned region. 
(B) XRF maps of a LB shown in (A). LB is marked with a dashed circle. (C) A LB from another PD 
sample indicated in an optical brightfield image and in a micrograph recorded before XRF measurements. 
The LB is marked by a red arrow. The black dashed square in the image of the on-axis microscope indicates 
the XRF scanned region. (D) XRF maps of a LB shown in (C). LB is marked with a dashed circle. Adapted 




3.1.3 Increased cholesterol levels in human midbrain tissue of PD patients 
A previous X-ray-based study of our work group found increased amounts of 
cholesterol crystallites within PD tissue compared to a MS patient measured by XRD 
(Carboni et al., 2017b). Since this study only compared one PD and one MS patient, a 
verification of these results was intended using a higher sample size and a different 
technique for a well-established quantification of cholesterol. A biochemical lipid 
extraction of human midbrain tissue was performed to assess the cholesterol content 
(Figure 20A). The analysis was performed in collaboration with the Department for Plant 
Biochemistry, Göttingen, Germany. In this analysis, MS and cancer patients were included 
in the CO group. Midbrain tissue of PD patients (0.34 ± 0.07 µmol/mg) showed increased 
cholesterol amounts compared to CO samples (0.18 ± 0.04 µmol/mg). Group comparison 
analysis (Student’s t-test) revealed a trend to statistical significance (p = 0.057; Figure 
20B).  
 
Figure 20. Quantification of 
cholesterol in human 
midbrain tissue of PD and 
CO samples. (A) 
Experimental procedure. Three 
tissue pieces of ca. 30 mg each 
were cut to have biological 
replicates for the following 
lipid extraction. Afterwards, 
cholesterol amounts were 
quantified using GC-MS. (B) 
The scatter plot shows 
cholesterol amounts 
(µmol/mg) of human midbrain 
samples from PD (n = 9) and 
controls (n = 10). Data given 
as mean ± SEM. Student’s t-




3.2 The interplay of iron and α-syn in vivo 
The present study aimed to elucidate if neonatal iron treatment could alter the effect 
of intrastriatal α-syn PFFs injections on behavior and PFFs-induced spreading of the α-syn 
pathology in C57BL/6J mice. The animals were treated with iron between p10 and p17 and 
received a stereotactic intrastriatal injection of either monomeric α-syn or PFFs at an age 
of approximately 12 weeks. Animals which were treated with the vehicle solution instead 
of iron are stated as control group and in figures abbreviated as ctrl in following chapters. 
The first part of this chapter focuses on the investigation of iron load in mouse brain 
sections and on the effects of iron and α-syn PFFs on the living animals in terms of 
treatment-related behavioral abnormalities. Other subchapters are dealing with analyses on 
mouse brain sections investigating α-syn spreading and its distribution through the brain as 
well as accumulation of immune cells.  
3.2.1 Quantification of iron in an iron intoxication mouse model 
Aiming to verify whether neonatal iron treatment per gavage leads to iron enrichment 
inside the adult mouse brain, two different analyses were used to assess iron load. In a first 
attempt, hyphenated ICP spectrometry was used to determine the iron amount in whole 
mouse brains. Therefore, mice were treated with different dosages of iron (60 mg/kg Fe, 
120 mg/kg Fe, 240 mg/kg Fe) or sorbitol as control and were sacrificed at six months of 
age (Figure 21A). The analysis was performed by Prof. Dr. Bernhard Michalke (Helmholtz 
Institute, Munich, Germany). The analysis showed that the iron amount in whole brains of 
vehicle-treated mice (65.70 ± 1.74 mg/kg Fe), 60 mg/kg Fe (66.57 ± 1.04 mg/kg Fe), 
120 mg/kg Fe (68.24 ± 3.34 mg/kg Fe) and 240 mg/kg Fe-treated mice 





Figure 21. Hyphenated ICP spectrometry analysis of brain tissue from iron-treated mice. (A) 
Experimental layout. C57BL/6J mice were treated with carbonyl iron (p10-17) and sacrificed at 6 months 
of age. (B) ICP spectrometric analysis of iron (mg/kg) measured in tissue from mice treated with different 
iron dosages (60 mg/kg, 120 mg/kg, 240 mg/kg) or 5 % sorbitol as control. Data given as mean ± SEM; 
60 mg/kg Fe n = 6, other groups n = 5; one-way ANOVA. 
 
Since similar studies of neonatal iron feeding verified iron enrichment specifically 
within the SN (Billings et al., 2016; Kaur et al., 2007), in another experiment, cryofixed 
mouse brains sections were freeze-dried and, subsequently, the iron amount (µg/g) in the 
SN on single sections was analyzed with XRF (Figure 22A). The XRF analysis was 
performed by Prof. Dr. Katarina Vogel-Mikuš (Faculty of Biology, University of Ljubljana, 
Slovenia) at the Elettra Synchrotron in Trieste, Italy. 
Photographs and XRF-based heat maps of one exemplary brain section of an iron-
treated and an untreated control animal are shown in Figure 22B,C. The analyzed SN-
containing areas are indicated within the exemplary sections as rectangles (Figure 22B,C). 
Compared to untreated control animals, mice treated with 60 mg/kg Fe or 120 mg/kg Fe 
showed increased iron amounts within the SN (Figure 22D). However, due to the inferior 





Figure 22. XRF-based iron analysis of iron-treated mice. (A) Experimental procedure. Iron-treated 
C57BL/6J mice were sacrificed at six months of age. Brains were separated and cryofixed. 30 µm thick 
brain sections were freeze-dried and then analyzed by XRF. (B) A photomicrograph and a X-ray-based 
iron heatmap of an exemplary nigral brain section of an animal treated with 120 mg/kg Fe. Rectangle 
indicates SN region in which iron was quantified. (C) A photomicrograph and a X-ray-based iron heatmap 
of an exemplary nigral brain section of a control animal. Rectangle indicates SN region in which iron was 
quantified. (D) XRF results within the SN of control mice as well as iron-treated animals (60mg/kg or 








3.2.2 The influence of iron and α-syn on motor and cognitive behavior 
To investigate the effects of iron treatment and α-syn PFFs injections on motor and 
cognitive behavior, mice performed the rotarod test and NOR test. All animals performed 
the rotarod weekly between day of α-syn injection (doi) and sacrifice and the NOR test 
twice – directly before the doi to investigate single iron effects and directly before sacrifice 
to investigate mutual effects of iron and α-syn PFFs on cognition (Figure 23A).  
 
Figure 23. Experimental layout and motor behavior of iron- and α-syn-treated mice. (A) 
Experimental layout. C57BL/6J mice were treated with carbonyl iron between postnatal day 10 and 17 and 
were injected with α-syn at ca. 3 months of age. Rotarod was performed weekly and NOR test was 
performed twice. (B) Results of the weekly performed rotarod test starting 10 weeks before sacrifice. The 
graph shows the averaged mouse performance per treatment group (n = 6-8 per group) over time. The 
vehicle-treated control group is labeled as ctrl. Data given as mean ± SEM, one-way ANOVA with 
repeated measures. 
 
To get stability in the mouse performance on the rod, the mice were pre-trained on 
the rotarod before the first test run. Rotarod results are demonstrated in Figure 23B. All 
animals showed inconsistent performances on the rotarod over time, evidenced by the 
significant changes in the means of the repeated measures over time (variable ‘time in 
weeks’; comparing means of the different time points; **p < 0.01; ANOVA with repeated 
measures). Joint and separate effects of the two treatment variables ‘iron treatment’ and ‘α-
syn injection’ were analyzed considering both variables as separate between-subjects 
factors within the ANOVA with repeated measures. Neither the combination of iron × time 
(p = 0.180), nor α-syn × time (p = 0.622), nor the interaction effect of iron × α-syn × time 
(p = 0.786) showed significant results within the ANOVA with repeated measures. Since 
the Mauchly-test for sphericity turned out significant for this analysis, the reported p-values 




that homoscedasticity measured by the Levene test is not true for the time points ‘8 and 7 
weeks before sacrifice’. In conclusion, the treatment groups did not show significant 
differences in their motor behavior measured by the rotarod test.  
To investigate the influence of iron and PFFs on cognitive behavior, the NOR test 
was used. Both STM and LTM were tested by modifying the timeframe between 
habituation and experimental phase (10 min vs. 24 h). Based on the interaction of the mouse 
with the novel and the familiar object a discrimination ratio was calculated as described 
beforehand (Bevins and Besheer, 2006; Tatenhorst et al., 2016) and compared between the 
treatment groups to assess the memory function. Data gathered at the STM time point 
meaning 10 min post habituation are shown in Figure 24. In order to assess the general 
mobility of the mice 10 min post habituation, the distance moved within the arena (in cm) 
was analyzed for both timepoints – before injection and before sacrifice of the mice. Since 
data of the 60mg/kg iron group were not normally distributed (Shapiro-Wilk test) at the 
timepoint before α-syn injection (Figure 24B), Kruskal-Wallis test was performed between 
all four iron groups, turning significant but without any significant pairwise group 
comparisons (Kruskal-Wallis test with Dunn’s post hoc test). Before sacrifice (Figure 24C), 
mice from the different treatment groups were also equally agile (two-way ANOVA).  
The NOR performed before α-syn injection revealed no significant STM difference 
between iron treatment groups (Figure 24D; one-way ANOVA). At 90 dpi, neither a 
significant interaction effect of iron × α-syn on STM nor a main effect of the separate 
treatment conditions was found (Figure 24E; two-way ANOVA, Levene test significant). 
Since the Levene test results showed that the requirement of homoscedasticity was not 
fulfilled for the latter analysis, treatment conditions of iron and α-syn were grouped. 
Subsequently, one-way Welch-ANOVA with Games-Howell post hoc test was performed, 
respectively, which also did not show significant difference between the groups. 
Data gathered at 24 h post habituation are shown in Figure 25. The mobility of mice 
at 24 h post habituation was analyzed for both recorded time points. Before α-syn injection 
(Figure 25B), iron treatment groups significantly differed in their mobility. Mice of the 
240 mg/kg iron group were significantly less mobile compared to both the 120 mg/kg iron 
group (*p < 0.05) and the 60 mg/kg iron group (**p < 0.01; one-way ANOVA with 
Tuckey’s post hoc test). No significant differences in the distance moved were found at the 





Figure 24. STM analysis of iron- and α-syn-treated mice. (A) Experimental procedure of the NOR. 
C57BL/6J mice were habituated to two identical objects for 5 min. After a 10 min break within the familiar 
cage, the STM was recorded while presenting one old/familiar (O) and one novel (N) object. (B,C) The 
distance moved was analyzed as an indicator of mobility at two time points – (B) before α-syn injection 
(n = 22-29) or (C) at 90 dpi (n = 8-14 per group). (D) STM performance of iron-treated mice before α-syn 
injection (n = 21-22). (E) STM analysis performed at 90 dpi. Two single graphs display the main effects 
of the two single variables – iron treatment and α-syn injection. Another graph shows the combined effects 
of iron and α-syn treatments (n = 8-13 per group). Data are shown as mean ± SEM, One-way and two-way 
ANOVA as well as Kruskal-Wallis test. Low, middle and high iron dosage (60, 120 and 240 mg/kg Fe) 
are indicated in graphs as iron-triangle. 
 
The analysis of LTM showed that before α-syn injection mice treated with 240 mg/kg 
iron performed significantly worse in the NOR compared to mice of the 60 mg/kg iron 
group (Figure 25D; *p < 0.05; due to significant Shapiro-Wilk test the Kruskal-Wallis test 
with Dunn’s post hoc test was used). LTM results showed no interaction effect of both 
variables iron × α-syn and also no main effect of the iron treatment at 90 dpi. However, a 




injected animals performed significantly worse in LTM compared to monomer-injected 
ones (Figure 25E; two-way ANOVA, *p < 0.05).  
 
Figure 25. LTM analysis of iron- and α-syn-treated mice. (A) Experimental procedure of the NOR. 
24 h after a habituation phase with two identical objects, LTM was analyzed while presenting one old (O) 
and one novel (N) object. (B,C) The distance moved was analyzed at two time points – (B) before α-syn 
injection (n = 22-29) and (C) at 90 dpi (n = 8-14). (D) LTM performance of iron-treated mice before α-
syn injection (n = 21-22). (E) LTM analysis at 90 dpi. Two single graphs display the main effects of the 
two independent treatment variables (iron and α-syn). Another graph shows the combined effects of iron 
and α-syn treatments (n = 8-13 per group). Data are presented as mean ± SEM. One-way and two-way 
ANOVA with Tuckey’s post hoc test as well as Kruskal-Wallis test. Low, middle and high iron dosage 
(60, 120 and 240 mg/kg Fe) are indicated in graphs as iron-triangle. 
 
Taken together, iron-treatment had a significant effect on LTM of mice before α-syn 
injection, whereas α-syn PFFs treatment affected LTM at 90 dpi. No interaction effect of 
iron and α-syn treatment was found on LTM or STM. Before α-syn injection, recordings at 
24 h post habituation revealed significant differences between iron treatment groups in the 




3.2.3 The influence of iron on α-syn spreading 
A major aim of this study was to investigate if postnatal iron feeding had an impact 
on α-syn spreading pathology. Therefore, six coronal brain sections were analyzed, which 
were stained with an antibody recognizing aggregated α-syn (anti-α-syn phospho S129 
antibody, EP1536Y). First, the amount of pS129-α-syn was quantitatively analyzed to 
determine iron-induced effects on α-syn spreading. The results of a semi-automated pS129-
α-syn quantification in whole brain sections are demonstrated in the following subchapter 
3.2.3.1. A second analysis method was used to assess the pS129-α-syn amounts in specific 
brain regions per section. Manually, the affected brain regions were marked, and it was 
assessed in which brain regions iron caused altered spreading pathology. These 
distributional effects are shown in subchapter 3.2.3.2. 
3.2.3.1 Quantitative analysis of α-syn spreading – iron reduced α-syn spreading 
For a quantitative analysis of α-syn spreading in mouse brains after iron and PFFs 
treatment, pS129-α-syn signal was evaluated in six different coronal brain sections named 
after their coordinates relative to Bregma. α-syn signal was calculated within the ROI which 
was either the injected or contralateral hemisphere by relativizing the signal area to the total 
analyzed area. Within the injected hemisphere of all six brain sections, α-syn monomer-
injected mice showed almost no signal (Figure 26A-F), an expected result due to the 
specificity of the applied antibody to aggregated forms. For that reason, the monomer-
injected animals were used as internal controls. Statistical analyses were only performed 
on basis of the four different iron-treated PFFs groups (ctrl/PFFs, 60 mg/kg Fe/PFFs, 
120 mg/kg Fe/PFFs, 240 mg/kg Fe/PFFs), not comparing PFFs and monomer groups. 
Animals of the ctrl/PFFs group were treated with vehicle instead of iron. 
PFFs-injected groups showed signal in all six sections. Four out of six rostral brain 
sections contained parts of the striatum which was the injected brain region. Even if the 
iron-free control group always showed a higher average on α-syn signal compared to the 
iron conditions, these differences did not reach significance in all four striatal sections 
(Figure 26A-D). The two caudal SN-containing sections exhibited more prominent group 
differences (Figure 26E-F). However, only the most caudal section (Figure 26F) showed a 
significant difference between the control and the high-dosed iron group (*p < 0.05; 





Figure 26. Threshold-based quantification of α-syn at the injected hemisphere of single sections. At 90 
dpi, immunostained (pS129-α-syn) brain sections were analyzed with the particle analysis tool of the software 
ImageJ. All six sections were selected based on the Paxinos mouse brain atlas (Paxinos and Franklin, 2003). 
(A-F) Scatter plots are used representing α-syn signal of each mouse per group (one data point = one mouse). 
The following sections were evaluated: (A) Bregma 1.54 mm (n = 5-8), (B) Bregma 0.38 mm as the injectional 
plane (n = 5-7), (C) Bregma 0.02 mm (n = 6-8), (D) Bregma -1.58 mm (n = 6-8), (E) Bregma -3.08 mm (n = 6-
7) and (F) Bregma -3.28 mm (n = 5-8). Low, middle and high iron dosage (60, 120 and 240 mg/kg Fe) are 
indicated in graphs as iron-triangle. The indicated control group (ctrl) was treated with the vehicle solution 




Furthermore, a signal average of all available brain sections per mouse was calculated 
separately for signal in both, the contralateral (Figure 27A) and ipsilateral hemisphere 
(Figure 27B). At the contralateral hemisphere no significant group differences were 
observed. At the injected hemisphere, the crtl/PFFs group showed significantly higher 
pS129-α-syn signal amounts compared to the 240 mg/kg iron group (*p < 0.05). In total, 
the α-syn amounts at the contralateral hemisphere were markedly lower compared to signal 
at the injected hemisphere of PFFs-injected mice. 
 
 
Figure 27. Averaged α-syn signal within both the injected and the contralateral hemisphere of iron- 
and PFFs-treated mice. Threshold-based α-syn signal analysis of immunostained (pS129-α-syn) brain 
sections at 90 dpi. An average of α-syn signal in four to six brain sections was calculated per mouse (n = 6-
8). The averaged α-syn signal per mouse is shown individually for both (A) the contralateral hemisphere 
and (B) ipsilateral hemisphere. Each data point within the scatter plots represents the α-syn signal of one 
evaluated mouse per group. Low, middle and high iron dosage (60, 120 and 240 mg/kg Fe) are indicated 
in graphs as iron-triangle. The indicated control group (ctrl) was treated with the vehicle solution instead 
of iron. Data are presented as mean ± SEM; Kruskal-Wallis test with Dunn’s post hoc test. 
 
Figure 28 shows pS129-α-syn signal at the contralateral hemisphere of all six 
individual sections. No significant differences between the four iron-treated PFFs groups 
were found. Taken together, α-syn pathology spread stronger to the injected than to the 
contralateral hemisphere and iron-treatment dose-dependently reduced α-syn amounts 






Figure 28. Threshold-based quantification of α-syn at the contralateral hemisphere of single sections. 
Threshold-based α-syn signal analysis of immunostained (pS129-α-syn) brain sections at 90 dpi. The 
following sections were evaluated: (A) Bregma 1.54 mm (n = 5-8), (B) Bregma 0.38 mm as the injectional 
plane (n = 5-7), (C) Bregma 0.02 mm (n = 6-8), (D) Bregma -1.58 mm (n = 6-8), (E) Bregma -3.08 mm (n = 6-
7) and (F) Bregma -3.28 mm (n = 5-8). Low, middle and high iron dosage (60, 120 and 240 mg/kg Fe) are 
indicated in graphs as iron-triangle. The indicated control group (ctrl) was treated with the vehicle solution 




3.2.3.2 Qualitative analysis of α-syn spreading to specific brain regions  
For a distributional analysis of α-syn clustering in brain regions, pS129-α-syn signal 
was rated per region with a 5-stage scale (−, +, ++, +++, ++++) and visualized in spreading 
maps (Figure 29). The darker the color in the heat maps the more signal was found within 
the brain regions. Spreading maps were only generated for PFFs-injected mice of the 
control group which was treated with vehicle and of the highest iron dosage group 
(240 mg/kg Fe), since this iron group showed the strongest effects on pS129-α-syn 
quantification demonstrated in chapter 3.2.3.1. This rating approach served as a rough 
region-specific quantification to assess the α-syn amount in brain regions and was rather 
used to focus differences in the distribution. Differences in the pathology stages between 
the groups, e.g. + vs. ++ pathology, do not imply statistical significance. In this concrete 
example, the difference in a specific brain region states that on average the α-syn pathology 
was rated one level higher in mice of one group compared to the other group. Thereby the 
maps represent trends of pathological differences between groups. A statistical analysis of 
group means per region is mentioned after the following description of the pathology maps. 
The pS129-α-syn spreading maps of both groups show that mostly the same brain 
regions were affected but with distinct differences in the quantity of aggregated α-syn. The 
rating approach revealed that PFFs-injected mice with vehicle treatment showed more 
regions with strong α-syn pathology (+++ or ++++). Group rating differences are visualized 
in subtraction heat maps (Figure 29). 
High α-syn pathology discrepancy between the two analyzed groups in specific 
regions with at least two level of distance (e.g. + vs. +++) were observed at the injected 
hemisphere within the cingulate cortex area 1, the primary motor cortex, perirhinal cortex, 
lateral amygdaloid nucleus, stria terminalis and the amygdalohippocampal area. Within the 
mentioned brain regions, the control group showed more pronounced pathology. At the 
contralateral hemisphere, such a distinct difference in pathology was only seen in the 
agranular insular area of the cortex showing stronger α-syn pathology for iron-treated mice. 
In other brain regions which showed an α-syn increase in iron-treated mice only one rating 
level distance between pathology in iron-treated mice and pathology in vehicle-treated mice 
was observed such as – vs. + or + vs. ++. The case that in some regions α-syn pathology 




the contralateral hemisphere than on the injected hemisphere (Figure 29). As stated above, 
the mentioned group differences do not represent statistically significant differences.  
 
Figure 29. Heat maps representing the distribution of pS129-α-syn in six coronal brain sections. The 
first two columns of heat maps represent pS129-α-syn signal of iron-treated (240 mg/kg Fe) or vehicle-
treated (ctrl) PFF-injected mice, respectively, at 90 dpi. Pathology in brain regions was graded with a 5-
stage scale as follows: ‘−‘ no positive structures, ‘+’ few (some positive structures), ‘++’ mild (more 
positive structures), ‘+++’ moderate (many positive structures covering a widespread part of the brain 
region), ‘++++’ severe (almost the whole brain region is covered with α-syn signal). For each brain region, 
the average per treatment group was calculated (n = 5-8 per group) and a color code was assigned to the 
scale. In the third column, signal subtraction heat maps comparing both treatment groups are shown. 
Therefore, signal stages of the control group were subtracted from the iron group meaning that equal signal 
stages were rated as 0 and represented in white. More α-syn pathology for iron animals is shown in green, 




For a statistical analysis, the Mann-Whitney-U-test was performed. The p-values as 
well as the group means and SEM values per evaluated brain region are listed in Suppl. 
Table 1 to Suppl. Table 6. Due to the low sample size and high variability in the α-syn 
pathology per group, statistical significance is rarely found in the individual brain regions. 
Associated to the subtraction heat map, a fourfold table summarizes the number of 
brain regions in which more α-syn signal was either found in iron-treated mice or in the 
vehicle-treated mice (Table 7). At the injected hemisphere, PFFs-injected control-treated 
mice exhibited more α-syn in a greater number of regions. The Fisher’s exact test of this 
2 × 2 contingency table shows a significant result (p = 0.0186) indicating the influence of 
iron on α-syn pathology. 
Table 7. Fourfold table associated to the subtraction heatmap of α-syn pathology in iron-treated PFFs-
injected mice. The quantity of brain regions is described which show more α-syn in PFFs-injected mice 
treated with either iron or vehicle (ctrl group). Fisher’s exact test indicates a significant difference (*p < 0.05). 
 Regions with more α-syn in the ctrl group 
Regions with more α-syn 
in the iron group 
Injected hemisphere 60 25 
Contralateral hemisphere 26 26 
 
3.2.3.3 Connectivity analysis of α-syn spreading 
This chapter is associated to the results presented in chapter 3.2.3.2. Accordingly, α-
syn signal was rated per brain region in six different brain sections using a 5-stage scale 
ranging from 0 = no pS129-α-syn signal to 4 = severe α-syn pathology. We aimed to further 
analyze differences of PFFs-injected mice treated with either iron or vehicle in the α-syn 
spreading to anatomically connected regions (Figure 30). Two intrastriatal injection sites 
described in the Allen Mouse Brain Connectivity Atlas (Oh et al., 2014) (©2020 Allen 
Institute for Brain Science. Allen Mouse Brain Connectivity Atlas, available from: 
https://connectivity.brain-map.org/) were used as described in chapter 2.2.5.1.3 to define 
the connectome of the injection site of the current experiment. Figure 30C displays all 
connectome-specific brain areas in the six evaluated brain sections. Afterwards, the 
connectivity maps were overlaid with the α-syn spreading maps and the subtraction heat 
map to indicate which group shows stronger spreading to areas anatomically connected to 










Figure 30. PS129-α-syn pathology in anatomically connected brain areas. (A) Striatal injection site of 
the current experiment. The circle indicates the injection radius according to injected volume of PFFs. (B) 
Serial two-photon tomography illustrations of the Allen Brain Atlas connectivity platform (©2020 Allen 
Institute for Brain Science. Allen Mouse Brain Connectivity Atlas, available from: 
https://connectivity.brain-map.org/) containing two intrastriatal injection sites which are marked with a red 
hair cross. The injection sites of two experiments (Exp. 158916311: https://connectivity.brain-
map.org/projection/experiment/158916311; Exp. 100142580: https://connectivity.brain-
map.org/projection/experiment/100142580) are located within the injection radius of the current 
experiment. (C-E) Illustration of six sectional planes assigned to the Bregma levels which are described in 
Figure 29. (C) Maps of six brain sections showing the connectivity (based on ©2020 Allen Institute for 
Brain Science. Allen Mouse Brain Connectivity Atlas) of brain regions to the injection site of the current 
study. EGPF spreading signal of both experiments mentioned in (B) were combined to illustrate the 
connectivity in the current study. (D) Pathology maps of pS129-α-syn as shown in Figure 29. Stars 
highlight regions connected to the injection site according to the Allen Brain Connectivity Atlas as 
illustrated in (C). (E) Signal subtraction heat maps as shown in Figure 29. Stars highlight regions connected 
to the injection site according to the Allen Brain Connectivity Atlas as illustrated in (C). 
 
Interestingly, in both groups α-syn spread to most regions of the connectivity maps, 
but also to several other brain regions. The fourfold table (Table 8) gives an overview on 
how many connectome-specific and other areas were affected by α-syn pathology. 
Accordingly, the vehicle-treated mice showed more connectome-specific brain areas with 
α-syn pathology compared to the iron group and less unspecific brain regions affected by 
α-syn compared to the iron group. However, the Fisher’s exact test of this 2 × 2 contingency 
table shows no significant association of the groups and the two outputs (connectome-
specific vs. other brain areas; p = 0.3636). 
 
Table 8. Fourfold table associated to the connectivity heat maps. The quantity of connectome-specific 
and other brain regions with α-syn pathology are described for PFFs-injected mice treated with either iron or 
vehicle (ctrl group). Fisher’s exact test not significant (p = 0.3636). 
 Fe group Ctrl group 
Connectome-specific brain 
areas with α-syn signal 66 75 
Other brain areas with α-





For a more detailed analysis on the α-syn amounts in the connectome-specific and 
other brain areas, in Figure 31 the α-syn rating average per brain area is shown which 
correspond to the means listed in Suppl. Table 1 – Suppl. Table 6. In Figure 31A, all 
connectome-specific brain regions were included (n) in which at least one of both groups 
detected pS129-α-syn signal. The data show significantly higher amounts of α-syn signal 
in connectome-specific brain areas for the control group. In connectome-independent brain 
areas no significant difference was found between both groups (Figure 31B). 
 
Figure 31. Averaged pS129-α-syn pathology rating in connectome-specific and other brain regions. 
The data are related to the 5-stage rating scale used in Figure 29 and represent pS129-α-syn affected brain 
regions in both contralateral and injected hemisphere. All brain regions were included in which at least 
one group showed α-syn signal. (A) A comparison of the averaged α-syn pathology ratings in connectome-
specific brain regions (n = 78 brain areas) of PFFs-injected mice treated with either iron or vehicle as 
control (ctrl). The graph is related to the data in Figure 30. (B) A comparison of the averaged α-syn 
pathology ratings in other brain regions (n = 198 brain areas) outside the connectome of PFFs-injected 
mice treated with either iron or vehicle as control (ctrl). The graph is related to the data in Figure 30. Mann-
Whitney-U test. Mean ± SEM; *p < 0.05; #p < 0.1. 
 
3.2.4 Iron-induced effects on the accumulation of immune cells 
After demonstrating that iron-treatment resulted in an altered distribution of pS129-
α-syn, the present analyses aimed to elucidate if iron also influenced inflammatory 
responses inside the brain which could contribute to changes in α-syn spreading pathology. 
Therefore, brain sections were used to analyze microglia and T cell amounts within the 
striatum as injection site and the SN as a known iron-enriched brain region of iron-treated 
animals. For the microglia analysis, immunolabeled CD11b+ cells were quantified (Figure 






Figure 32. Analysis of CD11b+ microglia in striatal sections of iron- and α-syn-treated mice. 
Immunostained brain sections of 30 µm thickness were analyzed. CD11b signal is shown in brown due to 
a DAB reaction and cells are shown in blue (Hematoxylin staining). (A) Micrographs of CD11b+ cells 
from mice treated with vehicle or 240 mg/kg Fe are shown. A close-up image is shown in the right corner 
of each micrograph. Scale bar 20 µm. (B-D) In brain sections containing (B) anterior (n = 6-7), (C) middle 
(60mg/kg Fe/PFFs n = 4; other groups n = 6-7) and (D) posterior (n = 5-7) striatum CD11b+ microglia of 
iron- and α-syn-treated C57BL/6J mice were quantified. Data of the injected hemisphere is shown. (E,F) 
Microglia counts were averaged over the three evaluated striatal sections. Data of (E) the injected 
hemisphere (all groups n = 7) and (F) the contralateral hemisphere (all groups n = 7) are shown separately. 





First, the intrastriatal microglia accumulation at the injected hemisphere of the 
analyzed sections is described. Mice of the ctrl/PFFs or ctrl/monomer group were treated 
with vehicle instead of iron. At the anterior striatum, microglia numbers of the vehicle/PFFs 
group did not significantly differ from the monomer-injected groups (vehicle/monomer and 
240 mg/kg Fe/monomer). Compared to the 60 mg/kg Fe/PFFs and 120 mg/kg Fe/PFFs 
group, the vehicle/PFFs group showed no significant changes in the microglia number, but 
a significant increase was observed compared to the highest iron dosage group 
(240 mg/kg Fe/PFFs; p < 0.01; Figure 32B). At the middle striatum, microglia 
accumulation was significantly increased in the vehicle/PFFs groups compared to the 
vehicle/monomer group (p < 0.05; Figure 32C). All of the three iron dosages in 
combination with PFFs injections showed unaltered microglia accumulation compared to 
the vehicle/PFFs and to the monomer-injected groups. At the posterior striatum, the 
microglia number of the vehicle/PFFs group did not differ significantly from the 
vehicle/monomer group. The vehicle/PFFs group showed also no microglia number 
changes compared to the 60 mg/kg Fe/PFFs group, however, it showed a significant 
increase of microglia compared to the 120 mg/kg Fe/PFFs and the 240 mg/kg Fe/PFFs 
group (p < 0.05; Figure 32D). 
Furthermore, an average of the microglia number within the injected hemisphere of 
all three sections was calculated. The vehicle/PFFs group showed a significant increase in 
microglia compared to both monomer-injected groups (vehicle/monomer; 
240 mg/kg Fe/monomer; p < 0.05). No difference was found between the vehicle/PFFs and 
60 mg/kg Fe/PFFs group. However, the microglia number of the vehicle/PFFs group was 
significantly increased compared to the 120 mg/kg Fe/PFFs and 240 mg/kg Fe/PFFs group 
(p < 0.01; Figure 32E). In addition to striatal sections, one SN section (part of the middle 
SN) was analyzed. All analyzed groups did not differ in the nigral microglia number at the 
injected hemisphere of this section (Figure 33A). 
Second, the contralateral hemisphere of all sections was analyzed regarding the 
microglia accumulation in striatum and SN. An average of the microglia number of all three 
sections was calculated. The vehicle/PFFs group showed a significant microglia increase 
compared to the vehicle/monomer group (p < 0.05) as well as to the 60 mg/kg Fe/PFFs 
(p < 0.05) and 240 mg/kg Fe/PFFs group (p < 0.01). No significant difference was 








Figure 33. Analysis of CD11b+ cells in a nigral section of iron- and α-syn-treated mice. CD11b+ cells 
in one SN section were analyzed separately for the (A) ipsilateral and (B) contralateral hemisphere (n = 6-
7). Data given as mean ± SEM. One-way ANOVA. 
 
Since T cells also play an important role in the immune response infiltrating the brain 
(Brochard et al., 2009; González et al., 2013; Kurkowska-Jastrzebska et al., 1999), mouse 
brain sections were immunolabeled for the T cell marker CD3 (Figure 34A). As for the 
microglia analysis, CD3+ cells were quantified within three striatal sections (Figure 34B-
D). Within the injected hemisphere of single sections, no significant differences in T cell 
amounts were found between the different treatment groups. Taking the average of the T 
cell counts per mouse over the three sections, no significant group differences were 






Figure 34. CD3+ T cell analysis in striatal sections of iron- and α-syn-treated mice. Brain sections 
were immunolabeled for CD3 and DAPI. Scale bar 20 µm. (A) Exemplary image of an immunostained 
CD3+ T cell indicated with an arrow. Scale bar 20 µm. At the ipsilateral hemisphere, T cell quantification 
is shown within the following striatal sections: (B) anterior, (C) middle and (D) posterior striatum. (E,F) 
Averaged T cell amounts within the striatum (E) at the injected hemisphere and (F) at the contralateral 







Only one sectional plane of the SN was analyzed regarding T cell numbers, but no 
significant iron- or PFFs-induced effect was found (Figure 35). For all mentioned T cell 
analyses Kruskal-Wallis test was used. 
 
 
Figure 35. T cell analysis in a nigral section of iron- and α-syn-treated mice. T cell quantification in 







3.3 The influence of iron on the α-syn pathology in vitro 
After demonstrating the effect of iron on α-syn pathology in the brain of C57BL/6J 
mice, the present analysis aimed to elucidate if iron also influences α-syn transmission in 
cortex neurons obtained from E 18.5 wild-type mouse embryos. To establish the iron-
treatment paradigm in cortex cultures, cells were treated with different concentrations of 
iron and afterwards stained for iron by means of a Prussian blue staining to assess the iron 
load in cultures. To exclude iron-induced toxicity, a ToxiLight assay was used. Iron-
mediated alterations of α-syn spreading in vitro were analyzed in microfluidic chambers. 
To this, cells were treated with iron and α-syn PFFs or monomers.  
3.3.1 Iron treatment of cortex neurons 
To verify that iron treatment of cortex cultures indeed led to high amounts of iron in 
the culture, a Prussian blue staining combined with DAB staining was used to detect iron 
resulting in a brown color of the target. Microscopy images showed that the amount of iron 
is higher in cells treated with 100 µM iron compared to treatment with lower iron dosages 
(Figure 36A). 
In another experiment, iron-induced toxicity in cortex neurons at specific time points 
after treatment was analyzed (Figure 36B). A ToxiLight bioassay kit was used measuring 
the release of adenylate kinase from damaged cells. Cells were treated with 10, 50, 100 or 
200 µM iron. As a control, cells were treated with vehicle solution. To perform the assay, 
medium was collected directly before treatment (div2), at the end of the treatment (24 h 
post treatment start), at div7 and at div14. The statistical analysis revealed no significant 
cytotoxicity or dosage-dependent effects of iron at the different measurement timepoints 





Figure 36. Cytotoxicity in cortex neuron cultures following iron treatment. (A) Exemplary micrographs 
of cells stained for iron using a modified Prussian blue staining protocol. Cells were treated with 10, 50, 100 
or 200 µM Fe at div2 for 24h. The control cells were treated with vehicle. Arrowheads show large intracellular 
iron deposits; the arrow indicates smaller iron-positive puncta within a cell. NC: negative control. (B) 
ToxiLight analysis of cortex neurons treated with different iron concentrations at div2 for 24h. Cell medium 




3.3.2 Microfluidic chamber model – the influence of iron on α-syn spreading 
To analyze if iron affects the α-syn spreading following PFFs treatment in vitro, the 
microfluidic chamber model was used. Cortex neurons were seeded in one compartment of 
the chamber and treated with iron and α-syn PFFs at 2 d and 3 d post preparation, 
respectively (Figure 37A). At div7, freshly prepared cortex neurons were seeded in the 
secondary cell compartment. At div14, cells were fixed and stained with an antibody 






Figure 37. Experimental layout and exemplary micrographs of α-syn spreading signal in 
microfluidic chambers. (A) Experimental layout. Cells in microfluidic chambers were treated with iron 
and α-syn PFFs for 24 h each. (B) Exemplary micrographs of intracellular pS129-α-syn signal appearing 
in the secondary cell compartment. MAP2 was used as a neuronal marker. Scale bar 50 µm. (C) Exemplary 
micrograph of α-syn signal in axons at the secondary cell compartment. In this exemplary chamber no cells 
were seeded to the secondary cell compartment. The cells were treated with PFFs. Spread α-syn fibrils 
were only transferred via axons to the secondary cell compartment. Scale bar 100 µm. 
 
Immunocytochemical staining revealed the presence of pS129-α-syn in cell bodies 
and axons at the secondary cell compartment in PFFs conditions. No signal was observed 
in monomer- or PBS-treated cells (Figure 37B). To more clearly visualize the distribution 
of pS129-α-syn, in some chambers cells were only seeded in the primary cell compartment 
and neurites thereof grew to the secondary cell compartment (Figure 37C). The micrograph 
shows that the pS129 signal was exclusively located in neurites within the secondary cell 
compartment. This suggests that PFFs, uptaken by cells in the primary cell compartment, 
spread from the perikarya to the neurites and no extracellular PFFs were observed travelling 
independently through the grooves to the secondary cell compartment.  
The α-syn signal was quantified by a threshold-based method. Subtracting the signal 
results of the PBS-treated chambers, monomer-treated cells showed neglectable signal at 
the secondary cell compartment (Figure 38). A statistical analysis (Kruskal-Wallis test with 
3 determined Dunn’s post hoc comparisons: Fe/monomer vs. Fe/PFFs, vehicle/monomer 
vs. vehicle/PFFs, Fe/PFFs vs. vehicle/PFFs) revealed a significant difference of 
Fe/monomer-treated cells compared to Fe/PFFs-treated cells (*p < 0.05). With vehicle 
treatment, the PFFs condition also significantly differed from its monomer control group 
(*p < 0.05). Comparing α-syn PFFs conditions, no significant difference was found 
between iron-treated and vehicle-treated cortex neurons (Fe/PFFs 0.015 ± 0.0048 vs 
vehicle/PFFs 0.013 ± 0.0042). In summary, the α-syn spreading results indicate that iron 
treatment did not significantly influence the α-syn amounts spread to the secondary cell 





Figure 38. Quantification of pS129-α-syn 
signal in the secondary cell compartment of 
microfluidic chambers. Cells were 
immunolabeled for pS129-α-syn. The graph 
shows a quantification of α-syn signal within 
the secondary cell compartment of 
microfluidic chambers (average of 1-3 
chambers per culture, n of cultures = 5, each 
data point within the scatter plot represents 
one culture). Signal of all conditions was 
normalized to the respective PBS control. 
Kruskal-Wallis test with three selected 
Dunn’s post hoc comparisons; *p < 0.05. 
 
3.4 Therapeutic approach: The influence of fasudil on the α-syn 
pathology 
Finally, we aimed to elucidate if treatment with the ROCK inhibitor fasudil could 
affect α-syn spreading pathology in mice. Fasudil has previously been shown to reduce α-
syn aggregation in vitro and also in vivo using the A53T mouse model (Tatenhorst et al., 
2016). In the current study, mice were injected with α-syn PFFs or monomers. One PFFs-
injected group was treated with 30 mg fasudil /kg bw which was supplied via the drinking 
water, according to the previously published protocol (Tatenhorst et al., 2016) (Figure 
39A). Motor behavior from doi to sacrifice and neuron survival at 90 dpi were analyzed to 
assess the health status of PFFs-injected mice. Later, pS129-α-syn signal was quantified in 
multiple brain sections to assess if fasudil alters spreading pathology, described in chapter 
3.4.3. Therefore, two different quantification methods were used.  
3.4.1 Motor behavior analysis 
To determine if PFFs treatment induced changes in motor behavior, mice performed 
the rotarod test weekly between doi and sacrifice (Figure 39A). The treatment 
(monomer/vehicle, PFFs/vehicle, PFFs/fasudil) of the mice and the interaction of 
‘treatment × time’ did not significantly affect the performance on the rotating rod (Figure 




showed a significant influence, meaning that the time on the rod for the average of all 
animals changed over time (****p < 0.0001).  
 
Figure 39. Experimental layout and evaluation of motor behavior of α-syn PFFs-injected mice 
treated with fasudil. (A) Experimental layout. C57BL/6J mice were injected with α-syn PFFs or 
monomers at 3 months (3mo.) of age and one group of the PFF-injected animals was treated with fasudil 
via drinking water between injection day (doi) and sacrifice at 90 dpi. Rotarod was performed weekly. (B) 
Results of the weekly performed rotarod test starting 13 weeks before sacrifice. The graph shows the 
averaged performance of mice per treatment group (monomer/vehicle n = 8, other groups n = 10) over 
time. Data given as mean ± SEM, one-way ANOVA with repeated measures. 
3.4.2 Dopaminergic neuron survival 
In order to investigate effects of α-syn PFFs on neuronal loss in mice, TH+ neurons 
as well as Nissl+ neurons were stereologically quantified in nigral brain sections at 90 dpi. 
Nissl staining was used to identify the total neuron count in SNpc. At the ipsilateral 
hemisphere, α-syn PFFs-injected mice showed lower counts for TH+ neurons compared to 
monomer-injected mice but these results did not differ significantly (Figure 40A; 
monomer/vehicle 11232 ± 862.5; PFFs/vehicle 10016 ± 432.0; PFFs/fasudil 8858 ± 774.4 
cells). The same trend was observed in Nissl+ neurons in the injected hemisphere (Figure 
40B; monomer/vehicle 13282 ± 965.7; PFFs/vehicle 12133 ± 457.5; PFFs/fasudil 
10629 ± 905.1 cells). At the contralateral SNpc also no significant group differences were 
found, neither in the quantification of TH+ neurons (Figure 40C; monomer/vehicle 
11217 ± 852.7; PFFs/vehicle 11273 ± 592.6; PFFs/fasudil 10373 ± 558.3 cells) nor in 
Nissl+ neurons (Figure 40D; monomer/vehicle 13569 ± 959.2; PFFs/vehicle 





Figure 40. Quantification of nigral TH+ and Nissl+ neurons of mice injected with α-syn PFFs or 
monomers and treated with fasudil. TH+ and total (Nissl+) neuron count was analyzed at 90 dpi. (A,B) 
Stereological quantification of (A) TH+ and (B) Nissl+ neurons at the ipsilateral hemisphere. (C,D) 
Stereological quantification of (C) TH+ and (D) Nissl+ neurons at the contralateral hemisphere. Data 
shown as mean ± SEM; monomer/vehicle n = 7, PFFs/vehicle n = 9, PFFs/fasudil n = 9; one-way 
ANOVA. 
 
3.4.3 The effect of fasudil treatment on α-syn spreading in vivo 
A major aim of this study was to investigate if the ROCK inhibitor fasudil had a 
beneficial impact on α-syn spreading pathology. Therefore, six coronal brain sections were 
analyzed. Paxinos atlas coordinates (Paxinos and Franklin, 2003) are described in chapter 
3.2.3.1. The sections were stained with an antibody recognizing α-syn fibrils (pS129). The 
pS129-α-syn amounts were quantitatively analyzed using two approaches – manual 




3.4.3.1 Manual quantification of α-syn 
In a manual quantification approach, pS129-α-syn immunostained sections were 
covered with a grid (150 µm × 150 µm per grid box) and analyzed as described in the 
according method chapter 2.2.5.1.1. The signal was rated per grid box using a color code 
grading system corresponding to low, medium and high signal amounts, respectively: 
yellow = 1-5 α-syn structures, orange = 6-10 α-syn structures, red = > 10 α-syn structures 
per box.  
In a first analysis, it was aimed to describe how much area of each brain section was 
generally affected (independent on the pS129 α-syn quantity evaluated in each counted 
box). Therefore, a sum of all rated boxes (boxes with low, medium, high signal amounts) 
in the contralateral or the injected hemisphere was calculated individually for each section 
and relativized to the total box number of the corresponding hemisphere to obtain a 
percentage (%). The monomer control group did not show pS129-α-syn signal in any of the 
analyzed sections, neither in the injected nor in the contralateral hemisphere (Figure 
41A,B). In all sections, PFFs-injected mice and PFFs-injected mice with fasudil treatment 
showed no significant differences in the total area affected by α-syn analyzing both 
hemispheres separately. In a next step, the signal output of all six sections demonstrated in 
Figure 41A was averaged per group. These results of the injected hemisphere are shown in 
Figure 41 C,D. The size of the affected area averaged over all sections (injected 
hemisphere) did not differ between the groups (Figure 41D).  
Comparing the averaged usage of the three different rating stages (low, medium and 
strong signal) between both PFFs-treatment groups, no significant difference was found. In 
an equal frequency in both groups, grid boxes were rated to contain low, medium or strong 
signal. The graph displays that low signal amounts were observed within largest parts of 
the α-syn-affected area (Figure 41C).  
Since for monomer-injected animals with vehicle-treatment no pS129-α-syn signal 
was expected, both PFFs groups were always additionally analyzed with a Student’s t-test 





Figure 41. Manual quantification of α-syn spreading in brain sections of fasudil-treated mice. Six coronal 
brain sections were immunolabeled with an antibody recognizing pS129-α-syn. Signal was manually analyzed 
using a color code rating scale. For each brain section, a sum of α-syn-positive grid boxes was separately 
generated for either (A) the injected or (B) the contralateral hemisphere. The sum was normalized to the total 
area. (C) Group-specific usage of the three different rating stages (low, medium, strong signal) at the injected 
hemisphere averaged over all sections. (D) Average of all sum scores of the injected hemisphere in six brain 
sections, which were presented in (A). Data are shown as mean ± SEM; n = 8-10; Kruskal-Wallis test with 





3.4.3.2 Threshold-based quantification of α-syn 
In order to verify the results of the manual α-syn quantification approach shown in 
chapter 3.4.3.1, in a second analysis a threshold-based quantification in ImageJ was 
performed. The same six coronal brain sections were analyzed. At the injected hemisphere, 
monomer-injected animals showed no pS129-α-syn signal (Figure 42A). 
 
Figure 42. Threshold-based quantification of pS129-α-syn in brain sections of fasudil-treated mice. 
At 90 dpi, pS129-α-syn signal in brain sections of PFFs-injected and fasudil-treated mice was analyzed 
with the particle analysis tool of the software ImageJ. All six sections were selected based on the Paxinos 
mouse brain atlas (Paxinos and Franklin, 2003). Quantification of pS129-α-syn signal is shown in separate 
graphs representing either the (A) injected hemisphere or (B) the contralateral hemisphere. Scatter plots 
are used representing α-syn signal of each evaluated mouse per group (n = 8-10) separately for each 
analyzed brain section. No outliers were excluded from the analysis. It was defined that outliers were not 
removed, when the strong deviation only occurred in one hemisphere of the mouse brain section. Data are 





In all sections, PFFs-injected animals (with and without fasudil) differed significantly 
from monomer-injected mice. Fasudil-treated mice did not significantly differ in their 
pS129-α-syn signal amount from mice without fasudil treatment (Kruskal-Wallis test with 
Dunn’s post hoc test). Since for monomer-injected animals no pS129-α-syn-positive signal 
was expected, both PFFs groups were additionally analyzed with a Student’s t-test showing 
no significant difference between the groups. Analyzing the contralateral hemisphere, also 







Until today, the diagnosis of PD relies on the occurrence of specific motor symptoms 
that arise relatively late in the progression of the disease. Up to now, a prevention or cure 
of the disease is not possible. At the time of diagnosis, the pathomechanisms that mediate 
PD are quite progressed, including the degeneration of the majority of nigrostriatal 
projections and dopaminergic neurons within the SN. The current state of research is aware 
of many individual influencing factors such as LB formation and spreading or metal 
dyshomeostasis, even though the details of PD pathogenesis remain unclear. It is 
inconclusive if pathological alterations in the PD brain such as α-syn aggregation, metal 
dyshomeostasis, oxidative stress or mitochondrial dysfunction represent a cause or 
consequence of the disease. 
One aim of the present work was to determine the distribution of iron and other 
elements in PD on a subcellular level. Therefore, in the first part of this doctoral thesis, 
elemental concentrations were analyzed in dopaminergic neurons of midbrain tissue from 
PD patients and controls using nanofocus XRF as a powerful technique to map and quantify 
trace elements simultaneously. The distribution of elements in two LBs was analyzed to 
reveal which elements were strongly correlated to α-syn pathology. Furthermore, the 
present work aimed to determine in more detail, if iron affects spreading of α-syn pathology 
in a mouse model of PD and secondly if the ROCK inhibitor fasudil has any therapeutic 
effects in the α-syn spreading paradigm. Iron is the most studied trace element in the context 
of PD and is already known to interact with α-syn, considered as one of the most relevant 
proteins for the pathogenesis of PD. Therefore, the second part of this doctoral thesis sheds 
light on the effect of iron on α-syn spreading pathology both in vivo and in vitro. Finally, 
in a therapeutic approach, the mouse model of α-syn PFFs injections was used to evaluate 
if α-syn spreading could be modified by ROCK inhibition by fasudil.  
4.1 PD characteristics in postmortem midbrain tissue of patients 
In previous studies, cerebrospinal fluid (CSF), serum or plasma samples of PD 
patients were used to analyze the quantities of iron and other trace elements in different 
biofluids demonstrating a dyshomeostasis of some elements in PD (Ahmed and Santosh, 
2010; Gangania et al., 2017; Maass et al., 2018; Zhao et al., 2013). Differences in trace 




(Forte et al., 2005). Therefore, trace elements are considered as potential biomarkers for 
PD. In the present study, X-ray based techniques were used to gain further insight into the 
role of trace elements within the SN of PD patients (Joppe et al., 2020).  
4.1.1 PD-related changes in trace element concentrations in neuromelanin-positive 
neurons  
Since the main pathophysiological changes in PD take place within the SN, analyzing 
the dyshomeostasis of trace elements in neuromelanin-positive neurons within the SN is 
important. 
Previous studies using X-ray-based techniques revealed significant differences in the 
accumulation of trace elements such as copper, iron or zinc in cell bodies within the SN 
from PD patients compared to controls (Carboni et al., 2017b; Davies et al., 2014; 
Szczerbowska-Boruchowska et al., 2012). In this work, we took advantage of the nanofocus 
beamline to measure more precisely absolute concentrations of trace elements within 
neuromelanin-positive neurons of SN tissue from PD patients and controls using XRF. 
Analyzing elemental concentrations on a single-cell level as a new approach, our analyses 
enabled to assess inter- and intraindividual differences (Joppe et al., 2020).  
The current study was a follow-up study to a previously conducted measurement 
assessing elemental content in neuromelanin-positive neurons from one single PD and one 
CO patient (Carboni et al., 2017b). For a better reliability of the present study, the sample 
size and respective neuron count were increased and as mentioned above a higher 
magnification employing a nanofocus beamline was used to precisely determine element 
levels within cell bodies. A great advantage of using XRF as detection method is that tissue 
can be left in a native state for the analysis and it was able to detect in total 12 trace elements 
simultaneously: iron, manganese, copper, zinc, arsenic, selenium, bromine, calcium, 
potassium, chlorine, sulfur and phosphorus. Comparing the results of the present and the 
pilot study, the same PD-related trends were observed such as an increase of iron and zinc 
and a decrease of copper. However, even though the sample size was increased no 
significant differences were found in all measured trace elements. Only copper levels 
showed marginal significance, being lower in PD patients. 
Copper is an important biometal in the brain. A corresponding dyshomeostasis of 




coupled plasma spectroscopy (Dexter et al., 1991). More precisely, particle-induced X-ray 
emission (PIXE) and XRF analyses could verify the copper reduction in neuromelanin-
positive neurons in the SN and showed same effects in the locus coeruleus of PD and 
incidental LB disease patients (Davies et al., 2014). The data of the present study 
demonstrated similar results for copper in nigral neurons. However, important variances of 
the data prevented the results to be significant on the 5 % level.  
An essential conclusion from the XRF data presented here was that although we could 
reproduce known trends in bioelemental quantifications for iron, copper and other 
elements, the observed inter- and intraindividual differences were important. In contrast to 
bulk analyses performed previously, we can show that elemental dysregulation does not 
affect all neurons in the same extent. This is not only true on an individual patient level, 
but even neurons from one patient can show different bioelemental amounts.  
Quantifying iron as the most described trace element in the context of PD, the present 
data could not verify the assumption of global iron enrichment in all nigral neurons of PD 
patients. This could also have implications for selective vulnerability of particular neuron 
groups. Analyzing the iron content in SN tissue with a microprobe mass analyzer, a study 
demonstrated a significant increase of the averaged iron signal in neuromelanin granules in 
PD patient tissue compared to tissue of controls (Good et al., 1992). Using X-ray based 
techniques, the aforementioned findings of an increased iron content in SN neurons could 
be verified (Davies et al., 2014). Both, measurements of single neuromelanin-positive 
neurons in SN using PIXE and XRF (Davies et al., 2014) as well as rapid-scanning XRF 
mapping of a whole section containing SN (Popescu et al., 2009), showed increased iron 
levels in PD samples. In the current study, we performed a local XRF analysis in neurons 
in the SN instead of averaging element concentrations over a wide part of the SN. This 
could be one reason for the high variance observed in our data. As a consequence of the 
high resolution, limiting the total imaging area, a further characterization of the scanned 
SN regions could not be conducted. It was not possible to determine if the measured cells 
were e.g. part of different nigrosomes.  
Furthermore, the disease state seems to impact iron amounts. A study using 
quantitative susceptibility mapping (QSM) showed that in patients with advanced disease 
state significantly higher iron values in QSM were found compared to patient with mild 




higher is the iron accumulation in the SN (An et al., 2018). Demonstrating higher iron levels 
in SNpc but lower iron serum levels in PD patients, a ratio of both iron levels in SNpc and 
in serum revealed a significant increase of iron in PD patients compared to controls (Costa-
Mallen et al., 2017) . Thereby, the authors concluded that in PD patients nigral and blood 
iron levels go in dyshomeostasis assuming a causal relation of both findings (Costa-Mallen 
et al., 2017).  
In addition to iron and copper as the most prominent PD-related trace elements, some 
studies already referred to dysregulated levels of selenium in PD patients. Accordingly, 
selenium was found to be significantly increased in blood plasma and CSF of patients 
(Maass et al., 2018; Zhao et al., 2013). Being an essential trace element in the brain, 
selenium is involved in neurogenesis modulation and the maintenance of redox balance or 
dynamics in mitochondria, but most interesting for PD is its antioxidant role (Cardoso et 
al., 2015). In the present study, selenium levels in neuromelanin-positive neurons of PD 
patients were tendentially reduced, however, the observed effect was influenced by strong 
interindividual differences. One study showed that a selenium-deficient diet could impact 
the vulnerability of dopaminergic neurons (Kim et al., 2000). This observation would fit 
the hypothesis of less selenium in dopaminergic neurons of PD patients. A recent 
epidemiological study analyzing soil compositions suggested a close relation of selenium 
to PD. They found that PD mortality significantly anticorrelated with selenium levels in 
geographical regions (Sun, 2018). 
For arsenic, zinc and manganese, PD and CO samples in the present study showed 
relatively similar distributions. For zinc and manganese, this goes in line with the results 
of an ICP-MS analysis (Genoud et al., 2017). One study reported an opposing relationship 
of zinc and iron, meaning that in brain regions where increased iron levels are found zinc 
levels are often reduced. This effect is vice versa in other brain regions (Popescu et al., 
2009). However, analyzing neuromelanin-positive neurons with PIXE, the zinc 
concentration did not significantly differ between the PD and control group (Davies et al., 
2014). One study, conducted similarly to our experiment, detected significant concentration 
changes in nigral neurons of PD patients in sulfur, chlorine, iron, calcium and zinc. In the 
extracellular space they showed significant differences for phosphorus, sulfur, chlorine, 
rubidium, iron and zinc. However, the authors stated significance below the 10 % level 
(p < 0.1) (Szczerbowska-Boruchowska et al., 2012). Although significant differences were 




within the PD group (Szczerbowska-Boruchowska et al., 2012). These observations fit the 
intragroup variances demonstrated in the present study.  
A suitable explanation for the detection of bromine showing high concentrations in 
single cells in the present analysis has not been found so far. Unlikely, the samples 
exhibited a contamination with bromine. The present results were in line with a published 
investigation showing also bromine in SN neurons with a high interindividual variance 
(Szczerbowska-Boruchowska et al., 2012). This high variance in bromine levels led to the 
speculation that some patients took occasionally medication that contained bromine. For 
example, the anti-anxiety agent bromazepam or the anti-Parkinsonian drug bromocriptine 
contain bromine. The latter one is an ergoline dopamine agonist widely used in the past to 
treat PD patients (Brooks, 2000; Guttman, 1997). However, the usage of these drugs has 
not been documented in the available medical records and thus cannot be proven neither 
excluded.  
In a CSF-based study, samples of PD patients showed reduced values of lead, 
chromium, cobalt, iron, silicon and tin, whereat the strongest differences compared to CO 
patients were shown for lead and chromium (Alimonti et al., 2007). Analyzing brain tissue, 
in the present study these elements could not be detected with the exception of iron. The 
case that some studies detected different trace elements in their samples can partly be 
explained by the different detection methods used. Not all methods are equal in sensitivity 
and specificity. In one study, the elemental content was determined in SN tissue from 
healthy individuals without neuropathological findings using both PIXE and energy-
dispersive X-ray spectroscopy (EDX). They detected iron, manganese, chromium and zinc 
with PIXE while EDX analyses could quantify iron, zinc, aluminum and silicon 
concentrations in tissue (Pánik et al., 2018). This indicates that in order to provide a 
complete elemental profile of PD it would be useful to combine different X-ray based 
methods in future studies. 
Even though no significant differences in trace elements were found, the question 
arose if an unsupervised clustering approach could correctly identify samples of PD or CO 
patients based on the combination of trace elements. Merely, 65.5 % of the samples were 
classified correctly based on the concentrations from iron, zinc, copper, selenium, arsenic, 
manganese and bromine. In another study analyzing neurons in SN, concentrations of 




samples from the two groups using a multiple discrimination analysis (Szczerbowska-
Boruchowska et al., 2012). The latter study used a comparable sample size to the present 
study of four PD and four CO patients (4-10 cells each). In our case, the strong variance 
between the used samples prevented from replicating the previous literature.  
One general issue of using tissue from patients of high age is that the medical histories 
of age-matched controls are quite heterogeneous, which could have significantly influenced 
the results. Three patients of the CO group were diagnosed with different kinds of cancer 
while one patient suffered from MS. It must be considered that MS is also a neurological 
disorder. In general, it is difficult to get brain samples from high age CO patients with a 
detailed medical record but without any clear pathology or at least without 
neurodegenerative pathology. The inclusion of different disease types in the CO group as 
well as the small sample size in the present study might explain the limited differences in 
trace element abundancies of PD and CO patients. In another study using a machine-
learning algorithm for group discrimination, an elemental profile of selenium, iron, arsenic, 
nickel, magnesium and strontium was shown to discriminate CSF samples of the PD and 
CO group (Maass et al., 2018). Therefore, the elemental profile is possibly also dependent 
on the used biological source material (e.g. brain tissue, serum, plasma, CSF).  
Taken together, our data resemble the results of previous studies analyzing elemental 
concentrations in neuromelanin-positive neurons, but our analyses did not reach statistical 
significance comparing PD and CO patients. One important reason is still the low sample 
size which is owed to a high time expenditure for XRF measurements with the used 
resolution and the restricted measurement time at the synchrotron. The novel single cell 
analysis in our study indicated that elemental concentrations are not necessarily similar 
between PD patients and could even strongly vary between neurons within the same patient. 
Nevertheless, these results are relevant indicating on the one hand that trace elemental 
changes could possibly be related to PD subtypes and on the other hand that particular 
neuron groups probably have a selective vulnerability for a dyshomeostasis of trace 
elements such as iron.  
4.1.2 X-ray-based characterization of LBs and their elemental composition  
LBs containing α-syn aggregates are one of the main hallmarks of PD. Here, LBs 
were identified in postmortem midbrain tissue sections from PD patients and analyzed with X-




spatial resolution. XRD was used to noninvasively localize and characterize crystalline 
structures whereas XRF enabled an analysis of the elemental concentrations in LBs (Joppe et 
al., 2020).  
First, the question if α-syn can be detected solely based on the XRD signal was 
investigated. In future experiments, this would enable an identification of α-syn-containing 
LB without any processing of the tissue. So far, α-syn-containing LBs always had to be 
visualized by immunohistochemical stainings (Spillantini et al., 1998), which possibly 
affects the elemental composition of the LBs due to the processing of the section like 
washing and staining. The XRD data did not conclusively show α-syn present in the LB, 
but as an indication it showed higher amounts of β-sheet proteins in the LB-defined ROI 
compared to β-sheet protein amounts in a neuron of a CO patient. Prospective XRD-based 
studies might shed light on the structural quality of LBs.  
Further analyses aimed to determine the elemental content of LBs, since little is 
known about trace element abundancies and their distribution in LBs of PD patients, even 
if several studies suggest an interaction of α-syn with trace elements especially with iron. 
It has been shown that iron can bind to α-syn and that the binding affinity is even increased 
for phosphorylated α-syn (Binolfi et al., 2006; Lu et al., 2011; Peng et al., 2010b). Another 
study suggested that α-syn levels are regulated by iron due to its 5´-UTR, which shows a 
close homology to the IRE of the ferritin mRNA (Friedlich et al., 2007). Therefore, it is 
relevant to further investigate the interplay of iron and α-syn in the disease state. Due to the 
fact that iron, but also copper and manganese were found to foster α-syn aggregation as 
previously reviewed (Carboni and Lingor, 2015), accumulation of these elements in α-syn 
aggregate-containing LBs was conceivable. Using immunohistochemical stainings, it has 
been already shown that iron deposits overlap with LBs (Castellani et al., 2000). In vitro 
and in vivo it was demonstrated that arsenic fostered the accumulation of α-syn (Cholanians 
et al., 2016), thus it might also be overabundant in LBs. Regarding the possible role of 
selenium for LB pathology, previous studies indicated that selenoproteins as 
Selenoprotein P (Sepp1) or GPX4 were colocalized with LBs (Bellinger et al., 2011, 2012). 
This observation would argue for selenium enrichment in LBs.  
To gain further insight into the elemental composition of LBs XRF analyses were 
conducted. In one LB, iron, zinc, manganese, selenium, arsenic and bromine were locally 




phosphate contains bromine and was added during the staining procedure of these sections, 
this could possibly explain strong bromine signal in the area of the LB. In a recent study, 
the elemental content was assessed in the olfactory bulb of patients with laser ablation-ICP-
MS (LA-ICP-MS) and the colocalization of α-syn aggregates with trace elements was 
analyzed (Gardner et al., 2017). Thereto, LA-ICP-MS results had to be combined with 
immunohistochemically stained α-syn aggregates. The analyses showed decreased amounts 
of copper in α-syn aggregates confirming the results of the present study. Iron amounts 
were decreased in their analysis. An increase of zinc again was in line with the observation 
in the present study (Gardner et al., 2017).  
The analysis of a second LB showed a different elemental composition. Only the 
absence of copper and the increase in bromine in the second LB were in accordance with 
the results of the first measured LB. Interestingly, the enrichment of iron could not be 
shown in the second LB. 
Due to the above-mentioned studies showing a clustering of LBs and iron (Castellani 
et al., 2000) and a general affinity of iron to bind α-syn (Binolfi et al., 2006; Peng et al., 
2010b) it was hypothesized that at least iron clustered in both measured LBs. However, in 
vitro experiments revealed that iron could also indirectly trigger the aggregation of α-syn 
(Levin et al., 2011; Li et al., 2011; Xiao et al., 2018) hypothesizing that both targets can 
impact each other not necessarily requiring cluster formation of iron and α-syn aggregates 
in LBs.  
Taken together, the current data demonstrated for the first time trace element 
abundancies and their distribution in LBs using XRF with nanofocus resolution. The two 
measured LBs showed a heterogeneous elemental pattern. One possible explanation for this 
heterogeneity could be that two LBs of different developmental stages were measured. 
There is a possibility that both LBs are of different ‘ages’ and that accumulation of for 
example iron or selenium is dependent on the age of the LB. More analyses of individual 
LBs are needed to describe the variety of elemental profiles of LBs and to discuss the 
relevance of different trace elements for LB pathology. Regarding the XRD analysis, it was 
not possible to visualize explicitly crystalline structures of α-syn in the LB, but we were 
able to detect β-sheet protein amounts. It is assumed that α-syn does potentially not 




4.1.3 The role of cholesterol in midbrain tissue of PD patients 
Using XRD, a previous study of our group revealed increased amounts of cholesterol 
crystals in one midbrain sample of a PD patient compared to one MS sample. Cholesterol 
was mainly located in the extracellular space and not within SN neurons (Carboni et al., 
2017b). Since no statistical conclusion could be drawn from this analysis, we aimed to 
investigate cholesterol amounts in a bigger sample cohort, using lipid extraction and 
following GC-MS to quantify the cholesterol amounts in midbrain tissue.  
In the present study, PD patients showed increased cholesterol levels in midbrain 
tissue reaching marginal statistical significance in comparison to CO samples. However, 
the interpretation of this data requires caution, as three samples of the CO group originated 
from cancer patients, whereas the majority of seven patients were diagnosed with MS. 
Therefore, it cannot be excluded that the observed cholesterol increase is biased by the 
overrepresentation of MS patients in the CO group. Little is known about cholesterol levels 
in the brain of MS patients so far, but other sample sources have been analyzed in some 
studies. In one study, plasma hydroxycholesterol levels increased in MS patients within 
five years of disease progression (Fellows Maxwell et al., 2019). Another study showed 
reduced levels of specific hydroxycholesterols in plasma for relapsing-remitting MS 
patients (Crick et al., 2017). In CSF, 25-hydroxycholesterol was increased for these patients 
whereas no difference was detected in cholesterol levels (Crick et al., 2017). In serum, total 
cholesterol and low density lipoprotein (LDL) cholesterol profiles were positively 
correlated with the disability status of MS patients (Ďurfinová et al., 2018). Even if no 
specific changes of cholesterol levels in the SN of MS patients are known so far, it must be 
kept in mind, that the heterogeneity in patients from the CO group (MS or cancer) could 
have influenced the output in the present study.  
In contrast to our PD study, different studies investigated cholesterol levels in source 
material such as plasma or serum of PD patients. Studies investigating plasma levels of PD 
patients showed that higher levels of total or LDL cholesterol were possibly associated with 
a decreased risk to develop PD. Furthermore, higher plasma levels of LDL cholesterol led 
to a better motor function over time in PD patients (Huang et al., 2016; Sterling et al., 
2016). High cholesterol levels in serum were also associated with a decreased risk for 




progression of PD (Huang et al., 2011; De Lau et al., 2006; Rozani et al., 2018; Simon et 
al., 2007).  
Inversely to blood and serum samples, in brain tissue of PD patients, increased 
cholesterol levels were found which confirms the data of the present study. One study 
investigated cholesterol content in the visual cortex as a region without LB pathology. Both, 
a lipidomics approach using liquid chromatography mass spectrometry as well as a 
validation with high performance liquid chromatography (HPLC), showed a significant 
increase of cholesterol in PD patients (Cheng et al., 2011). Oxysterols amounts were also 
increased. The authors therefore suggested an upregulation of the metabolism of cholesterol 
through oxysterols in the visual cortex and that this is probably related to selective 
expression changes in genes which play a role in lipid metabolism. Regions known to be 
affected by LB pathology in PD such as anterior cingulate cortex or amygdala did not show 
altered cholesterol amounts compared to controls (Cheng et al., 2011).  
In contrast, another study showed that metabolites of oxidative cholesterol were 
increased in cortex tissue of DLB patients compared to controls (Bosco et al., 2006). The 
results of the present study of an increase in cholesterol amounts in brain regions of PD 
patients thereby go partially in line with the literature. Although an above-mentioned study 
could not relate cholesterol increase to α-syn pathology in tissue of PD patients, other 
investigations suggest a link of both targets. Based on the results of the present study, a 
relation of cholesterol and α-syn pathology was also conceivable, since the analyzed 
midbrain is commonly known to be affected by α-syn pathology as also mentioned in the 
previous chapter. In an in vitro model with SH-SY5Y cells overexpressing α-syn, 
cholesterol metabolites were also increased. The study further suggested that cholesterol 
accelerated the aggregation of α-syn (Bosco et al., 2006). In primary neurons, the linkage 
of cholesterol and α-syn aggregates was confirmed, showing that a cholesterol synthesis 
inhibitor reduced α-syn aggregation-induced damage of synapses (Bate and Williams, 
2015). Furthermore, cholesterol was postulated to mediate the interaction of α-syn 
oligomers and charge-neutral membranes (van Maarschalkerweerd et al., 2015). In an 
MPTP model of PD, hypercholesterolemia fostered the degeneration of dopaminergic 
neurons in the midbrain of mice and led therefore to a worsening of PD pathology and 
symptomatology (Paul et al., 2017). A study in C. elegans reported that the neutral 
cholesterol ester hydrolase 1 (NCEH-1) attenuated the α-syn-dependent neurodegeneration 




assumption that cholesterol interacts with α-syn, which fosters the aggregation of α-syn and 
supports α-syn-related neurodegeneration. 
Taken together, our study reports a cholesterol increase in the SN of PD patients. It 
supports the literature on higher cholesterol levels in the brain of PD patients. Furthermore, 
not only trace elements, as described in the previous chapter, have been related to α-syn 
aggregation and pathology as a hallmark in PD, but also cholesterol has been shown to be 
linked with α-syn in previous literature. Due to the characteristic of α-syn being a common 
denominator for different possible targets in PD, the next chapters will exclusively address 
effects on α-syn pathology in mice in vivo and cortex neurons in vitro.  
4.2 Iron-dependent modulation of α-syn spreading pathology in vivo 
As mentioned in the previous chapter, a dyshomeostasis and relating thereto the 
enrichment of iron in PD has been reported in various studies using different biological 
sample sources from patients. Additionally, the positive effects of iron chelators on motor 
performance and iron levels in the SN, caudate nucleus and dentate nucleus of PD patients 
are evidence for a pertinent role of iron increase in the disease state of PD (Devos et al., 
2014; Martin-Bastida et al., 2017). Using preclinical cell and animal models, various 
positive effects of iron chelators were verified. The treatment of rodents or primates with 
chelators as deferiprone (Carboni et al., 2017a), clioquinol (Billings et al., 2016; Finkelstein 
et al., 2016) or VK-28 (Mandel et al., 2004) or with the quinazolinone compound PBT434 
(Finkelstein et al., 2017) prevented the accumulation of iron in SN, formation of nigral α-
syn aggregates, loss of dopaminergic neurons in the SN and rescued motor as well as 
cognitive functions of the animals. Chelating iron in PD models therefore consistently 
improved the health status and demonstrated already that iron seems to affect the α-syn 
pathology in PD models. In vitro experiments verified that iron can bind to α-syn (Binolfi 
et al., 2006; Davies et al., 2011; Peng et al., 2010b) and facilitates its aggregation (Golts et 
al., 2002; Kostka et al., 2008; Levin et al., 2011; Uversky et al., 2001). Since these studies 
provide evidence for an interaction of iron and α-syn, the question arose if these interactions 
could also have an influence on the spreading of α-syn pathology in the brain. 
In order to analyze the spreading pathology, the generation of α-syn PFFs and their 
injection into rodent brain regions such as striatum, SN or cortex are commonly used 




2019a; Polinski et al., 2018; Zhang et al., 2019a). To induce the iron brain load, mice were 
postnatally treated at p10 - p17 with different dosages of iron. The present iron intoxication 
model has also been used in several studies (Billings et al., 2016; Kaur et al., 2007; Peng 
et al., 2009, 2010a). In the present study, an intrastriatal injection of PFFs effected PFFs 
seeding which triggered α-syn propagation throughout the brain in the following weeks. 
Analyses demonstrated an iron-related reduction of pS129-α-syn amounts in the brain as 
well as a prevention of microglia accumulation in the injection site. Iron and α-syn 
treatment-related behavioral changes will be discussed first in the following chapter.  
4.2.1 The influence of iron and α-syn on motor and cognitive behavior 
In order to assess whether iron and α-syn PFFs treatment induced abnormalities in 
terms of cognitive or motor behavior of mice, the NOR and rotarod test were performed. 
The rotarod test is a commonly used behavioral test for PD animal models. Pure muscle 
strength, coordination skills and endurance belong to the abilities which are required to 
perform the rotarod test properly. 
In the present study, iron and α-syn treatment did not influence the performance on 
the weekly implemented rotarod test over a time frame of 90 dpi. The results go in line with 
previous investigations showing no significant motor abnormalities for PFFs-injected 
animals at 90 dpi. Iron does not seem to accelerate an PFFs-induced motor dysfunction in 
mice. In a study using intrastriatal injections of 5 µg of the same protein as in the present 
study, also no effects of PFFs injections on the rotarod were observed at 90 dpi but on 180 
dpi (Luk et al., 2012a). In another study, 10 µg PFFs were injected and led to a significant 
motor decline detected with the rotarod at three months post injection (Masuda-Suzukake 
et al., 2014). These data suggest a dose-dependent motor decline in regard to the amount 
of PFFs injected.  
The mentioned studies used the wire hang test as an additional indicator for motor 
decline but showed inconsistent results. Whereas an intrastriatal injection of 5 µg PFFs 
showed significant differences in mice at 90 dpi (Luk et al., 2012a), a higher dosage (10 µg 
PFFs) did not lead to motor decline (Masuda-Suzukake et al., 2014). Furthermore, recent 
studies suggested that bilateral compared to unilateral injections of PFFs and the injection 
of shorter fibrils compared to long fibrils significantly influence the effect on motor 




To conclude, in our selected setup, the result of an unchanged motor behavior for 
PFFs-injected mice at 90 dpi was as expected compared with a previous study. The 
literature suggests that longer time is needed for PFFs to impair motor behavior, which 
could be accelerated by the injection of higher PFFs dosages. Indeed, in this study the motor 
behavioral analysis was mainly performed to record concomitant effects of the treatment. 
The time frame of 90 dpi was selected, since at this time a well-advanced spreading of α-
syn fibrils through the brain has been previously reported (Luk et al., 2012a), and the main 
focus of the present study was on influencing the α-syn spreading. For future investigations 
targeting the effect of PFFs on the motor function, bilateral injections and the control over 
the length of injected fibrils needs to be considered to seed PFFs more effectively in terms 
of their effect on motor decline.  
Not much is known about direct effects of postnatal iron treatment on motor behavior. 
In one study, Sprague-Dawley rats were treated with 120 mg/kg bw iron between postnatal 
day 10 and 17. These rats did not show any abnormalities in motor behavior assessed by 
rotarod performance at 200 days of age (Chen et al., 2015). A53T mice treated with a low 
iron dosage (40 mg/kg bw) showed a reduced learning ability in the rotarod test but overall 
a stable motor performance (Carboni et al., 2017a). This effect on learning ability was not 
found in the present study using wild-type mice. Another study analyzing behavior of iron-
treated NMRI mice (37 mg/kg body weight) showed alterations in spontaneous motor 
behavior (Fredriksson et al., 1999). The few found studies investigating motor behavior of 
iron-treated animals therefore deal with other mouse models or another species.  
As a conclusion of the rotarod data, our results resemble the literature showing little 
evidence for motor abnormalities on the rotarod after neonatal iron treatment or α-syn PFF 
injections measured up to 90 dpi / 6 months of age. The accumulation of both treatments 
did also not result in a premature onset of motor decline compared to other studies. Thus, 
in the selected time frame, iron seems not to foster pathological effects of PFFs on brain 
regions important for the locomotor system such as the SN.  
Regarding the effect of iron on cognitive performances, iron treatment has been 
shown to induce cognitive decline in terms of memory function in mice and rats 
(Fredriksson et al., 2000; de Lima et al., 2005b, 2005a, 2007; Schröder et al., 2001). 
Therefore, in the present study object recognition was analyzed in terms of STM and LTM 




90 dpi. At three months of age (before α-syn injection), mice treated with the highest iron 
dosage showed an impaired LTM compared to the low iron dosage group. However, at six 
months of age (90 dpi), LTM impairment of iron-treated mice was absent. In turn, at 90 dpi, 
the PFFs injection significantly impaired LTM compared to the monomer injection of mice. 
The combination of iron and PFFs did not worsen the effect compared to PFFs-injected 
animals without iron treatment. At both measured time points, STM was not affected by 
the treatment conditions. 
At three months of age, iron treatment of rats at postnatal days 12-14 showed similar 
effects of a cognitive impairment on LTM but absent consequences on STM (de Lima et 
al., 2007). Iron treatment of Wistar rats affected LTM independent on the postnatal period 
when iron was applied (postnatal days 5-7, 12-14, 19-21 or 30-32), however, measuring 
STM only rats treated with iron between p19-21 showed a significant decline in object 
recognition memory (de Lima et al., 2005b). These results indicate that the treatment time 
point significantly influences if iron affects STM. Accordingly, in the present study, STM 
of iron-treated mice was not affected because iron was applied too early (at p10-17). The 
reasons for iron-induced cognitive impairment are not fully resolved. It is assumed that 
oxidative stress in connection with iron overload could impair the cognitive function. 
Accordingly, lipid peroxidation and protein carbonylation were found within the 
hippocampus, cortex and SN post neonatal iron intoxication (Dal-Pizzol et al., 2001). The 
induction of oxidative stress and damage due to iron accumulation further supports cell 
death in neurodegenerative diseases (Zecca et al., 2004).  
The present study showed for the first time cognitive decline due to intrastriatally 
seeded PFFs measured by the NOR at 90 dpi. A study using intracerebroventricular 
injections of α-syn showed that the injection of neither PFFs nor monomers but of 
oligomeric α-syn species induced a significant decline in LTM at 10-15 dpi (La Vitola et 
al., 2018). Concretely, small extracellular α-syn oligomers were found to disturb the 
synaptic plasticity, which could impair both the memory function and cognitive ability 
(Martin et al., 2012). Using the Y-maze test, intrastriatally PFFs-injected mice did not show 
any learning or memory decline at six months post injection (Luk et al., 2012a; Masuda-
Suzukake et al., 2013). However, in a recent rat study combining viral vector mediated α-
syn overexpression in prefrontal cortex with human α-syn PFFs inoculations into the 
striatum cognitive impairments were observed using the delayed matching to position 




reaction time task (5-CSRTT) (Espa et al., 2019). Therefore, PFFs injections were shown 
to affect different cognitive functions measured by different tests. Whereas the present 
study plead for an LTM dysfunction in terms of object recognition, no deficits were found 
in working memory analyzing spontaneous alternation behavior in literature. Spatial and 
working memory were affected in models where α-syn injections were combined with α-
syn overexpression.  
Using the NOR test, the distance moved in the arena of iron- and α-syn-treated mice 
was also analyzed in the present study as a variable of general mobility. Before α-syn 
injection, in the LTM condition, mice with the highest iron dosage were running 
significantly less in the arena compared to mice from the other two iron conditions. It is 
assumed that this is rather a separate effect than a cause for less interest on the novel object 
of this mouse group. Since the duration at the novel object was recorded as main LTM 
variable, one would rather expect that mice which move less show LTM values distorted 
upwards in terms of the duration spent at the novel object.  
Taken together, the present results showed that the highest iron dosage as well as α-
syn PFFs seeding affected the LTM separately. Both targets together did not worsen the 
effect in the used model meaning that no interaction effect of both treatments was found. 
Comparing the present results with previous literature, the time point of the observation at 
90 dpi could have been one major reason for the treatment-induced minor impairments 
observed in motor and cognitive behavior. Indeed, the behavioral analyses were mainly 
performed to record concomitant effects of the treatment. The focus was not necessarily on 
inducing motor or cognitive deficits. In general, available literature indicates that at the 
used measurement time points motor and cognitive decline seem to be test-specific, 
meaning that the test itself and its sensitivity also strongly influence the output. Possible 
reasons for the PFFs-induced cognitive decline are further discussed in chapter 4.2.3. 
4.2.2 Quantification analyses of iron 
Iron accumulation is an accompanying effect of aging which provides a possible 
explanation for an age-dependent susceptibility for neurodegenerative diseases (Ashraf et 
al., 2018). In PD, iron increase within the SN is widely reported. One explanation for iron 
accumulation in the SN is that neuromelanin which mainly occurs within the dopaminergic 
neurons in SN has a high affinity to bind iron. In PD samples, further iron deposits were 




2016; Ward et al., 2014). A recent MRI study with PD patients and controls analyzing the 
iron content in different brain regions showed an iron increase in the fascicula nigrale, 
globus pallidus, red nucleus, putamen, caudate nucleus and SN of PD patients (Chen et al., 
2019).  
To investigate the role of iron in neurodegeneration, models enriching brain iron in 
rodents were used to analyze iron effects in context of PD (Billings et al., 2016, 2019; Kaur 
et al., 2007) and other NDDs such as Huntington’s disease (Agrawal et al., 2018; Berggren 
et al., 2015, 2016). The used protocol of treating mice postnatally over several days with 
carbonyl iron per gavage is a common model in PD research (Billings et al., 2016; Carboni 
et al., 2017a; Chen et al., 2015; Finkelstein et al., 2016, 2017; Kaur et al., 2007; Peng et al., 
2009, 2010a; Schröder et al., 2001). The most commonly used treatment concentration of 
iron is our middle dosage of 120 mg/kg bw iron (Chen et al., 2015; Kaur et al., 2007; Peng 
et al., 2009, 2010a; Schröder et al., 2001). In the present study, dosages of 60 and 
240 mg/kg iron were additionally tested to enrich iron content in the brain. 
In order to proof that the used iron treatment method induced an enrichment within 
the mouse brain, the iron content in whole brains and nigral brain sections was analyzed.  
First, the total iron content in whole mouse brains was measured by hyphenated ICP 
spectrometry. Since this analysis could not detect any differences in the iron amount, it was 
postulated that iron enrichment happened in small and specific brain regions. By that, an 
analysis including the whole brain mass and thereby the iron variance of many brain regions 
would average out the iron increase in a few specific iron enriched areas. This hypothesis 
corresponds perfectly to a recently published study quantifying iron content within the 
midbrain, caudate putamen, cerebellum and cortex of wild-type and A53T mice treated 
postnatally with iron. Only in the midbrain a significant difference between iron-treated 
and control mice were observed with ICP-MS. With LA-ICP-MS raster scanning of mouse 
brain sections they could further specify that the observed iron effect in the midbrain can 
be attributed to the strong iron increase within the SN (Billings et al., 2019). 
Indeed, our XRF analysis of single sections of the SN showed higher amounts of 
nigral iron for iron-treated mice sacrificed at six months of age. Due to time restricted 
measurements at the synchrotron, only tissue from the 60 and 120 mg/kg iron groups could 
be measured and compared to control samples. Our observation goes in line with previous 




significantly higher iron concentrations in SN tissue of iron-treated wild-type mice. Even 
higher iron concentrations were reached when A53T mice were neonatally treated with iron 
(Billings et al., 2016). Using the same iron treatment protocol as in the present study, at 
two months of age, iron-treated B6D2 mice showed a significant iron increase in SN tissue 
measured by ICP-MS and in sections measured with MRI (Kaur et al., 2007). In one study 
treating NMRI mice with an amount of iron which is even lower than the lowest dosage of 
the present study, they found an iron enrichment within the basal ganglia but not in the 
frontal cortex which was also analyzed at four months of age using AAS (Fredriksson et 
al., 1999).  
Furthermore, studies used the model of iron enrichment to test iron chelator effects 
in the context of PD which showed predominantly positive effects on behavior, neuronal 
loss and nigral iron content of wild-type and A53T mice (Billings et al., 2016, 2019). One 
of these studies mentioned equal effects of clioquinol and L-DOPA treatment on nigral iron 
amounts, midbrain protein carbonyl levels and dopaminergic neuron counts in iron-treated 
wild-type mice (Billings et al., 2019).  
Treatment with chelators showed also benefits in other PD models, in which mice 
were not treated with iron to induce an enrichment. In A53T mice, iron chelator (clioquinol) 
treatment without previous iron enrichment led to a reduced formation of α-syn aggregates, 
reduced cell loss as well as motor and cognitive decline, and prevented a reduction of 
dendritic spine density of spiny neurons in hippocampus and striatum (Finkelstein et al., 
2016). Besides using the A53T mice to further link iron accumulation with PD pathology, 
MPTP toxicity models were used. Iron chelation was found to prevent MPTP-induced 
oxidative stress and neuronal cell loss (Kaur et al., 2003). In A53T mice, MPTP was shown 
to elevate the nigral iron levels. In the same study, the quinazolinone compound PBT434 
reduced nigral iron levels and showed beneficial effects on nigral dopaminergic neuron 
loss, on nigral α-syn accumulation and on the motor decline after MPTP or 6-OHDA 
treatment (Finkelstein et al., 2017). These studies indicate that iron dyshomeostasis is 
related to other pathomechanisms in PD, highlighting its important role as a therapeutic 
target in PD.  
Taken together, the mentioned studies as well as the results of the present analysis 
emphasize that iron intoxication models indeed elevate iron levels within the brain of 




showed the efficacy in preventing effects of iron intoxication. Positive effects of iron 
chelators in A53T mice or in toxin-based PD models (e.g. MPTP treatment) further 
emphasized the link of iron with other PD pathomechanisms. The impact of iron on α-syn 
pathology in PD was previously investigated in terms of α-syn aggregation. The present 
study focusses on the effect of iron on α-syn spreading, which will be further discussed in 
the following chapters.  
4.2.3 PFFs seeding in the brain and its effect on motor behavior and memory 
Brain sections were analyzed at 90 dpi to assess quantitative and qualitative 
differences in the propagation behavior of α-syn fibrils. Previous rodent studies reported 
advanced PFFs-induced α-syn spreading at 90 dpi, however, the pathology extent depended 
on the concentration of PFFs-injected and on the genotype of the animals (Blumenstock et 
al., 2017; Kim et al., 2016; Luk et al., 2012b, 2012a; Shimozawa et al., 2017; Terada et al., 
2018). The intrastriatal injection used in the present study is the most common method to 
seed α-syn PFFs in the brain but as recently reviewed there are also other models 
administering α-syn by gut injections, intraglossally, intramuscularly, intraperitoneally, 
through the sciatic nerve or as injections into the hippocampus, olfactory bulb or SN 
(Chung et al., 2019).  
The first intent was to analyze if the PFFs-induced α-syn spreading pattern 
corresponds to the previous literature independent on the postnatal treatment (control or 
iron). The α-syn spreading pattern of the present study overlaps with affected brain regions 
in similar studies using intrastriatal PFFs injections of wild-type mice analyzed at 30 dpi, 
60 dpi or 180 dpi. However, compared to studies with other injection sites, the affected 
brain regions differ (Chung et al., 2019). An experiment with similar settings as the present 
study detected same affected brain regions (Luk et al., 2012a). Both studies show a high 
involvement of cortical areas (cingulate, motor, insular, somatosensory, medial parietal 
association, temporal, visual, auditory ectorhinal, entorhinal and perirhinal cortex), 
amygdaloid nuclei (basal, lateral, central and intercalated amygdaloid nuclei) as well as a 
spreading to the SN and amygdalopiriform transition area (Luk et al., 2012a).  
Even if other similar studies did not provide spreading maps, they confirmed that the 
ipsilateral striatum, SN, auditory cortex, amygdala and anterior cingulate cortex were 
affected by the PFFs-based propagation pathology (Kim et al., 2016; Terada et al., 2018) 




injections in mice to establish a network model. Therefore, the authors first quantitatively 
analyzed PFFs-induced spreading at 1, 3 and 6 months post injection (Henderson et al., 
2019). The overall pattern of spreading at 3 months resemble the affected brain regions of 
the present data. The authors further paired the quantitative results with a network diffusion 
model integrating the anatomical connectivity and could show that PFFs spreading over 
time can be traced based on a synaptic connection network. Accordingly, this approach 
could demonstrate the vulnerability of regions to α-syn spreading. Henderson and 
colleagues identified the basolateral amygdala, rostral cortical regions and the piriform 
cortex as the most vulnerable regions in this model (Henderson et al., 2019), which were 
also affected in the present study. 
In line with previous approaches, the current study could also show that the α-syn-
affected regions are mostly anatomically interconnected. There is wide evidence that the 
striatum is innervated by the mainly affected brain regions such as the amygdala (Cho et 
al., 2013), motor cortex (McGeorge and Faull, 1989), the cingulate cortex (Kunishio and 
Haber, 1994), the somatosensory cortex (Wall et al., 2013), the insular cortex (Chikama et 
al., 1997), the ectorhinal cortex (Hunnicutt et al., 2016), the entorhinal cortex (Totterdell 
and Meredith, 1997), the perirhinal cortex (Hunnicutt et al., 2016), and the SN (Lynd-Balta 
and Haber, 1994). The spreading of α-syn to regions innervating the injection site are 
indicative for a retrograde transmission of α-syn fibrils as previously described (Paumier 
et al., 2015).  
However, both anterograde and retrograde spreading of α-syn was documented in a 
model of intrastriatal injections of LB extracts in mice and monkeys (Recasens et al., 2014). 
Pathology of α-syn in regions innervated by the striatum (SNpr, entopeduncular nucleus or 
globus pallidus) would suggest an anterograde spreading. Interestingly, α-syn pathology 
was only found within the SNpr in our model but could not be verified in other mentioned 
brain regions of anterograde spreading. Indeed, this observation fits to the results of 
previous connectome analyses of α-syn spreading (Henderson et al., 2019; Mezias et al., 
2020; Oliveira et al., 2019). All three studies reported a stronger propensity of α-syn to 
spread retrogradely. Mezias and colleagues observed that the spreading direction is shifting 
after time. They found that in the first months post injection retrograde spreading is 
predominant, but later than a post-injection period of nine months both propagation 
directions influenced the detected spreading pattern. It is supposed that the direction then 




the anterograde transport protein kinesin and on the retrograde transport protein dynein, the 
authors assume that this link could possibly be causative for the shift (Mezias et al., 2020). 
Henderson and colleagues investigated α-syn spreading at six months post injection as the 
longest time period and did not report such a shift (Henderson et al., 2019).  
In order to get a more precise insight on α-syn spreading to regions anatomically 
connected to the injection site, a connectome-based analysis was performed using the Allen 
Brain Atlas connectivity platform (©2020 Allen Institute for Brain Science. Allen Mouse 
Brain Connectivity Atlas, available from: https://connectivity.brain-map.org/). The 
analysis highlighted that several anatomical connections were affected by α-syn spreading 
but it also revealed the vulnerability of many other brain regions. Connectome-specific and 
unspecific α-syn spreading differences between iron-treated and control animals are 
discussed in chapter 4.2.4. It is striking that not all anatomical connections were affected, 
and the affected ones showed unequal α-syn amounts. As an assumption, this could be 
related to the availability of different neuron types within different brain regions. The 
spreading pattern could be also dependent on transmitter-specific circuits. For example, 
according to the connectome the globus pallidus or thalamic nuclei as part of the 
GABAergic circuits of the basal ganglia should have been affected but they showed no α-
syn pathology. Therefore, neurotransmitters could possibly be relevant for α-syn 
propagation pattern. One study suggested that the vulnerability of brain regions could be 
related to the count of neuronal projections between the areas and the projection length 
meaning that a higher count and shorter projections could increase the vulnerability. 
However, they also reported that some regions with a short length of projections were not 
affected by α-syn which again highlights that anatomical connectivity is important but not 
exclusively determining α-syn spreading pathology (Oliveira et al., 2019). 
In the context of affected brain regions, the question arose, if the effect of PFFs on 
object recognition memory could be explained by the presence of α-syn aggregates within 
crucial brain regions. Indeed, the insular, perirhinal and prefrontal cortex were affected 
which can be associated to memory function. The insular cortex was found to play an 
important role for object recognition memory since its cholinergic activity contributes to 
the familiarization with a specific object (Bermudez-Rattoni et al., 2005). Another study 
mentioned both insular and perirhinal cortex as essential areas for the consolidation of 
familiar objects (Balderas et al., 2008). Furthermore, involvement of the ventromedial 




shown in LTM (after 24 h) but not in STM (after 3 h) (Akirav and Maroun, 2006). In the 
rodent’s brain, the different parts of the prefrontal cortex are not clearly defined. In the 
present study, pS129-α-syn signal was observed within the infralimbic, prelimbic and 
cingulate cortex. Whereas the cingulate cortex (area 1) is commonly known to be a part of 
the dorsomedial prefrontal cortex and the infralimbic cortex as part of the ventromedial 
cortex, the prelimbic cortex is inhomogeneously assigned to either the ventromedial or 
dorsomedial cortex (Laubach et al., 2018). Furthermore, it was shown that the LTM of 
object recognition is dependent on hippocampal integrity (Clarke et al., 2010). 
Interestingly, in our model, hippocampus was only rarely affected.  
In STM, the entorhinal cortex was assigned to memory of object details and spatial 
locations (Suzuki et al., 1997). In the present study, no STM decline was found, although 
the entorhinal cortex was affected by α-syn pathology. However, motor deficits were also 
not observed even though strong α-syn pathology was present in the motor cortex and SN. 
One possible explanation for this observation is that at the timepoint of sacrifice the 
pyramidal tracts were not affected enough by α-syn aggregate pathology to induce motor 
deficits. Furthermore, a fundamental reason for motor deficits would be the degeneration 
of dopaminergic neurons inside the SN. However, PFFs-induced neurodegeneration in the 
SN was found to take place at later time points (Luk et al., 2012a; Paumier et al., 2015). 
Figure 43 provides an overview on the above-mentioned brain regions which are 
associated with object recognition in LTM and STM conditions, and simultaneously 
recapitulates the α-syn pathology for each region of PFFs-injected mice either treated with 
iron or with vehicle. This depiction summarizes that the mentioned regions are affected by 
α-syn pathology, which could explain why PFFs-injected mice showed a cognitive decline 
in the NOR test at 90 dpi. In the NOR test, PFFs-injected mice did not perform different 
from each other when they were treated with either iron or vehicle. Nevertheless, pS129-
α-syn pathology differences can be observed between both treatment groups. In several 
brain regions associated with object recognition, mice of the control group showed stronger 
pathology. These results suggest that the α-syn pathology in both groups exceeds a certain 
limit resulting in cognitive deficits, but pathology differences were not strong enough to 




Taken together, the current study demonstrated PFF-induced α-syn spreading to both, 
anatomically connected and other brain regions. Specific brain regions affected by α-syn 
pathology provide an explanation for PFFs-induced cognitive deficits.  
 
Figure 43. The detection of pS129-α-syn pathology in brain regions related to object recognition. This 
illustration represents the results shown in Figure 29 rating the pS129-α-syn signal amount per brain region 
by using a 5-stage-rating. Averaged results are shown for PFFs-injected mice treated with either iron or 
vehicle (ctrl). Black stars highlight brain areas which are associated with objection recognition as reported 
in previous literature (Akirav and Maroun, 2006; Balderas et al., 2008; Bermudez-Rattoni et al., 2005; 
Clarke et al., 2010; Laubach et al., 2018; Suzuki et al., 1997). 
4.2.4 The influence of iron on α-syn spreading 
Aiming to analyze if iron impacts the α-syn spreading pathology in the brain, 
postnatal iron treatment was combined with intrastriatal α-syn PFFs injections in mice. Due 




et al., 2001), it was supposed that iron could lead to disease progression by enhancing PFFs-
induced α-syn spreading.  
Contrary to our expectations, the threshold-based pS129-α-syn quantification in 
whole brain sections revealed that higher iron amounts resulted in lower pS129-α-syn 
values. The PFFs group without iron treatment showed significantly more pS129-α-syn 
signal within the nigral brain section and within the averaged signal over all six sections 
compared to mice treated with the highest iron dosage.  
These results raised the question how postnatal iron supplementation affects α-syn 
amounts in the brain. In PD patients, a colocalization of iron with LBs was shown 
(Castellani et al., 2000). Furthermore, it is known that iron can bind to α-syn (Binolfi et al., 
2006; Peng et al., 2010b) and that this binding affinity was even increased when α-syn was 
phosphorylated at Y125 or S129 at the C-terminal region (Lu et al., 2011). One hypothesis 
explaining the present results could be that PFFs and iron clustered and spread differently 
than PFFs-induced spreading without iron treatment. In this context, it must be claimed that 
it is still not completely understood how α-syn strains spread from cell to cell, but there 
exist many suggestions.  
The most prominent theory based on data from PFFs-injection studies is the axonal 
transport of α-syn fibrils. Spreading to anatomically connected regions assuming 
anterograde and retrograde transport as observed in the present study supports this 
hypothesis. In vitro studies also suggested the ability of PFFs to be intercellularly 
transmitted through a transsynaptic passage (Emmanouilidou and Vekrellis, 2016; Tran et 
al., 2014; Volpicelli-Daley et al., 2011). Another approach supports the hypothesis that 
pathological forms of α-syn are released from the cell through non-classical exocytosis 
(Jang et al., 2010; Lee et al., 2005). Furthermore, the results of other studies indicate an 
exosome-mediated transmission of a-syn from cell to cell (Alvarez-Erviti et al., 2011; 
Emmanouilidou et al., 2010; Xia et al., 2019) or an intercellular transfer through tunneling 
nanotubes (Abounit et al., 2016; Dieriks et al., 2017). However, it is also unknown if or 
how iron-α-syn-complexes could be transmitted from cell to cell or if iron impedes fibrils 
transmission such as the transsynaptic transport.  
If iron would impede transsynaptic transport to neurons from interconnected brain 
regions, this would support the hypothesis that α-syn aggregates follow different spreading 




spreading pattern so that α-syn spreading followed other routes, passing regions not 
analyzed in our evaluation. The α-syn spreading maps should provide insight into what 
happened to the pS129-α-syn in iron conditions. Referring to the α-syn spreading maps, 
overall, the affected brain regions were similar between iron- and control-treated animals, 
varying in the amount of pS129-α-syn detected in the areas. Hypothesizing that iron 
probably changes spreading routes of α-syn, in some brain regions iron-treated animals 
showed more signal compared to the control group or showed small signal amounts in 
regions where control animals lacked any signal. The latter effect was predominantly seen 
at the contralateral hemisphere in regions such as cingulate cortex (area 2), piriform cortex, 
ventral pallidum, primary visual cortex, secondary visual cortex (lateral part) or 
retrosplenial granular cortex. Interestingly, the retrosplenial granular cortex serves as a hub 
for regions as e.g. cingulate cortex and visual cortex, which are therefore connected. All of 
these connected areas were found to be involved in processing of perceptions in terms of 
direction, location, landmarks and navigation of mammalian species (Mitchell et al., 2018). 
This spreading to different regions compared to the control condition indicates altered 
spreading routes in iron-treated animals.  
On the one hand, the performed connectivity analysis of the present study further 
supports the idea of an iron-dependent pS129-α-syn redistribution pattern, since PFFs-
injected mice treated with the highest iron dosage showed significantly less α-syn signal in 
regions anatomically connected to the injection site. In addition, in these mice a higher 
number of other, connectome-independent regions were α-syn-affected, however, this 
number was not significantly different from the number of regions affected in the control 
group. Iron-treated animals did also not show significantly more α-syn signal in other, 
connectome-independent brain regions. Therefore, on the other hand, these results support 
the idea that iron possibly contributes to a mechanism that degrades pS129-α-syn 
aggregates, as it will be further discussed in chapter 4.2.5. But as mentioned in the previous 
paragraph, it could also be that α-syn spreads to regions not analyzed in this study. Either 
way, the aforementioned results suggest that iron impacts the connectome-based α-syn 
spreading, even if the mechanism is not fully elucidated yet. 
Iron-treated animals showed α-syn spreading differences in brain regions compared 
to control mice in all sectional planes so that an influence of iron on rather short or long 
axonal connections is unlikely from these results. A human study on adults reported that an 




striatum to other resting-state networks including brain areas distant from striatum. 
Furthermore, a reduced intrinsic connectivity within the striatum was associated to a higher 
iron content and was particularly observed in the caudate network (Salami et al., 2018). A 
MRI-based study on PD patients and controls verified a possible negative correlation of 
nigral iron load and functional connectivity and suggested that a striatal interconnectivity 
dysfunction mediates this correlation (Guan et al., 2019). The results of both studies plead 
for a change in connectivity after iron intoxication in the present mouse model which could 
have affected α-syn propagation. Other hypotheses would be that iron accumulation could 
be possibly linked to demyelination which could influence the pathology, or that iron 
accumulation affects specific cell types such as glia cells important for the α-syn transport 
to specific brain regions.  
An iron-dependent neuroinflammation which could influence pS129-α-syn spreading 
would be also conceivable. Microglia and T cell accumulation were analyzed to assess if 
iron influenced the migration or proliferation of both cell types. The results of an 
unexpected iron-induced prevention of microglia migration are further discussed in the next 
chapter.  
4.2.5 The influence of iron on fibril-induced accumulation of immune cells 
Neuroinflammation is a well-documented hallmark of different NDDs including PD. 
Neuroinflammatory mechanisms are known to be mediated by glia cells in terms of 
microgliosis and reactive astrogliosis or by the infiltration of peripheral immune cells such 
as T cells (Lee et al., 2010b; Wang et al., 2015a). As highlighted in the previous chapter, a 
prevention of α-syn spreading was observed in iron-treated animals. In order to investigate 
the hypothesis that iron affected α-syn spreading through an immune response, microglia 
accumulation and T cell infiltration into the injection site and SN were analyzed. These cell 
quantifications should enable to draw a conclusion on possible pathomechanisms. 
First, striatal sections were immunolabeled with a CD11b marker. The CD11b marker 
recognizes microglia as the main phagocytic cells of the brain as well as peripheral 
macrophages. In the present model, the injection of α-syn PFFs induced a significant 
increase in CD11b+ cells within the striatum of PFFs-injected mice without iron treatment 
compared to monomer-treated animals. This accumulation of microglia could either be a 
result of microglia migration or proliferation. Interestingly, in iron-PFFs-treated animals 




Previous studies showed that extracellularly available neuron-released α-syn species 
could activate microglial cells and mediate their migration (Kim et al., 2013; Lee et al., 
2010a; Zhang et al., 2005). In the present study, we expected that extracellularly available 
PFFs after their injection would trigger microglia accumulation in the striatum. Another 
study investigated this process in more detail and showed that α-syn binds to the cell 
adhesion molecule Integrin α-M (CD11b) and induces microglia migration (Wang et al., 
2015b). Accordingly, CD11b-binding of α-syn acting as a chemoattractant triggered the 
activation of NADPH oxidase 2 (Nox2) which induced H2O2 production. Afterwards, the 
Lyn kinase (SFK member) recognized H2O2-changes within the microglia and caused an 
actin filament rearrangement as well as directional microglia migration through 
phosphorylation of the F-actin–associated protein cortactin (Wang et al., 2015b). In other 
studies, it was in turn suggested that microglia migration triggered by α-syn was dependent 
on β1-integrin (Kim et al., 2014) and that a microglia-dependent increase in proliferation 
and cytokine production was impacted by an interaction of oligomeric α-syn and the Toll-
like receptor 2 (Kim et al., 2013, 2014). Furthermore, a strong correlation of microglia 
density and α-syn density was shown. Accordingly, α-syn fibrils showed a higher density 
of α-syn than ribbons or oligomers so that fibrils increased the density of present microglia 
more than other α-syn species (Peelaerts et al., 2015). This result further explains why 
PFFs-injected animals in the present study showed significantly increased amounts of 
CD11b+ microglia in the injection site compared to monomer-injected mice. 
In a study using intrastriatal PFFs injections similar to the present study, MHCII-
positive microglia were quantified in brain regions of the injected rats. Within the striatum 
as injection site a microglia peak was reached at two months post injection. In the following 
two months the microglia amount decreased to normal levels. Interestingly, the observed 
microglia peak at two months almost resembled the peak of neuritic α-syn aggregates 
within the striatum, which however decreased in a slower rate (Duffy et al., 2018). 
Furthermore, in the α-syn-affected agranular insular cortex increased microglia amounts 
were found at two months post injection (Duffy et al., 2018). These results further plead 
for a α-syn-dependent microglia migration in the model used in our study. The mentioned 
study additionally showed that within the SN a significant increase of MHCII-positive 
microglia was found at 2, 4 and 5 months post injection but this effect was absent after 1, 
3 and 6 months (Duffy et al., 2018). Confirming the mentioned study, in the present data 




Even if the cited studies provide an explanation for the observed intrastriatal 
microglia increase in the PFFs group without iron treatment, the role of migrated or 
proliferated microglia within the injection site is not fully understood. Microglia were 
shown to be the major scavenger cells of α-syn aggregates. Hereby, the activation level of 
the present microglia is crucial to degrade α-syn and prevent its spreading (Lee et al., 2008). 
However, due to the conformational state of α-syn within the striatum in the present study, 
clearance mechanisms appear rather unlikely, as the phagocytic ability of the microglia is 
inhibited in the presence of higher aggregates (Choi et al., 2015; Park et al., 2008). 
Specifically, aggregated α-syn bound to FcγRIIB and induced an upregulated expression 
of FcγRIIB impeding microglia-mediated phagocytosis (Choi et al., 2015).  
In the present study, PFFs-injected animals without iron treatment showed more 
PFFs-induced α-syn spreading and a significant increase of microglia in the injection site 
compared to iron-treated animals. These data rather support the hypothesis that migrating 
microglia in PFFs-injected mice without iron treatment facilitate α-syn spreading. This 
hypothesis is supported by a recent study showing that LPS-induced microglia activation 
in mice previously injected with a virus overexpressing α-syn enhanced α-syn spreading. 
After LPS-injection, stronger α-syn spreading to intrastriatally grafted dopaminergic 
neurons was shown. The authors further suggested that the activation state of microglia is 
highly influencing the α-syn spreading, since an IL-4 injection instead of LPS did not 
significantly increase α-syn transmission (George et al., 2019). In an MSA in vitro model, 
α-syn aggregates were also shown to be taken up by microglia-like cells. Starting from the 
uptake site, these cells carrying α-syn migrated to distal places and did not degrade α-syn. 
The authors therefore suggested that microglia could act as a transporter for α-syn 
(Valdinocci et al., 2018). This would further explain why α-syn spreading signal was not 
solely observed within brain regions anatomically associated to the connectome in the 
present study. Since microglia not necessarily travel along axons, it would be conceivable 
that microglia transport α-syn to brain regions which are not related to the connectome. 
In a recent study, α-syn oligomers-containing-exosomes derived from PD patients 
were intrastriatally injected in mice, uptaken by microglial cells and triggered their 
activation. Same effects were shown in vitro using BV-2 cells. Since exosome-treated BV-
2 cells exhibited increased amounts of accumulated α-syn, an augmented α-syn secretion 
into the extracellular space and a dysregulation of autophagy, the authors supposed that 




it is not clear by which underlying mechanism α-syn aggregates are uptaken in microglia. 
Of course, in the present study, injected fibrils in the extracellular space were not packed 
in exosomes so that the latter study deals with another uptake-mechanism. Nevertheless, 
fibrils could have been firstly taken up by neurons and could then have been released in 
exosomes as discussed in chapter 4.2.4. To conclude this part, it is assumed that the injected 
α-syn PFFs led to activation and migration of microglia which could be involved in the 
PFFs-induced α-syn spreading. 
Iron-treated mice of the present study showed less microglia accumulation and less 
α-syn pathology. In the following I will discuss effects of iron on microglia and how this 
might be related to less α-syn spreading. In one study, effects of iron overload and its 
lysosomal iron transporter natural resistance-associated macrophage protein-1 (Nramp1) 
were investigated in vivo and in vitro. In conditions with functional Nramp1, iron-overload 
in mice and BV-2 cells facilitated microglia-mediated degradation of α-syn oligomers 
compared to the nonfunctional Nramp1 condition (Wu et al., 2017). This leads to the 
assumption, that iron pre-conditioning could be involved in α-syn degradation in the 
present study. 
Another study showed that iron overload enhanced pro-inflammatory responses such 
as cytokine release of IL-1β and TNFα in microglia activated by LPS or MPP+ (Wang et 
al., 2013). This leads to the hypothesis that an induced inflammation fostered the 
degradation of α-syn aggregates in the present study. Accordingly, in one study, mice 
received an intraventricular injection of recombinant adeno-associated virus mediated 
expression of Interleukin (IL)-6 and additionally an intrahippocampal injection of α-syn 
fibrils. The results showed that inflammatory pre-conditioning of mouse brains reduced the 
α-syn pathology mediated by the injection of α-syn fibrils (Koller et al., 2017). Also in 
preclinical AD models, triggered inflammation was shown to attenuate the proteinopathy 
(Herber et al., 2007; Shaftel et al., 2007). Thus, it is conceivable that iron pre-conditioning 
could provoke similar effects on α-syn pathology. However, it is still unknown if iron 
overload itself provokes inflammation in the brain. Another study reported that classical 
activation of microglia impaired microglia migration (Lively and Schlichter, 2013). 
Therefore, it is supposed that iron overload led to an impairment of microglia and their 
migration and to an inflammatory pre-conditioning, causing less α-syn fibrils pathology 




In another experiment, the presence of T cells in the striatum and SN were analyzed. 
It is known from MPTP mouse models of PD that CD4+ and CD8+ T cells infiltrate the 
brain and especially the SN (Brochard et al., 2009; González et al., 2013; Kurkowska-
Jastrzebska et al., 1999). Against the expectations, in the present study, no significant 
intergroup differences in T cell amounts within the striatum or the SN were observed. Based 
on the literature, an increase of T cells would be expected in PFFs-treated animals. In a 
study by Harms and colleagues short α-syn fibrils were not only able to activate and recruit 
microglia but also peripheral cells as monocytes, macrophages and lymphocytes (Harms et 
al., 2017). Specifically, 8 weeks post α-syn PFFs injection into the SN of rats a significant 
T cell infiltration as well as monocytes/macrophages infiltration was observed within the 
SN. However, microglia amounts did not increase within the injection site (Harms et al., 
2017). In comparison to the present study, Harms and colleagues used a higher α-syn 
dosage (8 µg), a different injection site (SN), different animal species (rats) and an earlier 
time point of analysis (8 weeks post injection). Especially the latter mismatch could explain 
the different output in our study. Probably the acute immune response of T cells occurred 
earlier, and the analysis time point in our study was therefore too late to detect an 
infiltration. Another study made aware that the response of T cells could differ regarding 
different species of α-syn (monomer, nitrated, fibrillar). This means that changes in 
conformational stages of α-syn probably influence the type of T cell response during 
disease progression. An α-syn variant specificity of the response of CD4-positive T cells 
was recently shown, indicating the strongest CD4+ T cell infiltration into the brain after 
fibril treatment (Olesen et al., 2018). However, the authors injected α-syn (2 × 100 µg) 
subcutaneously in mice so that the method strongly differs from the method used in the 
present study which could also explain the different findings. 
4.2.6 Limitations and outlook of the α-syn spreading model 
In order to analyze the contribution of iron to PFFs-induced α-syn spreading, well-
established and published methods were used as discussed in previous chapters. However, 
one general issue of PFFs injections into the brain is the possibility of PFFs reflux into the 
injection channel. Even if the needle was always left in place for another 4 min after the 
intrastriatal injection to avoid reflux, it must be considered that some PFFs were probably 
taken up by the motor cortex as part of the injection channel. Therefore, the interpretation 




possibility that this is not necessarily a result of anterograde/retrograde spreading but might 
be caused by reflux during the injection. 
The present study and its analysis methods provide a comprehensive insight into iron-
dependent effects on α-syn spreading but spreading routes could not be holistically tracked. 
Thus, it is not clear if iron induced a degeneration or redistribution of α-syn aggregates. In 
order to complete our data in future studies, light sheet microscopy coupled with brain 
clearing methods (Becker et al., 2012; Costantini et al., 2015; Qi et al., 2019) will be the 
striking approach to-be for α-syn propagation experiments, answering the question of the 
iron’s role in PFFs-induced α-syn spreading. However, so far, no studies are available using 
this technique to track α-syn spreading. 
The comparison of α-syn spreading maps to the connectome already showed that iron 
reduced α-syn spreading to anatomically connected regions. Furthermore, several brain 
regions were affected in PFFs-injected mice treated with either iron or vehicle which did 
not resemble the connectome. Even if this could be a hint for different involved α-syn 
propagation mechanisms, another reason could be that the used connectome does not fully 
fit to the injection site in the present model. The connectome maps were generated based 
on two injection experiments of the Allen Mouse Brain Connectivity Atlas (©2020 Allen 
Institute for Brain Science. Allen Mouse Brain Connectivity Atlas) with injection sites 
fitting to the radius of our injection site. However, they injected much less volume and the 
injections were therefore much more specific. Even if the connectome maps of both 
experiments were combined, the injection site of the present study is not fully represented 
so that possibly more brain regions could belong to the connectome than described. 
Therefore, the connectome of the present injection site needs further investigation to fully 
define the effect of iron in the present model.  
Moreover, in further studies iron accumulation in different brain sections should be 
mapped and overlaid with pS129-α-syn signal in the brain. This analysis would help to 
answer the question if iron and α-syn cluster together in the brain. Comparing the present 
α-syn spreading results with iron distribution maps shown in different publications 
(Billings et al., 2019; Morello et al., 2009; Zumbrennen-Bullough et al., 2014) can already 
provide insights on the effects of iron on α-syn spreading. Providing iron maps of coronal 
brain sections of untreated wild-type mice, studies reported predominant iron accumulation 




putamen nucleus (Morello et al., 2009; Zumbrennen-Bullough et al., 2014). Indeed, in the 
SNpc the present α-syn analysis showed more α-syn signal in iron-treated mice compared 
to the control group. However, this pathology difference was only observed in one of the 
two measured nigral sections at the injected hemisphere and was not statistically 
significant. Regarding the iron availability in the globus pallidus and caudate-putamen 
nucleus, one sectional plane used in the present study resembled the sections used in above-
mentioned studies (Bregma -1.58 mm). In these brain regions, the iron group did not differ 
in α-syn signal from the control group.  
In a mouse study with a postnatal, oral iron treatment of mice between p10-17 which 
are comparable conditions to the present study, the distribution of iron deposits was 
illustrated in one nigral sectional plane for one vehicle- and one iron-treated mouse 
(Billings et al., 2019). Taking a closer look at these maps, the iron-intoxicated brain section 
showed in general more iron and a specific enrichment in parts such as the hippocampus 
and cortical regions. Most interestingly, there was a strong iron accumulation in the area 
where the entorhinal cortex, the amygdalopiriform transition area, the 
amygdalohippocampal area and the posteromedial cortical amygdaloid nucleus are located 
(Billings et al., 2019). In these regions, strong α-syn pathology could be observed in the 
present study, but the control group showed either more or equal α-syn amounts in these 
regions compared to the iron group. Thus, it is assumed that α-syn is rather not increased 
in regions with enriched iron accumulation. This could support the hypothesis that iron 
does not cluster with α-syn aggregates in this disease model but rather effects α-syn 
pathology indirectly for example by affecting the microglia accumulation as discussed in 
chapter 4.2.5.  
4.3 The effect of iron on α-syn spreading in cortical neurons 
After demonstrating the effect of iron on α-syn spreading in the brain of C57BL/6J 
mice, the present analysis aimed to elucidate if iron would influence spreading of seeded 
α-syn PFFs in vitro using cortical neurons. Therefore, cells in one compartment of a 
microfluidic chamber were treated with iron and α-syn PFFs. The transport of pS129-α-syn 
to the secondary cell compartment was analyzed. In cells treated with iron, no significant 
changes of the pS129-α-syn transmission to cells in the secondary cell compartment were 




The usage of microfluidic chambers to track the intracellular propagation of α-syn 
fibrils from one compartment to the other is a common model. Both, anterograde and 
retrograde propagation has been confirmed seeding PFFs either to the soma or the neurites, 
respectively (Volpicelli-Daley et al., 2011). Transmission of α-syn fibrils to second order 
neurons has also been described in the same device (Freundt et al., 2012). In another study, 
intercellular propagation was further investigated with a microfluidic device existing of 
three successive cell-containing chambers. This model showed α-syn aggregate arrival in 
the third chamber at 14 days post PFFs seeding (Tran et al., 2014). The mentioned studies 
showed that the microfluidic chamber itself is a practicable device to analyze α-syn 
propagation. In general, the present data could also verify α-syn fibrils propagation to the 
secondary cell compartment. Iron likely affects transmission mechanisms of α-syn which 
cannot be reproduced to a full extent with this setup.  
As already discussed in chapter 4.2.4, the literature mentions several mechanisms 
underlying α-syn transmission from cell to cell such as axonal transport and transsynaptic 
transmission, nonclassical exocytosis, exosome-mediated transmission or tunneling 
nanotubes. One microfluidic chamber experiment suggested that synapses were not 
required to transmit fibrils to second-order neurons, since α-syn was already transmitted to 
these neurons at a time point when synapses have not been formed (Freundt et al., 2012).  
Discussing contributory factors and circumstances of α-syn uptake and transport, a 
study using primary neurons revealed that the internalization of misfolded α-syn was 
associated with lysosomal processing. A dysfunctional lysosomal integrity was suggested 
to accelerate the transmission of α-syn (Karpowicz et al., 2017). Another study showed that 
lymphocyte-activation gene 3 (LAG3) bound to pathologic α-syn and thereby initiated its 
transmission and toxicity. Specifically, LAG3 was involved in the endocytosis of 
exogeneous α-syn fibrils (Mao et al., 2016). Furthermore, the internalization, fibrillation 
and propagation of α-syn was suggested to be mediated by members of the syndecan (SDC) 
family, especially by SDC3 (Hudák et al., 2019). Even if the ability of iron to foster α-syn 
aggregation has been extensively studied as discussed in the previous chapters, little is 
known about its possible effects on the above-mentioned mechanisms of α-syn propagation. 
In one study, oligomers were generated by applying iron and an organic solvent to α-
syn. These oligomers were found to improve synaptic transmission mediated by the 




et al., 2011). Therefore, iron possibly impacts α-syn spreading indirectly by helping to 
generate specific α-syn conformations that were more prone to spread compared to the 
PFFs used in the present study. This could further explain why an iron-related effect on α-
syn spreading was found in our in vivo model but not in the in vitro model. In the mouse 
brain, injected recombinant PFFs function as seeds and trigger aggregation and spreading 
of these aggregates throughout the brain. Iron could affect the α-syn aggregation and these 
aggregates are possibly prone to spread differently, which would support an iron-dependent 
redistribution of α-syn. Different spreading pattern cannot be investigated in the used 
microfluidic chamber model, but it can be assumed from the results that iron does not affect 
the uptake of the recombinant PFFs applied to the somata of neurons and their spreading.  
Furthermore, a recent publication using SN4741 cells showed that iron promoted α-
syn aggregation indirectly by decreasing the expression of TFEB. TFEB functions as 
transcriptional regulator of the autophagosome-lysosome pathway. Thereby, the TFEB-
mediated autophagosome-lysosome fusion was inhibited resulting in enhanced α-syn 
aggregation. In addition, the authors showed that cell-to-cell transmission of α-syn was also 
enhanced by iron enrichment, whereas TFEB overexpression attenuated this effect (Xiao 
et al., 2018). They further speculated that iron could foster a lysosomal dysfunction by 
TFEB-mediation, leading to an increased α-syn release via exosomes. The effect of 
lysosomal dysfunction on α-syn exosomal release and transmission has already been shown 
(Alvarez-Erviti et al., 2011). One study is interesting in this context of α-syn pathology that 
investigated another trace element: Mn2+ has also been shown to trigger the secretion of 
misfolded α-syn in exosomal vesicles (Harischandra et al., 2019). Therefore, it is possible 
that iron only affects one particular mechanism of transmission depending on the applied 
α-syn conformation. The microfluidic chamber model in the present study rather 
investigates axonal transport and transmission so that this model is probably not sensitive 
enough to investigate iron-affected mechanisms of α-syn fibrils spreading. Further 
experiments should also test if alterations in parameters as time point and duration of iron 
treatment or its dosage would change the output of this experiment.  
In regard to the in vivo study discussed in chapter 4.2 iron-related changes on α-syn 
spreading were supposed to be mediated through its effect on microglia. Accordingly, 
microglia could facilitate the spreading of α-syn. Since in the in vitro experiment only 
neurons were investigated, this could provide an explanation for absent iron-dependent 




α-syn uptake or transmission to other cell types such as microglia. In the context of 
exosomal release, one study suggested that microglia probably support α-syn transmission 
via exosomes. In their experiment, BV-2 cells were treated with exosomes containing 
oligomeric α-syn derived from PD patients. This treatment triggered an inhibition of 
autophagy, an intracellular accumulation of α-syn in the microglia as well as accelerated 
secretion of the protein suggesting a crucial role of microglia in the exosomal-mediated 
transmission (Xia et al., 2019).  
Of course, in vitro experiments do not fully mimic the circumstances as present in 
brains, simply due to the complexity of the brain e.g. with its diversity of cell types and its 
connectivity. The possibility that iron affects rather α-syn spreading to other cell types or 
affects α-syn propagation indirectly through its effects on glia cells as discussed in chapter 
4.2.5 provide explanations why no difference on α-syn spreading was found in iron-treated 
cortical neuron cultures. Therefore, further studies are needed, investigating the effect of 
iron on α-syn spreading in different cells types as microglia or mixed cultures to unravel 
which mechanism was responsible for the modulation of α-syn spreading in iron-treated 
mice.  
4.4 Therapeutic approach: the influence of fasudil on α-syn spreading 
Up till now, prevention or cure of PD is impossible so that therapeutic investigations 
are needed to reveal new target mechanisms and test the effectiveness of possible drugs. In 
NDDs, the signaling pathway of ROCK has been described as an interesting target. As 
recently reviewed, ROCK is involved in several cellular processes of NDDs such as 
autophagy, synaptic dysfunction or degeneration of axons (Koch et al., 2018). The ROCK 
inhibitor fasudil is a drug approved to treat sub-arachnoid hemorrhage-induced vasospasms 
in clinical use (Suzuki et al., 2007, 2008). In context of neurodegeneration, fasudil gained 
especially attention for its beneficial effects on animal- and cell-based ALS models 
(Günther et al., 2017; Tönges et al., 2014). Therefore, a multicenter clinical phase IIa trial 
is currently investigating disease-modifying effects of fasudil treatment in ALS patients 
(Lingor et al., 2019). Furthermore, the interest arose to analyze the effect of fasudil in PD 
due to the ability of fasudil to bind α-syn and its attenuating effects on e.g. α-syn 
aggregation or cell loss in toxin-based or α-syn mutation-based PD models (He et al., 2016; 
Li et al., 2017; Tatenhorst et al., 2016; Tönges et al., 2012; Zhang et al., 2019b; Zhao et al., 




of PD pathology besides the degeneration of dopaminergic neuron in the SN, the current 
study aimed at preventing α-syn fibrils spreading through the brain of PFF-injected mice. 
First, possible side effects of the α-syn PFFs injections were ruled out by 
investigating motor function of the mice and neuronal loss in the SN at 90 dpi. In the present 
study, mice injected with PFFs behaved similar to monomer-injected animals on the 
rotarod, irrespective of whether they were treated with fasudil or not. As extensively 
discussed in chapter 4.2.1, in the used conditions, an inconspicuous motor performance of 
PFFs-injected mice was expected based on the existing literature (Luk et al., 2012a). 
Previous studies did not report negative effects of fasudil treatment on motor behavior of 
mice (Tatenhorst et al., 2016; Tönges et al., 2014) so that unaltered motor behavior of these 
mice was expected.  
Second, it was analyzed if PFFs injections induced neurotoxic effects at 90 dpi in 
form of neuronal loss within the SN as a brain region directly connected to the injection 
site. One study already showed that fasudil treatment in an MPTP mouse model of PD 
could rescue dopaminergic neurons in the SN from degeneration (Tönges et al., 2012). In 
a 6-OHDA model, fasudil treatment was not sufficient enough to prevent dopaminergic cell 
loss (Tatenhorst et al., 2014). In the present analysis, PFFs injections did not lead to a 
significant cell loss at 90 dpi compared to monomer-injected mice. Accordingly, PFFs-
injected animals with additional fasudil treatment showed similar cell amounts as 
monomer-injected animals. This observation goes in line with the literature showing that 
neuronal loss in the SN of PFFs-treated rodents occurred at later time points, such as 180 
dpi (Luk et al., 2012a; Paumier et al., 2015). Thereby, it has been ensured that α-syn 
spreading could not have been massively influenced by neurodegeneration mechanism at 
the timepoint of analysis.  
With two quantification methods, it was shown that fasudil did not prevent PFFs-
induced α-syn spreading through the brain. The pS129-α-syn pathology was similar in 
fasudil-treated PFFs-injected mice compared to PFFs-injected mice with vehicle-treatment. 
These results were against the expectations, since a previous study already showed a close 
link of fasudil to α-syn pathology. The authors observed that fasudil could bind to tyrosine 
residues Y133 and Y136 in the C-terminal region of α-syn and led to a reduction of α-syn 
aggregation in vitro. In A53T mice, fasudil treatment resulted in less motor and cognitive 




2016). Furthermore, using a model of tauopathy, fasudil treatment of Drosophila reduced 
tau pathology by an enhancement of autophagy (Gentry et al., 2016).  
It may be that fasudil does not target the recombinant PFFs used in the present model. 
The aforementioned PD study reporting beneficial fasudil effects used a transgenic mouse 
model (Tatenhorst et al., 2016) so that the experimental conditions as well as the seeding 
mechanism could differ to the present study. Nigral injections of different α-syn strains in 
the rat brain showed differences in the efficiency of seeding and spreading of α-syn 
dependent on the used pathogenic α-syn strains such as fibrils, ribbons or oligomers 
(Peelaerts et al., 2015). It is possible that fasudil does not target the recombinant PFFs used 
in the present work but would have an influence on seeding or spreading of other α-syn 
strains. Furthermore, the fasudil dosage used in the present study was taken over from 
another experiment (Tatenhorst et al., 2016) but could be a too low-dosed treatment in this 
acute model of an immense PFFs seeding in the brain.  
Assuming a main transsynaptic transmission of fibrils, we supposed that fasudil 
likely affects the spreading pathology via synapses. The role of ROCK activity in synaptic 
function has been described in different studies (Koch et al., 2018). Furthermore, the 
inhibition of ROCK is already known to enhance the size of the postsynaptic density, alter 
the morphology of dendritic spines, and trigger long-term potentiation (Nakayama et al., 
2000; Swanger et al., 2015). The fact that no differences in spreading pathology were found 
could entail that α-syn fibrils are differently transmitted or fasudil is not able to stop α-syn 
transmission via synapses.  
Bringing together the present result with the iron PFFs in vivo study discussed in 
chapter 4.2, another reason to assume spreading prevention by fasudil was its known 
attenuating effects on inflammatory responses (Scheiblich and Bicker, 2017). The possible 
contribution of microglia on α-syn propagation has been extensively discussed in chapter 
4.2.5. In that chapter, it was also assumed that the beneficial influence of iron on spreading 
resulted from its attenuating effect on microglia accumulation in the injection site, which 
has to be further investigated. In the context of fasudil, an anti-inflammatory effect was 
assumed, which could prevent PFFs-induced microglia migration and the contribution of 
microglia in α-syn spreading. Accordingly, in several PD rodent studies, predominantly 
using the MPTP-intoxication model, fasudil or other ROCK inhibitors were shown to 




(Barcia et al., 2012; He et al., 2016; Li et al., 2017; Zhao et al., 2015). These inhibitory 
effects of fasudil on inflammation have also been described in studies analyzing fasudil in 
context of MS (Guo et al., 2014, 2019; Wang et al., 2019). In an AD model, rats were 
intracerebroventricularly injected with Aβ1-42. Treatment with fasudil reduced Aβ-induced 
neurodegeneration in the hippocampus. The prevention of the neurodegeneration was also 
linked to a fasudil-depending suppression of the inflammatory response, such as microglia 
activation and proliferation (Song et al., 2013). If microglia play a crucial role in the α-syn 
propagation, we would have expected a significantly reduced α-syn spreading after 
treatment with the ROCK-inhibitor fasudil. The application method could provide a 
possible reason why fasudil did not mitigate the severity of the α-syn pathology in the 
present study. The administered dosage in the literature (20-40 mg/kg bw) investigating 
inflammatory responses in PD models was always similar to the dosage applied in the 
current study (30 mg/kg bw). However, in the present study fasudil was applied via 
drinking water whereas the above-mentioned studies used a daily intraperitoneal injection 
of fasudil (He et al., 2016; Li et al., 2017; Zhao et al., 2015). These methodological 
differences might also explain the lack of an effect of fasudil treatment on α-syn spreading 
in our study.  
Taken together, it was assumed that fasudil treatment affects α-syn spreading due to 
its inhibitory effects on the synapse-related ROCK and its attenuating effects on the 
inflammatory response. In contrast, fasudil supplementation via drinking water did not alter 
α-syn spreading in PFFs-injected mice in the present analysis. On the one hand, the applied 
dosage of α-syn PFFs was probably too high or the dosage of fasudil too low to affect the 
α-syn spreading appropriately. On the other hand, the effect of fasudil could be α-syn 
species dependent, which would include the hypothesis that fasudil did not target the 
applied PFFs in our model. Within the scope of the doctoral thesis, effects of fasudil on 







5 Concluding remarks 
The experiments conducted within the scope of this doctoral thesis highlight α-syn 
pathology in PD as the major interface for known pathomechanisms and possible triggers 
of PD. The propagation of α-syn is a major hallmark in PD. Thus, investigating the relation 
of α-syn spreading with targets known to affect α-syn aggregation is an auspicious way to 
explore underlying pathomechanisms of disease progression, contributing to the 
development of new therapeutic strategies for PD patients. 
For the first time, a combination of X-ray techniques and an immunohistochemical 
staining allowed the visualization of trace elements as well as the detection of β-sheet rich 
structures in two nigral LBs of tissue from PD patients. Further experiments need to assess 
whether LBs present a sub-stratified elemental profile. Measurements of trace element 
concentrations in nigral neurons of PD-diagnosed end-stage patients revealed strong intra- 
and interindividual differences which argue for different subgroups of disease rather than 
a homogeneous pathology. Copper was identified as the most discriminating element 
comparing PD and control tissue. The present results highlight the strong variance of 
human samples which prevents to detect PD-relevant pathogenic trace element alterations 
in small sample sizes as feasible in synchrotron-based studies. In a side project using lipid 
extraction, a higher sample size was used to assess the role of cholesterol in PD, validating 
a cholesterol increase in PD samples. 
Since iron is the main described trace element in context of PD and related to α-syn 
aggregation, we were interested in analyzing its influence on α-syn spreading. In an acute 
mouse model of postnatal iron intoxication and intrastriatal α-syn PFFs injections, high-
dosed iron treatment modulated α-syn spreading and additionally suppressed the 
accumulation of microglia in the striatum. Our data indicate that microglia probably 
accumulate in the injection site to support α-syn spreading and that iron attenuates this 
microglia-mediated spreading. Our results lead to the hypothesis that iron either supports a 
redistribution of α-syn aggregate spreading in the brain or mediates indirectly α-syn 
aggregate degradation. Both, iron and PFFs treatment, affected LTM at different time 
points, underscoring its relevance for pathogenesis. 
In vitro, microfluidic chambers were shown as a useful model to investigate α-syn 




was not able to reproduce our in vivo data regarding an iron-dependent modulation of α-
syn spreading. This suggests, that other cell types, e.g. microglia, are involved in iron-
mediated effects, which were not studied in the present microfluidic chamber model.  
Finally, we analyzed if ROCK inhibition through an oral fasudil administration 
attenuated α-syn spreading. No side effects of PFFs or fasudil treatment in form of 
cytotoxicity or motor decline were observed. Fasudil appeared ineffective concerning the 
prevention or attenuation of α-syn spreading in mice. On the one hand, the applied dosage 
of α-syn PFFs was probably too high so that fasudil in its applied dosage could not affect 
the α-syn spreading appropriately. On the other hand, the effect of fasudil is probably α-
syn species dependent including the hypothesis that fasudil did not target the applied PFFs.  
Taken together, the present study underlines the heterogeneity of the pathology in PD 
patients and argues for different subgroups of the disease rather than for one homogeneous 
pathology. Iron was shown to modulate α-syn spreading and to affect behavior, rendering 
it an auspicious therapeutic target. The results support the approach to test iron chelators as 
therapeutic strategies, which is currently realized by a clinical trial testing the effectiveness 
of deferiprone in PD patients (FAIRPARKII, NCT02655315). More experiments are 
needed to even better understand the role of iron and ROCK inhibition in α-syn spreading 
pathology, and the present results may help to develop new experimental designs based on 
arising questions and, in translational prospective, to search for promising treatment 





Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease 
affecting approximately 1 % of the population above 60 years of age. It affects 
preferentially the extrapyramidal system, causing severe deficits in motor function. So far, 
the progression of the disease can neither be delayed nor cured. The dyshomeostasis of 
trace elements, especially of iron, and the presence of alpha-synuclein (α-syn) aggregate-
containing Lewy bodies (LBs) in the brain are two main pathologic events playing a crucial 
role in PD. The underlying pathomechanisms for spreading of α-syn through the brain are 
still unknown, but PD-related targets such as trace elements or the rho-associated protein 
kinase (ROCK) were suggested to affect its aggregation pathology. Identifying triggers that 
affect α-syn propagation is of fundamental importance since they could be considered as 
auspicious targets for new therapeutic strategies.  
In the present study, the elemental content of nigral neurons of PD patients and 
control patients without neurodegeneration was analyzed using X-ray fluorescence (XRF) 
and it was found that intracellular element concentrations differ substantially within and 
between patients. Copper was the most discriminating element between the groups. On a 
subcellular level, X-ray diffraction revealed the presence of β-sheet protein structures in a 
LB, whereas XRF measurements identified a varying distribution of trace elements such as 
iron, selenium or copper within two LBs. Furthermore, the relation of iron and α-syn was 
examined. With the objective to investigate the influence of iron on α-syn propagation 
through the brain, a murine α-syn fibrils injection model was combined with iron 
intoxication and revealed reducing and redistribution effects of iron on α-syn spreading and 
a reduced microglia accumulation. Both iron and α-syn fibrils treatment resulted in long-
term memory dysfunction in the novel object recognition test. Moreover, the influence of 
iron on α-syn spreading was investigated in cortical neurons using microfluidic chambers. 
Spreading of α-syn seemed not to be affected by iron in vitro, arguing for a more systemic 
mode of action in vivo. Since the ROCK inhibitor fasudil showed multiple protective effects 
in PD mouse models previously, we analyzed its effects on α-syn spreading in vivo. Here, 
the application of fasudil did not alter α-syn propagation. Taken together, the present work 
investigates the influence of trace elements, particularly iron, and ROCK inhibition on α-
syn spreading and thus contributes to a better understanding of PD pathophysiology and to 






The following pages contain supplementary tables which are related to the results 
shown in chapter 3.2.3.2 and describe the α-syn pathology in brain regions of PFFs-injected 
mice treated with vehicle or iron. Each table is related to a specific coronal brain section 
which is named after its distance to the Bregma, as stated in the Paxinos atlas. The 
individual brain regions were also abbreviated according to the Paxinos atlas (Paxinos and 
Franklin, 2003). Empty spaces in the column “p” of each table imply “no significant 
difference” referring to the respective performed Mann-Whitney-U test.  
 
 
Suppl. Table 1. Quantification of pS129-α-syn in individual brain regions in section ‘Bregma 1.54 mm’. The averaged α-syn group signal is shown for affected brain 
regions in section ‘Bregma 1.54 mm’. Abbreviations are used according to the Paxinos atlas (Paxinos and Franklin, 2003). Signal in each brain region was rated according to a 
5-stage scale from 0 (no α-syn signal) to 4 (severe α-syn pathology) and the group means as well as SEM values are presented per hemisphere. The ‘code’ is a simplified 
representation of the pathology rating to which the group means were again classified to (−, +, ++, +++, ++++). The code thereby represents the assessment stages used in Figure 
29 and differences regarding these 5 stages (−, +, ++, +++, ++++) between the two groups (240 mg/kg Fe/PFFs and control/PFFs) were marked in bold. For a statistical 
comparison, Mann-Whitney-U-test was performed for each brain region per hemisphere. Where applicable p-values are stated (#p < 0.1; *p < 0.05; **p < 0.01). 
Bregma 1.54 mm; interaural 5.34 mm    α-syn pathology  
  Injected hemisphere Contralateral hemisphere 
  control 240mg/kg Fe  control 240mg/kg Fe  
Brain regions 
Abbreviation 
Paxinos Mean SEM Code Mean SEM Code p Mean SEM Code Mean SEM Code p 
accumbens nucleus, core acbC 0.17 0.17 + 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
accumbens nucleus, shell AcbSh 0.67 0.21 + 0.71 0.29 +  0.17 0.17 + 0.14 0.14 +  
agranular insular area AID 1.83 0.60 ++ 1.29 0.42 ++  1.83 0.60 ++ 1.14 0.46 ++  
agranular insular area AIV 0.33 0.33 + 0.29 0.18 +  0.50 0.22 + 0.29 0.18 +  
caudal interstitial nucleus of medial longitudinal 
fasciculus CI 0.50 0.34 + 0.43 0.30 +  0.00 0.00 - 0.00 0.00 - 
 
cingulate cortex, area 1 Cg1 2.17 0.48 +++ 1.00 0.44 +  0.50 0.22 + 0.43 0.30 +  
cingulum, anterior forceps of corpus callosum, 
external capsule cg fmi ec 1.83 0.40 ++ 0.86 0.40 +  1.33 0.42 ++ 1.00 0.31 + 
 
dorsal endopiriform nucleus DEn 0.33 0.21 + 0.14 0.14 +  0.00 0.00 - 0.00 0.00 -  
dysgranular insular cortex DI 1.83 0.54 ++ 1.29 0.52 ++  1.33 0.49 ++ 0.71 0.36 +  
granular insular cortex GI 0.50 0.22 + 0.57 0.30 +  0.50 0.22 + 0.43 0.30 +  
infralimbic cortex IL 0.33 0.21 + 0.14 0.14 +  0.17 0.17 + 0.00 0.00 -  
prelimbic cortex PrL 1.50 0.50 ++ 0.14 0.14 + * 0.33 0.21 + 0.00 0.00 -  
primary motor cortex M1 1.50 0.43 ++ 0.71 0.36 +  0.67 0.21 + 0.14 0.14 +  
somatosensory 1, jaw region; primary 
somatosensory cortex S1J S1 0.50 0.34 + 0.14 0.14 + 
 
0.17 0.17 + 0.00 0.00 - 
 
striatum Cpu 1.33 0.42 ++ 1.14 0.26 ++  1.00 0.26 + 0.29 0.18 +  







Suppl. Table 2. Quantification of pS129-α-syn in individual brain regions in section ‘Bregma 0.38 mm’. The averaged α-syn group signal is shown for affected brain 
regions in section ‘Bregma 0.38 mm’. Abbreviations are used according to the Paxinos atlas (Paxinos and Franklin, 2003). Signal in each brain region was rated according to a 
5-stage scale from 0 (no α-syn signal) to 4 (severe α-syn pathology) and the group means as well as SEM values are presented per hemisphere. The ‘code’ is a simplified 
representation of the pathology rating to which the group means were again classified to (−, +, ++, +++, ++++). The code thereby represents the assessment stages used in Figure 
29 and differences regarding these 5 stages (−, +, ++, +++, ++++) between the two groups (240 mg/kg Fe/PFFs and control/PFFs) were marked in bold. For a statistical 
comparison, Mann-Whitney-U-test was performed for each brain region per hemisphere. Where applicable p-values are stated (#p < 0.1; *p < 0.05; **p < 0.01). 
Bregma 0.38 mm; interaural 4.18 mm    α-syn pathology  
  Injected hemisphere Contralateral hemisphere 
  Control 240mg/kg Fe  Control 240mg/kg Fe  
Brain regions 
Abbreviation 
Paxinos Mean SEM Code Mean SEM Code p Mean SEM Code Mean SEM Code p 
adrenergic group C1 OR claustrum C1 0.33 0.21 + 0.43 0.20 +  0.50 0.34 + 0.57 0.43 +  
agranular insular area AIP 0.67 0.21 + 0.57 0.30 +  0.00 0.00 - 1.14 0.40 ++ * 
cingulate cortex, area 1 Cg1 2.17 0.60 +++ 1.57 0.30 ++  0.67 0.33 + 0.29 0.18 +  
cingulate cortex, area 2 Cg2 1.83 0.60 ++ 0.86 0.26 +  0.00 0.00 - 0.29 0.18 +  
corpus callosum; external capsule cc ec 0.67 0.33 + 0.57 0.30 +  0.00 0.00 - 0.43 0.20 +  
dorsal endopiriform nucleus DEn 0.67 0.21 + 0.14 0.14 +  0.17 0.17 + 0.14 0.14 +  
granular insular cortex; dysgranular insular 
cortex GI DI 2.00 0.45 ++ 1.14 0.34 ++  1.67 0.49 ++ 0.71 0.47 +  
interstitial nucleus of posterior limb of anterior 
commissure IPACL 0.17 0.17 + 0.14 0.14 +  0.17 0.17 + 0.00 0.00 -  
lateral preoptic nucleus LPO 0.17 0.17 + 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
lateral septal nucleus LSV 0.00 0.00 - 0.14 0.14 +  0.00 0.00 - 0.14 0.14 +  
lateral septal nucleus LSI LSI 0.00 0.00 - 0.14 0.14 +  0.00 0.00 - 0.14 0.14 +  
nuclei of stria terminalis BSTLV 0.17 0.17 + 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
nuclei of stria terminalis BSTMV BSTMA 0.17 0.17 + 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
nuclei of stria terminalis BSTLD 0.17 0.17 + 0.29 0.29 +  0.00 0.00 - 0.00 0.00 -  
olfactory tubercle  Tu 0.00 0.00 - 0.57 0.20 + * 0.00 0.00 - 0.00 0.00 -  
piriform cortex Pir 0.33 0.33 + 0.43 0.30 +  0.00 0.00 - 0.14 0.14 +  







Suppl. Table 2 continued. 
Bregma 0.38 mm; interaural 4.18 mm    α-syn pathology  
  Injected hemisphere Contralateral hemisphere 
  Control 240mg/kg Fe  Control 240mg/kg Fe  
Brain regions 
Abbreviation 
Paxinos Mean SEM Code Mean SEM Code p Mean SEM Code Mean SEM Code p 
second somatosensory cortex S2 1.50 0.50 ++ 0.29 0.18 + # 1.83 0.54 ++ 0.29 0.18 + * 
somatosensory 1, dysgranular zone S1DZ 1.00 0.63 + 0.29 0.18 +  0.00 0.00 - 0.00 0.00 -  
somatosensory 1, forelimb region S1FL 1.67 0.61 ++ 0.86 0.26 +  0.67 0.33 + 0.29 0.18 +  
somatosensory 1, hindlimb region S1HL 2.50 0.43 +++ 1.14 0.34 ++ * 0.83 0.31 + 0.14 0.14 +  
somatosensory 1, barrel field  S1BF 0.50 0.34 + 0.29 0.18 +  0.00 0.00 - 0.00 0.00 -  
striatum CPu 1.50 0.22 ++ 1.57 0.30 ++  0.67 0.21 + 0.57 0.30 +  
supplementary motor cortex M2 2.67 0.42 +++ 2.00 0.44 ++  1.00 0.45 + 0.57 0.20 +  








Suppl. Table 3. Quantification of pS129-α-syn in individual brain regions in section ‘Bregma 0.02 mm’. The averaged α-syn group signal is shown for affected brain 
regions in section ‘Bregma 0.02 mm’. Abbreviations are used according to the Paxinos atlas (Paxinos and Franklin, 2003). Signal in each brain region was rated according to a 
5-stage scale from 0 (no α-syn signal) to 4 (severe α-syn pathology) and the group means as well as SEM values are presented per hemisphere. The ‘code’ is a simplified 
representation of the pathology rating to which the group means were again classified to (−, +, ++, +++, ++++). The code thereby represents the assessment stages used in Figure 
29 and differences regarding these 5 stages (−, +, ++, +++, ++++) between the two groups (240 mg/kg Fe/PFFs and control/PFFs) were marked in bold. For a statistical 
comparison, Mann-Whitney-U-test was performed for each brain region per hemisphere. Where applicable p-values are stated (#p < 0.1; *p < 0.05; **p < 0.01). 
Bregma 0.02 mm; interaural 3.82 mm    α-syn pathology  
  Injected hemisphere Contralateral hemisphere 
  Control 240mg/kg Fe  Control 240mg/kg Fe  
Brain regions 
Abbreviation 
Paxinos Mean SEM Code Mean SEM Code p Mean SEM Code Mean SEM Code p 
agranular insular area AIP 0.50 0.22 + 0.25 0.16 +  0.67 0.21 + 0.38 0.26 +  
anterior part of anterior commissure aca 0.00 0.00 - 0.13 0.13 +  0.17 0.17 + 0.13 0.13 +  
caudal interstitial nucleus of medial 
longitudinal fasciculus  CI 0.33 0.21 + 0.38 0.18 + 
 
0.33 0.21 + 0.13 0.13 + 
 
cingulate cortex, area 1 Cg1 1.50 0.22 ++ 2.13 0.40 +++  0.17 0.17 + 0.38 0.18 +  
cingulate cortex, area 2 Cg2 1.00 0.26 + 1.25 0.16 ++  0.17 0.17 + 0.00 0.00 -  
corpus callosum cc 0.17 0.17 + 0.13 0.13 +  0.17 0.17 + 0.00 0.00 -  
dorsal endopiriform nucleus DEn 0.17 0.17 + 0.13 0.13 +  0.17 0.17 + 0.00 0.00 -  
granular insular cortex; dysgranular insular 
cortex GI DI 1.50 0.56 ++ 1.00 0.27 + 
 
1.17 0.48 ++ 0.63 0.18 + 
 
Internal capsule ic 0.00 0.00 - 0.13 0.13 +  0.00 0.00 - 0.00 0.00 -  
interstitial nucleus of posterior limb of anterior 
commissure IPACL 0.00 0.00 - 0.13 0.13 + 
 
0.00 0.00 - 0.00 0.00 - 
 
lateral preoptic nucleus LPO 0.33 0.21 + 0.13 0.13 +  0.00 0.00 - 0.00 0.00 -  
lateral globus pallidus LGP 0.00 0.00 - 0.13 0.13 +  0.00 0.00 - 0.00 0.00 -  
lateral septal nucleus  LSD 0.00 0.00 - 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
lateral septal nucleus  LSV 0.00 0.00 - 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
nuclei of stria terminalis BSTMA 0.00 0.00 - 0.25 0.16 +  0.00 0.00 - 0.00 0.00 -  
nuclei of stria terminalis BSTLD 0.67 0.67 + 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  







Suppl. Table 3 continued. 
Bregma 0.02 mm; interaural 3.82 mm    α-syn pathology  
  Injected hemisphere Contralateral hemisphere 
  Control 240mg/kg Fe  Control 240mg/kg Fe  
Brain regions 
Abbreviation 
Paxinos Mean SEM Code Mean SEM Code p Mean SEM Code Mean SEM Code p 
nuclei of stria terminalis BSTMV 0.00 0.00 - 0.13 0.13 +  0.00 0.00 - 0.00 0.00 -  
nuclei of stria terminalis BSTLI 0.00 0.00 - 0.38 0.38 +  0.00 0.00 - 0.13 0.13 +  
piriform cortex Pir 0.33 0.21 + 0.25 0.16 +  0.00 0.00 - 0.13 0.13 +  
posterior part of anterior commissure  acp 0.00 0.00 - 0.13 0.13 +  0.17 0.17 + 0.13 0.13 +  
posterior part of anterior commissure  acp (below IPACL) 0.00 0.00 - 0.13 0.13 +  0.00 0.00 - 0.38 0.18 +  
primary motor cortex M1 2.33 0.49 +++ 1.00 0.38 + # 0.50 0.22 + 0.25 0.16 +  
second somatosensory cortex S2 0.50 0.34 + 0.13 0.13 +  0.33 0.21 + 0.25 0.16 +  
septofimbrial nucleus  SFI 0.00 0.00 - 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
somatosensory 1, dysgranular zone S1DZ 0.00 0.00 - 0.13 0.13 +  0.00 0.00 - 0.00 0.00 -  
somatosensory 1, forelimb region S1FL 0.33 0.33 + 0.25 0.16 +  0.17 0.17 + 0.25 0.16 +  
somatosensory 1, hindlimb region S1HL 0.83 0.40 + 0.63 0.32 +  0.33 0.21 + 0.25 0.16 +  
somatosensory 1, barrel field  S1BF 0.00 0.00 - 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
striatum  CPu 1.50 0.22 ++ 1.25 0.25 ++  0.33 0.21 + 0.25 0.16 +  
supplementary motor cortex M2 2.50 0.22 +++ 1.75 0.31 ++  0.67 0.21 + 0.38 0.18 +  








Suppl. Table 4. Quantification of pS129-α-syn in individual brain regions in section ‘Bregma -1.58 mm’. The averaged α-syn group signal is shown for affected brain 
regions in section ‘Bregma -1.58 mm’. Abbreviations are used according to the Paxinos atlas (Paxinos and Franklin, 2003). Signal in each brain region was rated according to 
a 5-stage scale from 0 (no α-syn signal) to 4 (severe α-syn pathology) and the group means as well as SEM values are presented per hemisphere. The ‘code’ is a simplified 
representation of the pathology rating to which the group means were again classified to (−, +, ++, +++, ++++). The code thereby represents the assessment stages used in Figure 
29 and differences regarding these 5 stages (−, +, ++, +++, ++++) between the two groups (240 mg/kg Fe/PFFs and control/PFFs) were marked in bold. For a statistical 
comparison, Mann-Whitney-U-test was performed for each brain region per hemisphere. Where applicable p-values are stated (#p < 0.1; *p < 0.05; **p < 0.01). 
Bregma -1.58 mm; interaural 2.22 mm    α-syn pathology  
  Injected hemisphere Contralateral hemisphere 
  Control 240mg/kg Fe  Control 240mg/kg Fe  
Brain regions 
Abbreviation 
Paxinos Mean SEM Code Mean SEM Code p Mean SEM Code Mean SEM Code p 
accessory basal amygdaloid nucleus; 
accessory basal amygdaloid nucleus; 
ventromedial hypothalamic nucleus (central 
part) BMA VMHC BMP 0.83 0.48 + 1.00 0.33 +  0.00 0.00 - 0.38 0.18 +  
amygdalostriatal transition area; striatum AStr CPu 1.00 0.26 + 0.00 0.00 - ** 0.17 0.17 + 0.25 0.16 +  
anterior cortical nucleus of amygdala  ACo 0.00 0.00 - 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
Basal amygdaloid nucleus BLV 0.17 0.17 + 0.38 0.18 +  0.17 0.17 + 0.00 0.00 -  
basal amygdaloid nucleus BLA 2.00 0.52 ++ 1.75 0.53 ++  1.67 0.67 ++ 1.50 0.33 ++  
central amygdaloid nucleus  CeMPV 1.67 0.49 ++ 1.63 0.56 ++  0.50 0.22 + 0.13 0.13 +  
central amygdaloid nucleus CeC 0.83 0.40 + 1.38 0.53 ++  0.50 0.22 + 0.25 0.16 +  
central amygdaloid nucleus  CeL 1.17 0.48 ++ 1.88 0.67 ++  0.17 0.17 + 0.00 0.00 -  
central medial nucleus  CM 0.17 0.17 + 0.00 0.00 -  0.17 0.17 + 0.00 0.00 -  
corpus callosum cc 0.33 0.21 + 0.00 0.00 -  0.17 0.17 + 0.00 0.00 -  
dorsal endopiriform nucleus DEn 0.17 0.17 + 0.50 0.27 +  0.00 0.00 - 0.88 0.35 + # 
ectorhinal cortex Ect 1.83 0.54 ++ 0.88 0.30 +  1.17 0.48 ++ 0.25 0.16 + # 
intercalated amygdaloid nuclei  I 1.17 0.48 ++ 1.00 0.42 +  0.83 0.54 + 0.00 0.00 -  
intermediodorsal thalamic nucleus  IMD 0.17 0.17 + 0.38 0.18 +  0.17 0.17 + 0.38 0.18 +  
medial amygdaloid nucleus (posterodorsal 
subdivision) MePD 0.33 0.21 + 0.13 0.13 + 
 
0.00 0.00 - 0.00 0.00 - 
 
medial amygdaloid nucleus (posteroventral 
subdivision) MePV 0.17 0.17 + 0.00 0.00 - 
 








Suppl. Table 4 continued. 
Bregma -1.58 mm; interaural 2.22 mm    α-syn pathology  
  Injected hemisphere Contralateral hemisphere 
  Control 240mg/kg Fe  Control 240mg/kg Fe  
Brain regions 
Abbreviation 
Paxinos Mean SEM Code Mean SEM Code p Mean SEM Code Mean SEM Code p 
lateral amygdaloid nucleus LaVL 1.67 0.61 ++ 0.50 0.38 +  1.50 0.67 ++ 0.88 0.35 +  
lateral amygdaloid nucleus LaDL 2.17 0.54 +++ 0.88 0.48 +  1.67 0.49 ++ 1.13 0.40 ++  
lateral hypothalamic area LH 0.17 0.17 + 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
lateral parietal association cortex LPtA 1.33 0.33 ++ 0.88 0.23 +  0.17 0.17 + 0.13 0.13 +  
lateral posterior nucleus LPMR 0.17 0.17 + 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
medial forebrain bundle  mfb 0.50 0.22 + 0.25 0.16 +  0.00 0.00 - 0.13 0.13 +  
medial parietal association cortex  MPtA 1.17 0.31 ++ 0.75 0.25 +  0.17 0.17 + 0.25 0.16 +  
mediodorsal thalamic nucleus, medial part  MDM 0.17 0.17 + 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
nigrostriatal fibers ns 0.00 0.00 - 0.13 0.13 +  0.00 0.00 - 0.13 0.13 +  
nucleus of stria terminalis BSTIA 1.33 0.42 ++ 1.00 0.50 +  1.00 0.63 + 0.00 0.00 - * 
paraventricular thalamic nucleus  PV 0.50 0.34 + 0.63 0.18 +  0.50 0.34 + 0.63 0.18 +  
perirhinal cortex PRh 2.17 0.40 +++ 1.00 0.27 + * 1.33 0.61 ++ 1.13 0.52 ++  
periventricular hypothalamic nucleus Pe 0.00 0.00 - 0.00 0.00 -  0.17 0.17 + 0.00 0.00 -  
piriform cortex  pir 0.67 0.49 + 0.38 0.18 +  0.00 0.00 - 0.00 0.00 -  
 posterolateral cortical amygdaloid nucleus  PLCo 0.00 0.00 - 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
posterior thalamic nuclear group Po 0.17 0.17 + 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
retrosplenial granular cortex RSG 0.17 0.17 + 0.13 0.13 +  0.00 0.00 - 0.00 0.00 -  
retrosplenial agranular cortex  RSA 0.67 0.33 + 0.63 0.26 +  0.00 0.00 - 0.00 0.00 -  
 rhomboid thalamic nucleus Rh 0.33 0.21 + 0.00 0.00 -  0.33 0.21 + 0.00 0.00 -  
second somatosensory cortex S2 2.00 0.45 ++ 1.25 0.49 ++  0.50 0.22 + 0.13 0.13 +  
somatosensory 1, barrel field  S1BF 1.17 0.31 ++ 1.25 0.37 ++  0.50 0.22 + 0.25 0.16 +  
somatosensory 1, trunk region  S1Tr 1.50 0.34 ++ 1.25 0.31 ++  0.67 0.21 + 0.25 0.16 +  
stria terminalis st 2.83 0.65 +++ 0.63 0.50 +  0.17 0.17 + 0.00 0.00 -  
ventral endopiriform nucleus VEn 0.00 0.00 - 0.13 0.13 +  0.00 0.00 - 0.00 0.00 -  
ventrolateral thalamic nucleus VL 0.17 0.17 + 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  








Suppl. Table 5. Quantification of pS129-α-syn in individual brain regions in section ‘Bregma -3.08 mm’. The averaged α-syn group signal is shown for affected brain 
regions in section ‘Bregma -3.08 mm’. Abbreviations are used according to the Paxinos atlas (Paxinos and Franklin, 2003). Signal in each brain region was rated according to 
a 5-stage scale from 0 (no α-syn signal) to 4 (severe α-syn pathology) and the group means as well as SEM values are presented per hemisphere. The ‘code’ is a simplified 
representation of the pathology rating to which the group means were again classified to (−, +, ++, +++, ++++). The code thereby represents the assessment stages used in Figure 
29 and differences regarding these 5 stages (−, +, ++, +++, ++++) between the two groups (240 mg/kg Fe/PFFs and control/PFFs) were marked in bold. For a statistical 
comparison, Mann-Whitney-U-test was performed for each brain region per hemisphere. Where applicable p-values are stated (#p < 0.1; *p < 0.05; **p < 0.01). 
Bregma -3.08 mm; interaural 0.72 mm    α-syn pathology  
  Injected hemisphere Contralateral hemisphere 
  Control 240mg/kg Fe  Control 240mg/kg Fe  
Brain regions 
Abbreviation 
Paxinos Mean SEM Code Mean SEM Code p Mean SEM Code Mean SEM Code p 
amygdalohippocampal area AHiPM 1.67 0.76 ++ 1.50 0.50 ++  0.00 0.00 - 0.00 0.00 -  
amygdalopiriform transition area APIR 2.33 0.67 +++ 1.33 0.61 ++  0.00 0.00 - 0.00 0.00 -  
basal amygdaloid nucleus  BLP 2.83 0.75 +++ 2.33 0.80 +++  0.00 0.00 - 0.00 0.00 -  
cingulum cg 0.33 0.21 + 0.00 0.00 -  0.33 0.21 + 0.17 0.17 +  
ectorhinal cortex Ect 2.00 0.52 ++ 0.83 0.54 +  1.33 0.49 ++ 1.33 0.42 ++  
entorhinal cortex, lateral part LEnt 1.83 0.48 ++ 0.67 0.33 + # 0.67 0.21 + 0.83 0.31 +  
habenulointerpeduncular tract  fr 0.33 0.33 + 0.00 0.00 -  0.17 0.17 + 0.00 0.00 -  
hippocampus (dentate gyrus, stratum lucidem, 
stratum radiatum, pyramidal cell layer, CA3 
field) 
DG Mol GrDG 
PoDG SLu Rad Or 
Py CA3 0.17 0.17 + 0.50 0.34 + 
 
0.00 0.00 - 0.00 0.00 - 
 
interpeduncular fossa  IPF 0.17 0.17 + 0.17 0.17 +  0.17 0.17 + 0.17 0.17 +  
mammillary peduncle mp 0.00 0.00 - 0.17 0.17 +  0.00 0.00 - 0.33 0.21 +  
medial lemniscus ml 0.00 0.00 - 0.33 0.21 +  0.00 0.00 - 0.00 0.00 -  
medial terminal nucleus of accessory optic tract MT 0.00 0.00 - 0.50 0.50 +  0.00 0.00 - 0.00 0.00 -  
peripenduncular nucleus PP 0.17 0.17 + 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
perirhinal cortex PRh 1.83 0.48 ++ 1.33 0.42 ++  1.17 0.40 ++ 1.33 0.42 ++  
posterior forceps of corpus callosum; 
commissure of fornix  fmj dhc 0.17 0.17 + 0.00 0.00 - 
 
0.00 0.00 - 0.00 0.00 - 
 







Suppl. Table 5 continued. 
Bregma -3.08 mm; interaural 0.72 mm    α-syn pathology  
  Injected hemisphere Contralateral hemisphere 
  Control 240mg/kg Fe  Control 240mg/kg Fe  
Brain regions 
Abbreviation 
Paxinos Mean SEM Code Mean SEM Code p Mean SEM Code Mean SEM Code p 
primary auditory area Au1 1.17 0.48 ++ 0.83 0.31 +  0.00 0.00 - 0.00 0.00 -  
primary visual cortex V1 1.00 0.26 + 0.67 0.33 +  0.00 0.00 - 0.17 0.17 +  
retrosplenial granular cortex RSG 0.17 0.17 + 0.17 0.17 +  0.00 0.00 - 0.00 0.00 -  
retrosplenial agranular cortex  RSA 0.33 0.21 + 0.33 0.21 +  0.00 0.00 - 0.00 0.00 -  
secondary auditory cortex, dorsal area AuD 1.50 0.43 ++ 0.83 0.31 +  0.00 0.00 - 0.00 0.00 -  
secondary auditory cortex, ventral area AuV 1.50 0.50 ++ 1.00 0.52 +  0.33 0.21 + 1.33 0.61 ++  
secondary visual cortex, lateral part V2L 1.50 0.34 ++ 1.00 0.37 +  0.00 0.00 - 0.17 0.17 +  
substantia nigra, lateral part SNL 0.00 0.00 - 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
substantia nigra, pars compacta (compact part)  SNC 2.00 0.26 ++ 2.17 0.54 +++  0.00 0.00 - 0.00 0.00 -  
substantia nigra, pars reticularis (reticular part)  SNR 0.50 0.22 + 0.50 0.34 +  0.00 0.00 - 0.00 0.00 -  
supramammillary nucleus SuM 0.00 0.00 - 0.00 0.00 -  0.00 0.00 - 0.17 0.17 +  
temporal cortex, association area TeA 1.50 0.56 ++ 1.17 0.48 ++  0.67 0.33 + 1.67 0.67 ++  
ventral tegmental area VTA 0.50 0.22 + 0.67 0.21 +  0.00 0.00 - 0.17 0.17 +  
visual cortex 2, mediolateral part  V2ML 0.33 0.21 + 0.67 0.33 +  0.00 0.00 - 0.00 0.00 -  
visual cortex 2, mediomedial part  V2MM 0.50 0.22 + 0.33 0.21 +  0.00 0.00 - 0.00 0.00 -  








Suppl. Table 6. Quantification of pS129-α-syn in individual brain regions in section ‘Bregma -3.28 mm’. The averaged α-syn group signal is shown for affected brain 
regions in section ‘Bregma -3.28 mm’. Abbreviations are used according to the Paxinos atlas (Paxinos and Franklin, 2003). Signal in each brain region was rated according to 
a 5-stage scale from 0 (no α-syn signal) to 4 (severe α-syn pathology) and the group means as well as SEM values are presented per hemisphere. The ‘code’ is a simplified 
representation of the pathology rating to which the group means were again classified to (−, +, ++, +++, ++++). The code thereby represents the assessment stages used in Figure 
29 and differences regarding these 5 stages (−, +, ++, +++, ++++) between the two groups (240 mg/kg Fe/PFFs and control/PFFs) were marked in bold. For a statistical 
comparison, Mann-Whitney-U-test was performed for each brain region per hemisphere. Where applicable p-values are stated (#p < 0.1; *p < 0.05; **p < 0.01). 
Bregma -3.28 mm; interaural 0.52 mm    α-syn pathology  
  Injected hemisphere Contralateral hemisphere 
  Control 240mg/kg Fe  Control 240mg/kg Fe  
Brain regions 
Abbreviation 
Paxinos Mean SEM Code Mean SEM Code p Mean SEM Code Mean SEM Code p 
amygdalohippocampal area AHiPM 3.20 0.80 ++++ 1.13 0.55 ++ # 0.00 0.00 - 0.00 0.00 -  
amygdalopiriform transition area APir 3.00 0.77 +++ 2.00 0.63 ++  0.00 0.00 - 0.00 0.00 -  
cingulum cg 0.20 0.20 + 0.50 0.19 +  0.20 0.20 + 0.25 0.16 +  
commissure of fornix dhc 0.00 0.00 - 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
dorsal nucleus of medial geniculate body MGD 0.20 0.20 + 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
ectorhinal cortex Ect 2.00 0.00 ++ 1.75 0.49 ++  1.00 0.32 + 1.38 0.42 ++  
entorhinal cortex, lateral part LEnt 1.80 0.49 ++ 1.75 0.45 ++  0.80 0.20 + 0.75 0.16 +  
hippocampus, inner part (dentate gyrus, 
stratum lucidem, stratum radiatum, oriens 
layer, pyramidal cell layer, CA3 field) 
DG Mol GrDG PoDG 
SLu Rad Or Py CA3 0.20 0.20 + 0.50 0.19 +  0.00 0.00 - 0.00 0.00 -  
hippocampus, outer part (CA1 field, oriens 
layer, pyramidal cell layer, stratum radiatum, 
Stratum lacunosummoleculare) CA1 Or Py Rad LMol  0.80 0.37 + 0.38 0.26 +  0.00 0.00 - 0.00 0.00 -  
interfascicular nucleus IF 0.00 0.00 - 0.13 0.13 +  0.00 0.00 - 0.13 0.13 +  
magnocellular nucleus of medial geniculate 
body MGM 0.20 0.20 + 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
medial lemniscus ml 0.80 0.20 + 0.75 0.49 +  0.00 0.00 - 0.00 0.00 -  
medial terminal nucleus of accessory optic 
tract MT 0.60 0.24 + 0.38 0.18 +  0.00 0.00 - 0.00 0.00 -  







Suppl. Table 6 continued. 
Bregma -3.28 mm; interaural 0.52 mm    α-syn pathology  
  Injected hemisphere Contralateral hemisphere 
  Control 240mg/kg Fe  Control 240mg/kg Fe  
Brain regions 
Abbreviation 
Paxinos Mean SEM Code Mean SEM Code p Mean SEM Code Mean SEM Code p 
parabigeminal nucleus  PAG 0.20 0.20 + 0.13 0.13 +  0.00 0.00 - 0.00 0.00 -  
parabrachial pigmented nucleus  PBP 0.60 0.24 + 0.25 0.16 +  0.00 0.00 - 0.00 0.00 -  
peripenduncular nucleus PP 1.00 0.32 + 0.50 0.27 +  0.00 0.00 - 0.00 0.00 -  
perirhinal cortex PRh 2.00 0.32 ++ 1.88 0.35 ++  1.00 0.32 + 1.13 0.40 ++  
posterior intralaminar thalamic nucleus  PIL 0.00 0.00 - 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
posteromedial cortical amygdaloid nucleus PMCo 1.40 0.60 ++ 1.13 0.55 ++  0.00 0.00 - 0.00 0.00 -  
postthalamic nuclear group (triangular part); 
deep mesencephalic nucleus PoT DpMe 0.20 0.20 + 0.25 0.16 +  0.00 0.00 - 0.13 0.13 +  
primary auditory area Au1 2.20 0.37 +++ 1.13 0.44 ++  1.60 0.24 ++ 0.25 0.16 + ** 
primary visual cortex V1 0.40 0.24 + 0.38 0.18 +  0.00 0.00 - 0.00 0.00 -  
retrosplenial granular cortex RSG 0.00 0.00 - 0.25 0.16 +  0.00 0.00 - 0.00 0.00 -  
retrosplenial agranular cortex  RSA 0.40 0.40 + 0.50 0.19 +  0.00 0.00 - 0.00 0.00 -  
secondary auditory cortex, dorsal area AuD 1.40 0.40 ++ 1.25 0.41 ++  0.60 0.40 + 0.25 0.16 +  
secondary auditory cortex, ventral area AuV 2.20 0.37 +++ 1.13 0.44 ++  1.60 0.24 ++ 0.88 0.30 +  
secondary visual cortex, lateral part V2L 1.00 0.32 + 1.00 0.42 +  0.00 0.00 - 0.25 0.16 +  
subiculum S 1.00 0.45 + 0.88 0.40 +  0.20 0.20 + 0.13 0.13 +  
substantia nigra, lateral part SNL 0.00 0.00 - 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
substantia nigra, pars compacta (compact 
part)  SNC 1.40 0.51 ++ 1.13 0.35 ++  0.00 0.00 - 0.00 0.00 -  
substantia nigra, pars compacta (compact 
part);next to PBP SNC 0.80 0.37 + 0.75 0.41 +  0.00 0.00 - 0.00 0.00 -  
substantia nigra, pars reticularis (reticular 
part)  SNR 1.40 0.51 ++ 1.13 0.23 ++  0.00 0.00 - 0.00 0.00 -  
suprageniculate thalamic nucleus SG 0.20 0.20 + 0.00 0.00 -  0.00 0.00 - 0.00 0.00 -  
temporal cortex, association area TeA 2.20 0.37 +++ 1.75 0.41 ++  1.20 0.58 ++ 1.50 0.42 ++  
ventral tegmental area VTA 0.60 0.24 + 0.38 0.18 +  0.40 0.24 + 0.13 0.13 +  
visual cortex 2, mediolateral part  V2ML 0.40 0.24 + 0.63 0.26 +  0.00 0.00 - 0.00 0.00 -  
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